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1. INTRODUCTION 
 
1.1. BACKGROUND 
 
Parkinson’s disease (PD) was first described by James Parkinson in 1817 (Parkinson, 
1817). It is the second most common neurodegenerative disorder affecting 1-2% of the 
population over the age of 65 years. Although 5-10% of PD cases belong to a familial 
form of the disease, the remaining 90-95% of are apparently sporadic. 
The neuropathological features of idiopathic PD are the appearance of intracellular 
protein aggregates known as Lewy bodies (LBs) (Lewy, 1912) and the degeneration of 
neurons in the pars compacta tier of the substantia nigra (SNC) with consequent loss of 
dopaminerginc innervation to the caudate and putamen (nigo-striatal pathway). Other 
areas of the brain can also be affected in idiopathic PD including locus coeruleus or the 
dorsal motor nucleus of the vagus and the limbic system. Whether the LBs existence is 
triggering this neuronal degeneration or the neuronal dysfunction is promoting the 
appearance of these aggregates is still unknown. The phenotype of idiopathic PD is 
characterized by resting tremor, rigidity, postural inestability and bradykinesia, which at 
first respond to L-DOPA treatment. 
Additional non-motor features like postural abnormalities, dysautonomia, dystonic 
cramps, anxiety, depression or dementia are characteristic. Most of these symptoms tend 
to get worse over time. 
The term parkinsonism refers to a syndrome including a combination of all these clinical 
features as well as many other diseases which most likely result from loss or dysfunction 
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of the dopaminergic neurons in the SN. Although the most common cause of this 
syndrome is PD, other etiologies can lead to its appearance: Dementia with Lewy bodies 
(DLB; OMIM #127750), progressive supranuclear palsy (PSP; OMIM #601104), 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP17; OMIM 
#600274), autosomal recessive form of Segawa’s syndrome (OMIM #605407), X-linked 
recessive Filipino type of dystonia (XDP; OMIM #314250), multiple system atrophy 
(MSA) or drug-induced parkinsonism (Shy and Drager 1960; Steele, Richardson et al. 
1964; Lee, Pascasio et al. 1976; Langston, Ballard et al. 1983; Foster, Wilhelmsen et al. 
1997; Hansen LA 1997; Segawa 1999; Wenning and Geser 2003). 
 
 
1.2. EPIDEMIOLOGY 
 
Data on the prevalence and incidence of PD are of interest for several reasons. 
Epidemiological studies can provide insights into suspected risk factors, protective 
factors and primary causes of the disease;, these data can also provide critical information 
to inform public health planning. This latter point has become of special interest in the 
last years, as longevity of the population increases and the incidence of PD rises with age. 
Since PD was first described, a number of epidemiological studies have been performed. 
However, since these studies were methodologically limited, being mostly small case-
control or register-based studies, it was not until the end of the twentieth century that 
large studies reached a stage with sufficient number of PD patients to examine incidence 
and potential risk factors. A limitation of this work is that a reliable and easily applicable 
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diagnostic test for PD is not yet available. Sophisticated imaging techniques such as CT 
or PET may be helpful to diagnose PD, but their usefulness for population 
epidemiological studies is still limited. Thus, a diagnosis of PD for these kind of studies 
is primarily based on clinical criteria. As will be argued latter, these criteria are still 
controversial and a long-term follow-up of patients is needed to improve accuracy of 
diagnoses. Definitive diagnosis requires post-mortem confirmation. Thus, estimates of 
the prevalence and incidence of PD may vary according to the methodology utilized to 
make the diagnoses. Hence, the stricter the diagnostic criteria used, the lower the 
estimates of prevalence and incidence are. 
 
1.2.1. Prevalence 
Prevalence denotes the total number of cases of disease on a given time. The prevalence 
of PD in industrialized countries is generally estimated at 0.3% of the general population 
and about 1-2% in people over 60 years of age. Age, however, is clearly the greatest 
factor in PD expression. A European study of 15,000 participants over 65 reported that 
the prevalence of PD from 65 to 89 years old increases steadily from 0.6 to 3.5% (De 
Rijk, Launer et al., 2000). De Lau and colleagues reviewed age-specific prevalence rates 
obtained from studies across different populations (figure 1). This review clearly shows 
that PD is an age-related disease, being rare before 50 in all reviewed populations (De 
Lau and Breteler, 2006). As the elderly population increases in size, the prevalence of PD 
increases as well, making prevalence studies difficult to perform. 
From an etiological point of view, PD may result from different environmental exposition 
and genetic background that are both due to intercultural differences. Some studies have 
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addressed the issue of ethnicity in relation to the occurrence of PD, obtaining conflicting 
results. Thus, some groups support the idea that prevalence of PD varies by ethnicity, 
being less common in black and Asian populations than in white and hispanic groups 
(Mayeux, Marder et al., 1995; Morens, Davis et al., 1996; Van Den Eeden, Tanner et al., 
2003). These reported differences may result from difference in response rates, survival, 
and case-ascertainment rather than from real differences in PD across ethnic groups. It is 
also possible that a delay in diagnosis due to limited access to appropriate health services 
among some groups could have resulted in the observed discordant rates of disease. 
 
 
1 
 
Figure 1: Population-based prevalence studies of Parkinson's 
disease (Figure modified from De Lau and Breteler, 2006). 
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Many studies have reported higher prevalence of PD in men than in women (Mayeux, 
Marder et al., 1995; Morens, Davis et al., 1996; Baldereschi, Di Carlo et al., 2000; Van 
Den Eeden, Tanner et al., 2003). This difference may be due to the hypothetical 
neuroprotectve effect of estrogen that has been shown to have numerous effects on 
dopamine synthesis, transmission and release (Saunders-Pullman, 2003). Another 
possible explanation for this difference is that PD increases with age and woman 
constitute a greater proportion of aged population than men, although many studies 
attempt to adjust for this potential confound. 
 
1.2.2. Incidence 
The term incidence refers to the number of new cases of a disease per unit of time, 
usually 1 year. Incidence rates are theoretically not affected by differences in survival of 
patients and therefore better measures of the risk of disease than prevalence estimates. 
However, population-based incidence estimates are much harder to obtain than record-
based data, as they require large cohorts and long follow-up periods. Also, if the follow-
up of a cohort is incomplete, substantial misclassification may occur, which will typically 
lead to underestimate disease risk. The incidence of PD has been difficult to ascertain 
with a high degree of certainty, but more accurate estimates have become available with 
the advent of better diagnostic guidelines as those mented previously. 
The correlation of PD and aging is even more striking from studies of disease incidence. 
A meta-analysis of 25 incidence studies (Twelves, Perkins et al., 2003) estimated an 
overall population incidence of 16-19 per 100,000 per year. However, De Lau and 
collaborators in 2004 (De Lau, Giesbergen et al., 2004) reported that incident rates 
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increase after the age of 50, especially in men, and rapidly increase over the age of 75. 
They stated that risk of developing any parkinsonian features between the ages of 55 and 
85 years is 8.5% for men and 7.7% for women. Between the ages of 75 and 85, the 
incident rate is 6.8 for men and 4.5 for women per 1,000 people per year. Over the age of 
85, it increases to 12.1 and 10.2 for men and women respectively.  
Similar incidence rates have been published by different groups worldwide, establishing 
that onset of PD rarely occurs before 50 with a sharp increase after age of 60. (Rajput, 
Offord et al., 1984; Wang, Shi et al., 1991; Mayeux, Marder et al., 1995; Morens, Davis 
et al., 1996; Baldereschi, Di Carlo et al., 2000; Macdonald, Cockerell et al., 2000; Chen, 
Chang et al., 2001; Benito-Leon, Bermejo-Pareja et al., 2004; De Lau, Giesbergen et al., 
2004). Interestingly, some studies observed a decline in incidence in the highest age 
groups (Morens, Davis et al., 1996; Bower, Maraganore et al., 1999), but this is likely an 
artifact caused by increased diagnostic uncertainty due to comorbid disorders and 
selective loss to follow-up (figure 2). 
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1.2.3. Parkinson’s disease epidemiology in Spain 
In 2005, Von Campenhausen and colleagues (Von Campenhausen, Bornschein et al., 
2005) provided an overview on the prevalence and incidence of PD in certain European 
countries by systematically searching for epidemiological studies performed in these 
countries. As for Spain, nine accessible studies were identified (figure 3). In the first 
three, a three-phase door-to-door study was performed in Bidasoa region (Bergareche, De 
La Puente et al., 2004), central Spain (Benito-Leon, Bermejo-Pareja et al., 2003) and 
Cantalejo region (Claveria, Duarte et al., 2002). In these reports, individuals were first 
screened by interviewers and those who screened positive were examined by a 
neurologist. With this methodology, prevalence estimates were 1.5% (Bergareche et al), 
Figure 2: Prospective population-based incidence studies of Parkinson's 
disease (Figure modified from De Lau and Breteler, 2006). 
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1.5% (Benito-León et al) and 1.3% (Claveria et al) in persons older than 65 years. 
Benito-León and coworkers (Benito-Leon, Bermejo-Pareja et al., 2004), also performed a 
study on PD incidence by following 5,160 parkinsonism-free subjects for a period of 3 
years, obtaining an annual incidence rate of 186.8 standardized to the European 
population. 
Martinez-Suarez and Blázquez-Menes (Martinez-Suarez and Blazquez-Menes, 2000) 
performed a study in Asturias to estimate the prevalence of PD in this Spanish region. 
Records of prescriptions were obtained from the pharmacy sub-directorate of Health and 
consumption Ministry, which covers 100% of the population in Asturias and estimated a 
crude prevalence of PD of 0.2%. 
Similar results were obtained by Errea and colleagues in lower Aragon (Errea, Ara et al., 
1999), by collecting data from hospital record, medical files from specialist in the region, 
and retirement homes. A 0.2% prevalence of PD was estimated. Viñés and collaborators 
(Vines, Larumbe et al., 1999) estimated PD incidence in Navarra on 8.2/100,000 between 
1994 and 1995 by collecting data of diagnosed cases from family doctors, physicians, 
private neurologists and National Health Service. 
Finally, Criado-Álvarez and Artazcoz Sanz (Artazcoz Sanz and Vines Rueda, 1995; 
Criado-Alvarez, Romo-Barrientos et al., 1998), by obtaining information from the 
Pharmaceutical Service of Health and Consume Ministry of Spain, estimated that PD 
prevalence was 2.7% and 0.16% in Castilla la Mancha and Navarra respectively. 
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1.3. CLINICAL FEATURES 
 
Parkinson’s disease is a clinical syndrome whose phenotype is characterized by the 
cardinal features akinesia/bradykinesia, muscular rigidity and resting tremor. Not all 
cardinal features need to be present, but at least two should be for a diagnosis of PD, with 
at least one of them being resting tremor or akinesia/bradykinesia. Among these cardinal 
symptoms, akinesia (meaning absence of movement) is the one contributing more to the 
disability caused by PD. The terms bradykinesa/hypokinesia (meaning slowness and 
Figure 3: Parkinson’s diseas epidemiology in Spain. Map of Spain showing prevalence (blue) and 
incidence (red) data obtained by studies performed by Bergareche, De La Puente et al. (1); Benito-León, 
Bermejo-Pareja et al. (2); Benito-León, Bermejo-Pareja et al. (3); Claveria, Duarte et al. (4); Martinez-
Suarez and Blázquez-Menes (5); Errea, Ara et al. (6); Viñés, Larumbe et al. (7); Criado-Álvarez, Romo-
Barrientos et al. (8); and Artazcoz Sanz and Viñés Rueda (9).  
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decreased amplitude of movement) are more appropriate, as only a minority of patients 
suffer from absolute loss of movement. This symptom affects all voluntary and 
involuntary movements. Thus, automatic and habitual movements such as swinging the 
arms while walking, eyes blinking, swallowing saliva or making gestures while talking 
are partially lost. These, together with monotonous speech, impair the patient’s ability to 
communicate. Although slowness is a general feature of parkinsonian movements there 
are instances in which repetitive movements are preformed at abnormally high 
frequencies with very small amplitude. Parkinsonian subjects usually have problems with 
both executing and programming a certain movement. Thus, patients with advanced 
disease status may suffer what is known as “freezing”, a situation in which they are 
completely unable to start walking. Interestingly, this impairment is more pronounced 
when patients have to self-initiate movements rather than when they respond to an 
external stimuli.  
Another of the cardinal clinical features of PD is muscular rigidity. This is defined as a 
constant increased resistance of a joint to passive movement, resulting in stiffness and a 
reduced ability to relax limb muscles. When this feature is present along with resting 
tremor, a characteristic type of resistance is observed that has been given the name of 
“cogwheel-like” rigidity.  
The third cardinal feature, resting tremor, is the most conspicuous of parkinsonism and 
was the reason for the original name, shaking palsy, given by James Parkinson in 1817 
(Parkinson, 1817). Resting tremor mostly occurs in the upper limbs but also in the legs 
and head. Since this tremor is absent during voluntary actions, this feature is not 
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necessarily impairing. PD patients can also suffer from other kinds of tremor such as 
postural and action tremor, re-emergent tremor and orthostatic tremor. 
Additional features of PD that aid in the differential diagnosis are an asymmetric onset of 
symptoms (only in one side of the body), resting tremor (although this may be absent in 
PD it is almost always absent in diseases such as PSP, FTDP-17, etc…) and a substantial 
response to L-dopa therapy. 
Resting tremor is often the first symptom recognized in PD, but the illness sometimes 
starts with bradykinesia and resting tremor may be absent throughout the course of the 
disease. The early symptoms of PD (resting tremor, bradykinesia and rigidity) are usually 
improved with L-dopa therapy or other dopamine agonists. As time goes on, symptoms 
that do not respond to L-dopa, such as flexed posture, freezing and loss of postural 
reflexes, develop. Moreover, the bradykinesia that first responded to L-dopa in the earlier 
stages increases and stops responding to the therapy. Abnormal involuntary movements 
(dyskinesis) are common in PD patients primarily as a consequence of the prolonged 
dopaminergic therapy. 
Besides the features discussed so far, non-motor symptoms have been described to be a 
frequent feature of PD and, in many cases, these reduce quality of life to a greater extent 
than the motor symptoms. These include autonomic, sensory (pain), cognitive and 
neuropsychiatric symptoms. These include symptoms like orthostatic hypotension, 
bladder disturbances, obstipation (a severe constipation caused by intestinal obstruction), 
fatigue, anxiety, sleep disturbances, decreased motivation and apathy, depression, 
slowness in thinking (bradyphrenia) and cognitive decline. 
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1.4. PATHOLOGY 
 
Motor symptoms of PD are primarily related to extensive loss of the dopaminergic 
neurons of the SNC, causing a decrease in the dompaminergic innervation in the caudate 
and putamen. There appears to be substantial redundancy in these systems as frank 
clinical manifestation of PD only presents after the pathology has reached an advanced 
stage in which approximately 50% of the dopaminergic cells of the SNC are lost with a 
consequent depletion of about 80% of striatal dopamine. Dopaminergic cell loss also 
affects other neurotransmitter systems. Peripherally there is decreased tyrosine 
hydroxylase (TH) activity and decreased dopamine in the adrenal medulla, possibly 
explaining the autonomic manifestations in PD patients. Centrally, neurotransmitter level 
alterations are detected in the nucleus basalis of Meynert, locus coeruleus and Raphe 
nuclei, as well as changes in the glutamatergic and GABAergic pathways. Thus, PD is 
not only a loss-of-dopamine-related pathology, but a multisystem neurodegenerative 
disease in which diverse neural pathways and several neurotransmitter systems are 
involved.  
The pathological hallmark lesions of PD are the Lewy body (LBs), which are neuronal 
eosinophilic cytoplasmic inclusions containing aggregated ubiquitinated proteins; 
spindle-like or thread-like branching Lewy neurites (LNs) in surviving neurons; and 
distinct neuronal inclusions called pale bodies. 
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1.4.1. Lewy bodies 
LBs were first described by Frederic H. Lewy in the nucleus basalis of Meynert and the 
dorsal vagal nucleus in patients with PD (Lewy, 1912) and were named Lewy bodies in 
his honor by Tretiakoff who confirmed their presence in the substantia nigra (Tretiakoff, 
1919). There are two types of LBs: the brainstem (classical) type and the cortical type. 
Brainstem-type LBs are easily seen by light microscopic examination of hematoxylin and 
eosin (HE)-stained sections as extraordinarily large spherical eosinophilic 
intracytoplasmatic inclusions that displace other cell components, possessing a dense core 
and a peripheral halo (figure 4A). Cortical LBs are also eosinophilic, but irregular in 
shape, being poorly defined structures often without a conspicuous halo or central core 
(figure 4B). 
Ultrastructually, both brainstem-type and cortical LBs are composed of filamentous 
structures (Duffy, 1965; Kosaka, 1978). 
LBs are typically found in dopaminergic neurons of the SNC, but are also seen in all 
other populations of neurons that selectively degenerate in the PD brain. Thus, they can 
be found at the hypothalamus, nucleus basalis of Meynert, locus ceruleus, dorsal raphe 
nucleus, dorsal vagal nucleus, intermediolateral nucleus of the spinal cord, and sacral 
autonomic nucleus (Jager and Bethlem, 1960; Ohama and Ikuta, 1976; Oyanagi, 
Wakabayashi et al., 1990; Kakita, Takahashi et al., 1994; Wakabayashi and Takahashi, 
1997a). LBs are also seen in the neurons of the amygdaloid nucleus and cerebral cortex, 
particularly in deep layers (V and VI) of the limbic system (Braak, Braak et al., 1994a; 
Wakabayashi, Hansen et al., 1995). Similar inclusions are also found in the peripheral 
autonomic nervous system, including the sympathetic ganglia, enteric nervous system of 
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the alimentary tract, cardiac and pelvic plexuses, adrenal medulla, salivary gland and skin 
(Den and Bethlem, 1960; Okazaki, Lipkin et al., 1961; Ohama and Ikuta, 1976; Kosaka, 
1978; Wakabayashi, Takahashi et al., 1988; Oyanagi, Wakabayashi et al., 1990; Takeda, 
Yamazaki et al., 1993; Braak, Braak et al., 1994a; Kakita, Takahashi et al., 1994; 
Wakabayashi, Hansen et al., 1995; Wakabayashi and Takahashi, 1997a; 1997b; Iwanaga, 
Wakabayashi et al., 1999). The widespread distribution of LB pathology may correspond 
to a variety of motor and non-motor symptoms of PD. 
Despite their size it is not clear whether these LBs are causative of PD pathology or a 
consequence of it.  
Their exact composition is unknown, but more than 70 different molecules have been 
identified in LBs (Wakabayashi, Tanji et al., 2007). These molecules are structural 
elements of the LB fibril, α-synuclein-binding proteins, synphilin-1-binding proteins, 
components of the Ubiquitin-Proteasome System, proteins implicated in cellular 
response, proteins associated with phosphorylation and signal transduction, cytoskeletal 
proteins, cell cycle proteins, cytosolic proteins that passively diffuse into LBs, etc. Of 
these components, α-synculcein (Spillantini, Schmidt et al., 1997), dj-1 (Bandopadhyay, 
Kingsbury et al., 2004), lrrk2 (Greggio, Jain et al., 2006; Zhu, Babar et al., 2006), parkin 
(Schlossmacher, Frosch et al., 2002) and pink1 (Gandhi, Muqit et al., 2006) are PD-
linked gene products (figure 4C, D). 
 
1.4.2.  Lewy neurites 
Lewy neurites are degenerating neural processes found in affected brain regions both in 
PD and in diffuse Lewy body disease. The term was first coined by Braak and colleagues 
Javier Simón Sánchez  Introduction 
 15
in 1994 (Braak, Braak et al., 1994b). They share some histological properties with LBs, 
including ubiquitin reactivity and may result from the same pathological process as LBs. 
In many affected brain regions LNs are more numerous than LBs and this abundance may 
facilitate studies into LN pathogenesis. 
 
1.4.3. Pale bodies 
Besides, in the SN and locus ceruleus, distinct neuronal inclusions called pale bodies are 
seen in the cytoplasm of pigmented neurons, showing well-defined, less eosinophilic 
areas without halos (figure 4E) (Pappolla, Shank et al., 1988; Dale, Probst et al., 1992). 
These bodies contain sparse granular and vesicular substructures and filaments identical 
to those seen in LBs (Takahashi, Ohama et al., 1994). In these nuclei, pale bodies are 
frequently found in close association with LBs (figure 4F) (Gibb, Scott et al., 1991; 
Takahashi, Ohama et al., 1994). Pale bodies are weakly positive for ubiquitin and are 
intensely immunolabeled with anti-α-synuclein (Wakabayashi, Hayashi et al., 1998; 
Kuusisto, Parkkinen et al., 2003). 
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Some authors (Braak, Del Tredici et al., 2003; Braak, Ghebremedhin et al., 2004) devised 
a staging system of LB pathology in PD with six consecutive clinical stages (1-3 being 
premotor and 4-6 motor stages) in which different brain areas are gradually affected 
marked by the continual development of LBs and LNs (figure 5): During the course of 
PD, neuronal damage in the brain is not random. The reason for the preferential 
vulnerability of some neuronal types and the resistance of others is still not properly 
understood. Thus, this damage occurs almost completely around areas related to motor 
functions, particularly the superordinate centers of the somatomotor, visceromotor, and 
limbic systems. All vulnerable cells in PD are projecting neurons with axons 
disproportionately long and thin in relation to the size of their soma, which is poorly 
Figure 4: Pathological hallmark lesions of Parkinson’s disease. Lewy bodies (LBs) and Lewy 
neurites in patients with Parkinson’s disease (A,C,E,F), dementia with LBs (B) and incidental LB 
disease (D). A: Concentric LB in a pigmented neuron in the substantia nigra. HE. B: Cortical LB in the 
temporal cortex. HE. C: Typical LB in a pigmented neuron in the SN labeled with anti-α-synuclein. 
Note that the central core is not stained. D: Many Lewy neurites in the dorsal vagal nucleus labeled 
with anti-a-synuclein. E: Pale body in a pigmented neuron in the substantia nigra. HE. F: Co-
occurrence of a pale body and two LBs in a pigmented neuron in the substantia nigra. HE. A-F: bar, 10 
μm. (Figure modified from Wakabayashi, Tanji et al., 2007). 
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myelinated or unmyelinated. These intraneural lesions evolve sequentially in a 
predictable manner. 
At first (stage 1) no more than a few isolated LNs appear at the dorsal motor nucleus and 
in the adjoining intermediate reticular zone. The large projection cells of this nucleus 
generate long unmyelinated preglionic fibers that connect the central nervous system with 
the postganglonic nerve cells of the enteric nervous system. A few spindle-shaped LNs 
also appear in these axons. LNs can be found in select neuronal types within the enteric 
nervous system in vasoactive intestinal polypeptide neurons of the Auerbach plexus. 
The pathology of the dorsal motor nucleus worsens in stage 2 and the following stages 
and spreads to the lower Raphe nuclei and magnocellular portions of the reticular 
formation, in particular de gigantocellular reticular nucleus. In addition, first LNs are 
seen in the coeruleus-subcoreruleus complex. All these nuclei function together as 
components of the “gain setting” system whose descending tracts comprise a pain control 
system. In addition, they work as a motor control system by regulating the sensitivity and 
excitability of medullary and spinal pre motor and motor neurons. 
In stage 3, damage reaches the pontine tegmentum and enters the basal portions of the 
midbrain and forebrain. In this stage, the first LNs appear in the SNC, followed by the 
appearance of granular aggregates, pale bodies and LBs within the melanized projecting 
neurons. Macroscopic changes can not be destinghushed in this stage. At the same time, 
the damage reaches the central subnucleus of the amygdala and extends to the basolateral 
nuclei. A distinctive network of LNs gradually fills the central subnucleus and makes it 
distinguishable from surrounding structures. Additional regions involved in this stage are 
the cholinergic tegmental pedunculopontine nucleus, the oral raphe nuclei, the 
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cholinergic magnocellular nuclei of the basal forebrain and the hypothalamic 
tuberomamillary nucleus. These three stages may be correlated with soft non-motor 
clinical findings such as those described before. In subsequent stages, the pathological 
alterations take an ascending course with increasing involvement of the cerebral cortex. 
Thus, in stage 4 a thick network of LNs appears in a specific portion of the cerebral 
cortex between the hallo and the neocortex. Many of the projecting neurons display LBs. 
The Amygdala and Ammon’s horn also become affected and display a plexus of LNs. 
In the final stages (4-5) the neurodegenerative process reaches its greatest extent. SNC 
appears almost devoied of melanin-containing neurons and is pale upon microscopic 
inspection. Starting at the temporal mesocortex, inclusion bodies gradually appear in the 
entire neocortex. In these latest motor phases, a broad cell loss is detected accompanied 
by the presence of LBs in the surviving cells not only in the SNC, but also in the locus 
coreuleus, nucleus basalis of Meynert, brainstem cranial motor nuclei and even peripheral 
divisions of the autonomic nervous system. Severe damage to the autonomic, limbic and 
somatomotor systems that began in the presymtomatic or premotor phase can become 
compounded by functional deficits on the part of the cerebral cortex. 
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1.5. MECHANISMS OF NEURODEGENERATION 
 
There is extensive neural loss in PD in the ventrolateral and caudal portions of the SNC, 
differing from the pattern observed in normal aging brains (primarily located in the 
dorsomedial SNC cells). The molecular mechanisms underlying neurodegeneration in 
these cells in PD patients are still unknown. However, there is a large body of evidence 
suggesting that oxidative stress, mitochondrial dysfunction, and aberrant proteolitic 
degradation (proteotoxicity) may be relevant to the pathogenesis. 
 
 
 
Figure 5: Staging system of Lewy body pathology in Parkinson’s disease. A, B PD presymptomatic and 
symptomatic phases. A: The presymptomatic phase is marked by the appearance of Lewy neurites/bodies in 
the brains of asymptomatic persons. In the symptomatic phase, the individual neuropathological threshold is 
exceeded (black arrow). The increasing slope and intensity of the colored areas below the diagonal indicate 
the growing severity of the pathology in vulnerable brain regions (right). The severity of the pathology is 
indicated by darker degrees of shading in the colored arrow left. B: Diagram showing the ascending 
pathological process (white arrows). The shading intensity of the colored areas corresponds to that in A. 
(Figure modified from Braak, Ghebremedhin et al., 2004. 
Javier Simón Sánchez  Introduction 
 20
1.5.1. Protein degradation and mishandling 
Protein aggregation and abnormal processing of proteins have been reported to be 
involved in the pathology of several neurodegenerative diseases like Huntington’s 
(OMIM #143100) and Alzheimer’s disease (AD, OMIM #104300). In PD α-synculein is 
present in LBs (Spillantini, Schmidt et al., 1997) and mutations in the gene encoding α-
synuclein (SNCA) cause a form of familial PD (Polymeropoulos, Lavedan et al., 1997). In 
its native state, α-synuclein is a soluble and unfolded protein. Owing to a central 
hydrophobic region, it tends to aggregate and form soluble protofibrils first and insoluble 
fibrils last. These soluble protofibrils, are thought to be able to form pores in the 
membranes, collapsing the ion gradients (Volles, Lee et al., 2001). The insoluble fibrils 
created later, are the main constituent of LBs. There are various factors promoting the 
aggregation of α-synculein: mutations (Conway, Harper et al., 1998; Narhi, Wood et al., 
1999; Conway, Lee et al., 2000; Tabrizi, Orth et al., 2000), post-translational 
modifications (phosphorylation, nitration and gycosylation) (Giasson, Duda et al., 2000; 
Shimura, Schlossmacher et al., 2001; Fujiwara, Hasegawa et al., 2002; Anderson, Walker 
et al., 2006), exposure to certain chemicals (like MPTP or paraquat) and dopamine itself 
by forming a dopamine-α-synuclein adduct (Conway, Rochet et al., 2001). 
Abnormal and misfolded proteins are normally targeted via ubiquitination to the 
proteasome, where they are degraded in an ATP-dependent manner. Dysfunction of the 
Ubiquitin Proteasome System (UPS) may thus, lead to the accumulation of aggregated 
proteins. The first evidence of a role of the UPS in neurodegeneration emerged after the 
identification of mutation in PARK2 in autosomal recessive PD patients (Kitada, 
Asakawa et al., 1998). This gene encodes an E3 ligase protein (parkin) that catalyzes the 
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addition of ubiquitin molecules to target proteins for their degradation in the proteasome. 
Patients with mutations in this gene have a notable absence of LBs when a homozygous 
deletion is present. When compound heterozygous deletions are noted, LBs have been 
rarely found. This suggests that parkin has a significant role in LBs formation, but that 
neurodegeneration leading to PD can occur without LBs.  
Further support for the role of the UPS in neurodegeneration was provided when 
mutations in UCHL-1 (a gene encoding ubiquitin C-termial hydrolase L1) where 
identified in an apparent autosmal dominant PD family (Leroy, Boyer et al., 1998). The 
protein encoded by this gene has an important role on recycling polyubiquitin chains back 
to monomeric ubiquitin. However, the evidence for this mutation as a cause of PD is 
weak. 
 
1.5.2. Mitochondrial dysfunction and oxidative stress 
Mitochondrial involvement in the pathogenesis of PD began to be studied with the 
observation that exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), an 
herbicide and contaminant of illicit street drugs, caused symptoms matching those of PD 
in human substance abusers and in animal models (Burns, Chiueh et al., 1983; Langston, 
Ballard et al., 1983). MPTP is metabolized to 1-methylphenylpyridinium (MPP+) by the 
monoamine oxidase B (MAO-B) in glial cells. MPP+ is subsequently selectively taken up 
by dopaminergic terminals and concentrated in neuronal mitochondria, where it inhibits 
complex I of the respiratory chain leading to an inhibition of ATP synthesis and the 
generation of free radicals (Volles, Lee et al., 2001). Additional support for 
mitochondrial dysfunction in PD pathogenesis comes from evidence that the insecticides 
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such as rotenone and paraquat, induce a conformational change in α-synuclein and 
significantly accelerate the rate of formation of fibrils in vitro (Uversky, Li et al., 2001). 
A parkinonian-like syndrome in animal models with protein deposits that resemble LBs 
was seen when the animals were exposed to widely-used herbicide paraquat (Mccormack, 
Thiruchelvam et al., 2002). These chemicals also inhibit mitochondrial complex I, and 
dopamine neurons seem to be most severely affected (Nicklas, Vyas et al., 1985; Ramsay 
and Singer, 1986).  
As briefly noted above, inhibition of complex I can lead to the depletion of ATP levels, 
hence impairing all ATP-dependent cellular processes, and augmenting the production 
and accumulation reactive oxygen species (ROS) that cause oxidative stress. There is 
evidence of oxidative stress in postmortem PD brains, showing elevated levels of lipid 
peroxidation markers and nitrated proteins within the SNC and LBs (Ilic, Jovanovic et 
al., 1999; Agil, Duran et al., 2006).  
The preferential loss of nigral neurons in PD has been attributed to the highly oxidative 
intracellular environment within dopaminergic neurons. Metabolism of dopamine either 
by monoamine oxidase or by auto-oxidation leads to the production of free radicals and 
other ROS that, along with those created from the respiratory chain failure, can lead to 
both modifications of proteins and depletion of intracellular glutathione (GSH), a potent 
molecular antioxidant and an essential cofactor for the glutathione peroxidase family of 
enzymes. Reduced levels of glutathione and oxidized glutathione are indeed the earlier 
markers of nigral cell loss in PD brains. Interestingly, ROS species target the respiratory 
chain itself, resulting in further damage to the cell. 
Javier Simón Sánchez  Introduction 
 23
Identification of mutations in genes encoding the mitochondrial protein pink1, and a 
protein directly related to mitochondrial function, dj-1, in familial autosomal recessive 
PD (Bonifati, Rizzu et al., 2003; Valente, Abou-Sleiman et al., 2004), further support a 
primary role of oxidative stress in PD.  
 
 
1.6. ETIOLOGY OF PD 
 
1.6.1. Environmental versus genetic factors 
Whether genetic factors are related to the appearance of PD has been an area of much 
discussion. The idea that there was little or no genetic contribution to the etiology of the 
disease was supported by a series of twin studies in the 1980s that failed to demonstrate 
significantly higher concordance of PD in monozygotic versus dizygotic twins. 
(Duvoisin, Eldridge et al., 1981; Ward, Duvoisin et al., 1983; Eldridge and Ince, 1984; 
Ward, Duvoisin et al., 1984). This, along with striking results from epidemiological 
studies linking PD to environmental causes such as viral infection or neurotoxins, 
strengthened the idea that genetic factors contributed little to the etiology of PD. Part of 
this latter evidence was driven by the 1918’s pandemic influenza associated with post-
encephalic PD, pointing to viral infection as a major cause for PD. This association 
seemed so strong that it lead some authors to establish that PD would disappear as a 
clinical entity (Poskanzer and Schwab, 1961; Lipczynska-Lojkowska, 1979). 
Other facts supporting the theory that environmental factors are critical in the etiology of 
PD, was the observation that drug users in the 1980s exposed to 1-methyl-4-phenyl-
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1.2,3,6-tetrahydropyridine (MPTP) developed parkinsonian-like features (Davis, 
Williams et al., 1979; Langston, Ballard et al., 1983). This work lead to intense scrutiny 
of neurotoxins, including pesticides, as possible causes of PD. Some epidemiological 
studies have found that pesticide exposure was associated with a high risk of PD 
(Semchuk, Love et al., 1992; Seidler, Hellenbrand et al., 1996; Liou, Tsai et al., 1997; 
Gorell, Johnson et al., 1998; Uversky, Li et al., 2001; Petrovitch, Ross et al., 2002). 
However, these reports have not been consistent and structured prospective 
epidemiological studies are underway to establish the role of such factors. 
Since all these reports were published, data on the familial aggregation of PD is still 
conflicting. In 1990 Johnson et al (Johnson, Hodge et al., 1990), reexamined twin studies 
performed in the early 1980s (Duvoisin, Eldridge et al., 1981; Ward, Duvoisin et al., 
1983; Eldridge and Ince, 1984; Ward, Duvoisin et al., 1984) and argued that since nearly 
80% of the function of dopaminergic neurons of the SN must be lost before symptoms 
occur, reliance on clinical diagnosis alone and lack of follow up, makes a determination 
of concordance extremely insensitive. In 1992 Burn and collaborators used positron 
emission tomography to measure 18fluorodopa uptake (18F-dopa PET) into basal ganglia 
for the diagnosis of preclinical dysfunction of the SN (Burn, Mark et al., 1992). 
Concordance rate amongst monozygotic versus dizygotic twins increased when using this 
methodology. Two consecutive studies performed by Piccini and collaborators further 
supported the idea of inheritance in PD. They first reported that unaffected family 
members of PD patients showed nigrostriatal dopaminergic dysfunction. Later they found 
an increased concordance rate in monozygotic compared to dizygotic twins (Piccini, 
Morrish et al., 1997; Piccini, Burn et al., 1999).  
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Later, by means of case-control studies, positive family history was found to be the 
greatest risk factor for PD next to age (Duvoisin and Johnson, 1992; De Michele, Filla et 
al., 1995; Marder, Tang et al., 1996). In these studies, 10-24% of PD patients were found 
to have a positive family history for the disease. The relative risk in first degree relatives 
of PD patients ranged from 4 to 10. Interestingly, the relative risk among relatives of a 
PD subject, seemed to increase with the number of affected family members (Lazzarini, 
Myers et al., 1994). 
An important step forward in favor of a genetic contribution to the etiology of PD was 
taken with the identification of several families in which PD was inherited in an 
autosomal dominant manner (Waters and Miller, 1994; Payami, Bernard et al., 1995; 
Plante-Bordeneuve, Taussig et al., 1995; Wszolek, Pfeiffer et al., 1995; Golbe, Di Iorio et 
al., 1996; Maraganore, Schaid et al., 1996; Morrison, Godwin-Austen et al., 1996). The 
largest of these families (Golbe, Di Iorio et al., 1990) was a kindred with autosomal 
dominant Lewy body parkinsonism, originally from Contursi, Italy. As discussed below, 
further genetic analysis identified mutations in SNCA as causative of the disease in this 
family (Polymeropoulos, Lavedan et al., 1997). After this finding, family studies and 
whole-genome linkage analysis have allowed the identification of twelve more loci 
related to the appearance of different variants of the disease, eight of which have been 
identified to be following classical Mendelian inheritance patterns (table 1). Although 
these cases account only for 5% of the total PD cases, they have generated considerable 
interest because understanding their pathology may help to understand the molecular 
basis of sporadic PD.  
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1.6.2. Mendelian variants of PD 
To date there is strong evidence linking six genes to Mendelian forms of PD with both, 
autosomal dominant (SNCA, PARK1, OMIM #168601 and PARK4, OMIM #605543; 
LRRK2, PARK8 OMIM #607060) and autosomal recessive PD (PRKN, PARK2 OMIM 
#602544; PINK1, PARK6 OMIM #605909; DJ-1, PARK7 OMIM #606324; ATP13A2, 
PARK9 OMIM #606693). All these loci are referred as PARK loci because patients with 
mutations in these genes have clinical features overlapping with those of idiopathic PD 
(table 1).  
 
 
 
• SNCA, PARK1 and PARK4: As previously noted, Golbe and colleagues (Golbe, Di 
Iorio et al., 1990) , identified a kindred with autosomal dominant Lewy body 
parkinsonism, originally from Contursi (Italy) that emigrated to New Jersey/New York in 
1905. This was the largest PD family characterized thus far, and consisted of at least 60 
affected members in four generations. Apart from a relative paucity of tremor, younger 
onset (~ 46 years) and long disease course, there were not major clinical features that 
differed from idiopathic PD. Linkage analysis of this family performed by Polymeropulos 
PARK loci Origin Gene Chromosome Form of PD Age at onset 
PARK1 Italy SNCA 4q21 AD 40s 
PARK2 Japan PRKN 5q25.2-q27 AR 20-40 
PARK3 Europe Unknown 2p13 AD 60s 
PARK4 Iowa SNCA 4q21 AD 30s 
PARK6 Italy PINK1 1p35-p36 AR 30-40 
PARK7 Europe DJ-1 1p36 AR  30-40 
PARK8 Japan LRRK2 12q12 AD ∼ 60 
PARK9 Jordan, Italy and Brazil ATP13A2 1p36 AR, Kufor-Rakeb 20-40 
Table 1: Genetic causes of Parkinson’s disease. AD, autosomal dominant; AR, autosomal recessive; J, juvenile; YOPD, early-onset PD. 
Javier Simón Sánchez  Introduction 
 27
and colleagues in 1996 (Polymeropoulos, Higgins et al., 1996), mapped the disease to 
chromosome 4q21-q23. As this region was the first to be related to PD, it was given the 
designation of PARK1. Among the candidate genes in that region, SNCA (Gene: SNCA, 
Protein: α-synuclein) was one of the best candidates. This 140 aminoacid protein was a 
neuron-specific presynaptic membrane protein originally identified because it encodes the 
NACP peptide (non-Amyloid-β component of Alzheimer’s disease amyloid plaques) 
precursor. Sequencing analysis of this gene, identified a heterozygous G>A transition at 
position 209 of exon 4 (A53T) in this family. A group of three apparently unrelated 
Greek families were later identified as carrying the same mutation. Since it was found in 
three unrelated PD kindreds and it was absent in 314 chromosomes from control 
European samples (200 from an area near Contursi) it was defined as causative of the 
disease (Polymeropoulos, Lavedan et al., 1997). Later, two other point mutations in this 
gene (A30P and E46K) were identified to be responsible for autosomal dominant PD in a 
German (Kruger, Kuhn et al., 1998) and a Spanish kindred (Zarranz, Alegre et al., 2004). 
α-synuclein is expressed in the central nervous system and is the major component of 
LBs and Lewy neurites (Spillantini, Schmidt et al., 1997). Although it has an unknown 
function it has been suggested to be related to synaptic plasticity, neuronal differentiation, 
axonal and synaptic vesicles transport and molecular chaperone activity. It is thought that 
SNCA mutations may promote PD pathogenesis by accelerating LBs formation through 
the α-synuclein fibril formation. Thus, it has been shown in vitro that the A53T and 
A30P mutations accelerate α-synuclein fibril formations. However, the fibrilization 
caused by A30P mutation is slower (Conway, Harper et al., 1998). Although little work 
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on the E46K mutation has been performed to date, the pathology in these cases suggests 
that E46K mutation would have an effect on fibril formation.  
Singleton and colleagues in 2003 (Singleton, Farrer et al., 2003), gave an exciting 
breakthrough on the understanding of the pathology of PD with the discovery of a 
genomic triplication of the wild type form of SNCA in an family with autosomal 
dominant early-onset parkinsonism with dementia, known as the Iowa kindred (Waters 
and Miller, 1994). This locus is usually referred as PARK4 because the disease was 
initially linked to another region on chromosome 4p (Farrer, Gwinn-Hardy et al., 1999). 
The study by Singleton and colleagues (Singleton, Farrer et al., 2003) not only suggested 
that increased expression in wild-type α-synuclein might enhance the risk of developing 
PD but also that the actual level of wild type protein might determine disease onset. It has 
been shown that SNCA triplication, which occurs in the Iowa family, causes a doubling 
in the amount of α-synuclein in blood (Miller, Hague et al., 2004). 
These results were consistent with haplotype data suggesting that genetic variability in the 
SNCA promoter contributes to the risk of developing PD. Thus, several groups (Kruger, 
Vieira-Saecker et al., 1999; Tan, Matsuura et al., 2000; Farrer, Maraganore et al., 2001) 
reported a significant association of a dinucleotide polymorphism (NACP-rep1) in the 
promotor region of SNCA with PD compared to healthy controls in a white population 
from Europe and America. Similar results were obtained in Asian populations (Mizuta, 
Nishimura et al., 2002; Tan, Tan et al., 2003; Tan, Chai et al., 2004). These publications, 
along with those showing that these alleles increase α-synuclein expression (Chiba-Falek 
and Nussbaum, 2001; Chiba-Falek, Touchman et al., 2003; Chiba-Falek, Kowalak et al., 
2005), support evidence that mutant α-synuclein behaves differently from the wild-type 
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protein in a quantitative rather than qualitative manner. While other groups did not find 
such an association in different cohorts (Parsian, Racette et al., 1998; Izumi, Morino et 
al., 2001; Khan, Graham et al., 2001; Holzmann, Kruger et al., 2003; Spadafora, Annesi 
et al., 2003), meta analysis at all studies showed a robust association (Mellick, 
Maraganore et al., 2005). 
The earlier triplication report (Singleton, Farrer et al., 2003) promoted several groups to 
screen for similar mutations in other PD pedigrees. In 2004 Farrer and colleagues 
described SNCA multiplication in one out of forty two familial Swedish-American 
probands with early-onset parkinson they assayed (Farrer, Kachergus et al., 2004). That 
same year, duplications in SNCA were described in families with clinical phenotypes 
resembling that of idiopathic PD (Chartier-Harlin, Kachergus et al., 2004; Ibanez, Bonnet 
et al., 2004). The results from these reports lead to the conclusion that the severity of the 
disease is affected directly by the dosage effect according to the gene copy number. 
Therefore, SNCA duplication appears to cause a disease similar to idiopathic PD, whereas 
SNCA triplication causes a disorder that ranges clinically and neuronpathologically from 
PD to diffuse LB disease with a earlier age at onset (Singleton and Gwinn-Hardy, 2004). 
Efforts to identify SNCA copy number changes in normal sporadic PD cases have largely 
failed, concluding that SNCA multiplications are not a common cause of PD (Johnson, 
Hague et al., 2004).  
Although in vivo data corroborate the hypothesis that elevated levels of α-synuclein might 
be deleterious to dopaminergic neurons (Masliah, Rockenstein et al., 2000; Lo Bianco, 
Ridet et al., 2002), the underlying mechanism by which this occurs remains to be 
identified. Of potential relevance to this matter is the work of Cuervo et al. (Cuervo, 
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Stefanis et al., 2004) showing that certain species of α-synuclein impair degradation 
machinery in the cell, resulting in a toxic gain-of-function effect caused by the 
accumulation of damaged and misfolded proteins.  
 
• PRKN, PARK2: Mutations in PRKN are the most common cause of Autosomal 
Recessive Juvenile Parkinsonism (AR-JP). AR-JP as a clinically defined entity has been 
studied for decades, primarily in Japan (Yamamura, Sobue et al., 1973; Yamamura, 
Arihiro et al., 1993; Takahashi, Ohama et al., 1994; Ishikawa and Tsuji, 1996). It is 
defined as a kind of parkinsonism with age at onset before 40 years, foot dystonia at 
onset, hyperreflexia of the lower limbs, diurnal fluctuations, slow progression of the 
disease, good levodopa response and early onset levodopa-induced dyskinesias. Although 
according to this description it is clinically distinguishable from idiopathic PD, some 
molecular-genetics-based studies suggested that these features are not locus-specific but 
more frequent in AR-JP than in idiopathic PD (Klein, Pramstaller et al., 2000; Lucking, 
Durr et al., 2000).  
Since impairment of the function of mitochondrial respiratory chains had been reported in 
PD (Mizuno, Ohta et al., 1989; Schapira, Cooper et al., 1989; Hattori, Tanaka et al., 
1991), a causal relationship between the inhibition of respiratory chain functions and the 
release of superoxide anions within mitochondria was reported (Hasegawa, Takeshige et 
al., 1990; Guidot, Mccord et al., 1993), Mn-superoxide dismutase is inducible by these 
released anions (Hassan, 1988), and increased activity of this enzyme had been reported 
in SN of PD patients (Saggu, Cooksey et al., 1989); thus a possible role of this protein in 
PD was suspected. By linkage analysis of a diallelic polymorphism witin the Mn-
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superoxide dismutase gene (SOD2), Matsumine and colleagues, found a family with AR-
JP showing perfect segregation of the disease with the SOD2 locus (Matsumine, Saito et 
al., 1997). By extending the linkage analysis to thirteen families with AR-JP, they 
discovered strong evidence for the localization of the AR-JP gene at chromosome 6q25.2-
27, including the SOD2 locus. However, sequence analysis of the SOD2 coding region 
did not reveal any causative mutation. These results were confirmed a year later in 
several families with distinct ethnic backgrounds (Jones, Yamamura et al., 1998). Further 
analyses, with additional markers in this region, allowed them to construct a detailed 
genetic map of the linked region which localized the AR-JP locus to a 6,9 cM region 
within this chromosome band, excluding SOD2. Since a high proportion of families with 
different ethnicity were found to have linkage to this AR-JP locus, it was established as a 
common locus for early-onset Parkinsonism (Tassin, Durr et al., 1998).  
In 1998, Kitiada and collaborators (Kitada, Asakawa et al., 1998) investigated a small 
chromosomal deletion in a Japanese AR-JP patient, previously described by Matsumine’s 
group (Matsumine, Yamamura et al., 1998). By positional cloning within this deletion, 
they isolated a 2,960 bp cDNA with a 1,395-base-pair open reading frame, encoding for a 
465 aminoacid protein with moderate similarity to ubiquitin at the amino terminus and a 
RING-finger motif at the carboxy terminus. The gene spanned more than 500 kb and had 
12 exons, five of which were deleted in that particular patient. The gene was named 
PARK2/PRKN and the encoded protein parkin.  
Parkin is an E3 Ubiquitin-Protein ligase (Shimura, Hattori et al., 2000; Zhang, Gao et al., 
2000) with a ubiquitin-like domain (32% identity to Ubiquitin) at its N-terminus end, and 
two RING finger motifs separated by a cysteine-rich region known as IBR (in Between 
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Ring) at its C-terminus end. E3 ligases are part of the cellular machinery that target 
proteins with ubiquitin molecules for their degradation in the proteasome. 
As extensively reviewed (Giasson and Lee, 2001; Ciechanover and Brundin, 2003), this 
ubiquitin–proteasome system (UPS) plays a major role in many vital cellular processes, 
and its dysfunction has been implicated in the pathogenesis of neurodegenerative 
disorders. Ubiquitin is a 76 aminoacid protein that is covalently linked to the lysine side 
chain of a substrate. This is called ubiquitination and occurs through three sequential 
steps catalyzed by ubiquitin-activating (E1), ubiquitin-conjugating (E2) and ubiquitin-
ligase (E3) enzymes. By repeating this process, additional ubiquitin molecules are linked 
to a previously linked ubiquitin resulting in the formation of a polyubiquitin chain. Poly-
ubiquitinated proteins are recognized by the 26S proteasome, a protein complex with 
proteolitic activity, for their degradation into peptide fragments. The 19S cap subunit 
(located on both ends of a central 20S subunit) recognizes the polyubiquitin chain, 
removes it and cleaves it into single ubiquitin monomers with deubiquitinating enzymes 
such as ubiquitin C-terminal hydrolase L1 (UCH-L1). Afterwards it unfolds the targeted 
protein and feeds it into the inner chamber of the 20S subunit. There, the target protein is 
proteolyticaly cleaved into small peptides that are released to the cytosol. It is easy to 
hypothesize how a failure in parkin (E3 ubiquitin-protein ligase), may avoid some 
proteins to be properly degraded causing dysfunction and eventually the death of certain 
neurons. Several groups have focused their research on identifying different parkin 
substrates. Thus CDCrel-1, Synphilin-1, glycosilated α-synuclein, Pael-Receptor, a-
Tubulin/b-Tubulin, Synaptogamin XI, p38, WSEPT5_v2/CDCrel-2 and Cyclin E has 
been proposed as putative parkin substrates (Zhang, Gao et al., 2000; Chung, Zhang et 
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al., 2001; Imai, Soda et al., 2001; Shimura, Schlossmacher et al., 2001; Choi, Snyder et 
al., 2003; Corti, Hampe et al., 2003; Huynh, Scoles et al., 2003; Ren, Zhao et al., 2003; 
Staropoli, Mcdermott et al., 2003). 
Since the first mutation was identified in PRKN (Kitada, Asakawa et al., 1998) a 
multitude of mutations have been described: deletions of single or multiple exons, 
duplications or triplications of exons, frameshift mutations, point mutations (both 
missense and nonsense mutations) and splice site (intronic) mutations (Abbas, Lucking et 
al., 1999; Lucking, Durr et al., 2000; West, Periquet et al., 2002; Mata, Alvarez et al., 
2005). A comprehensive review of 42 articles (those published between 1998 and 2003) 
on the identification of parkin mutations revealed a total of 95 different mutations 
including 40 exon rearrangements (26 deletions and 14 multiplications), 43 single base 
pair substitutions and 12 small deletions or insertions of one or several base pairs. The 
most common mutations were deletions of exon 4, exon 3, exons 3 and 4, a point 
mutation in exon 7 (c.924C>T), and a single base pair deletion in exon 2 (255/256delA). 
These five alterations account for 35% of all PRKN mutations described thus far 
(Hedrich, Eskelson et al., 2004). 
Whether heterozygous PARK2 mutations are involved in the development of late-onset 
autsomal dominant PD is still a field of much discussion. Thus, some groups have 
reported heterozygous Late-onset-PD-cases-mutation carriers in families with parkin 
mutation. A good example is a Brazilian kindred reported by Khan and colleagues (Khan, 
Horta et al., 2005). In this family, an affected family member is identified to carry a 
heterozygous deletion in exon 4 of PARK2. Interestingly, another sibling who possessed 
an identical PARK2 haplotype by descent was unaffected. The authors argued that this 
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supported the idea that genomic variation elsewhere or environmental influence, might be 
interacting with the single deletion to cause disease, although clearly it could also suggest 
no causal relationship of disease. Besides this report, several have been published 
showing PARK2 mutations in late-onset PD cohorts. Klein and collaborators described 
two affected female individuals carrying a heterozygous deletion in heterozygous state in 
late onset PD patients, concluding that this gene may be important in the etiology of the 
more frequent late-onset typical Parkinson's disease (Klein, Pramstaller et al., 2000). 
Oliveira et al showed that heterozygous mutations, especially in exon 7, trended to a later 
age at onset than compound heterozygotes and homozyogtes, concluding that 
heterozygous mutations in PARK2 act as susceptibility alleles for late-onset PD (Oliveira, 
Scott et al., 2003) . Similar results were later obtained by other groups (Foroud, Uniacke 
et al., 2003; Schlitter, Kurz et al., 2006).  
Conversely, several groups concluded after their experiments that PARK2 is not involved 
in the pathogenesis of late-onset PD, either familial or sporadic. Oliveri and collaborators 
(Oliveri, Zappia et al., 2001) failed to find any PARK2 mutation in 23 patients from 18 
families with autosomal recessive late-onset PD and 95 patients with sporadic late-onset 
PD. However, since they did not perform dosage analysis, their results are incomplete. 
Beside this “incomplete” report, some groups failed to find any association between 
heterozygous mutations in PARK2 and late-onset PD (Lincoln, Maraganore et al., 2003; 
Munhoz, Sa et al., 2004; Poorkaj, Moses et al., 2005; Kay, Moran et al., 2007). 
 
• PARK3: In 1998 Gasser and colleagues mapped PD to a 10.3 cM region within 
chromosome 2p13 in 6 families with autosomal dominant PD that clinically resembled 
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typical sporadic PD (Gasser, Muller-Myhsok et al., 1998). The mean age of onset ranged 
from 54 to 63 years and LBs were present. No further neurological deficit was observed 
except for dementia, which was prominent in several affected individuals. Results from 
F-Dopa-PET and J-IPT-SPECT scanning further supported the diagnosis of typical PD. 
Further analysis of genetic markers within this 10.3 cM region showed that two of 
families supporting linkage to this locus, shared a common haplotype segregating with 
the disease. This haploype covered an interval of 3.2 cM and was given the name of 
PARK3. Although no genealogical link was found between these two families, the 
ancestors of both of them originate from neighboring regions of southern Denmark and 
northern Germany. This finding may indicate the existence of a founder mutation which 
might also be present in other PD cases from the same area. In 2001, in order to narrow 
down the shared haplotype in these two families, West and colleagues (West, Zimprich et 
al., 2001), genotyped 17 microsatellite markers on chromosome 2p13 in all available 
family members. They managed to refine the disease locus to a 2.5 Mb region within 
chromosome 2p13. Sequencing of all 14 genes contained in that area failed to find any 
causative mutation. In 1999 Klein and collaborators (Klein, Vieregge et al., 1999), 
evaluated patient and control population from northern Germany for those markers in 
chromosome 2p13. They found that more controls than PD patients shared the presumed 
full or partial haplotype with affected members of the previously described two families. 
Therefore, the putative founder mutation on chromosome 2p13 appears to be a rare cause 
of sporadic or familial PD in patients from southern Denmark/northern Germany. In 2002 
DeStefano and colleagues (Destefano, Lew et al., 2002), performed a genomewide scan 
using 103 multiplex families and identified four regions with evidence of linkage to PD. 
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One of these regions was on chromosome 2, coinciding with the location of PARK3 
locus. In addition to evidence of linkage, they also observed association between a 
specific allele of a marker within PARK3 locus and the age at onset of PD. Given this 
association they focused on this marker when typing additional individuals and observed 
both an increase in the lod score value and a decrease in the P value. These results 
suggest that this marker is in linkage disequilibrium with a putative causative mutation or 
a factor influencing age of onset in these families. In 2003 Karamohamed and colleagues 
(Karamohamed, Destefano et al., 2003), defined a smaller haplotype containing three 
SNPs associated with onset age containing the sepiapterin reductase gene (SPR). Pankratz 
et al. in 2004 (Pankratz, Uniacke et al., 2004), performed genome-wide linkage analysis 
over families with two or more members having a reported age at PD onset and identified 
several chromosomal regions linked to the age at onset, including one overlapping with 
PARK3 locus. Although the gene containing mutations that cause this variant of PD has 
not yet been described, this locus seems to be related to the age at onset. Until mutations 
are identified, this should be considered as a putative PARK locus. 
 
• PINK1, PARK6: Valente and collaborators on 2001 (Valente, Bentivoglio et al., 
2001), identified a family (the Marsala kindred) for which linkage to PARK2 was 
excluded. After performing homozygosity mapping, they identified a second locus for 
AR-JP (PARK6) on the short arm of chromosome 1 (1p35-p36). They mapped a 12.5 cM 
region containing a large number of both genes and predicted transcripts. 
In order to assess the role of PARK6 in parkin-negative AR-JP in Europe, the same group 
performed linkage analysis in 28 European AR-JP families in which PARK2 mutations 
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had been excluded (Valente, Brancati et al., 2002). Multipoint analysis in 8 families 
showing evidence of linkage to PARK6 and the subsequent haplotype analysis, refined 
the PARK6 locus to a 9 cM region on chromosome 1p35-p36. Hatano and colleagues in 
2004 (Hatano, Sato et al., 2004), found five Asian families with linkage to PARK6, 
indicating that this form of parkinsonism is not limited to European countries. 
That same year, Valente and collaborators identified a consanguineous Spanish family 
with linkage to PARK6 locus. This family presented a recombination event that narrowed 
the candidate area to 3.7 cM. Further SNPs mapping and new short tandem repeat 
markers, allowed them to define a 2.8 Mb region of homozygosity containing 40 genes. 
Sequence analysis of candidate genes in affected members from each of the described 
consanguineous families, led to the identification of two homozygous mutations in the 
PTEN-induced putative kinase 1 gene (PINK1): G390D in the Spanish family and 
W4370PA in both Italian families (Valente, Abou-Sleiman et al., 2004). PINK1 contains 
eight exons spanning 1.8 kilobases and encodes a 581 aminoacid protein. The transcript is 
ubiquitously expressed and is predicted to encode a 34 aminoacid mitochondrial targeting 
motif and a highly conserved protein kinase domain that shows a high degree of 
homology to the serine/threonine kinases of the Ca2+/calmodulin family. The mutations 
they described occurred in the serine/threonine kinase domain and thus, putatively 
affected the kinase activity or substrate recognition. They hypothesized that pink1 might 
phosphorylate mitochondrial proteins in response to cellular stress, protecting against 
mitochondrial dysfunction.  
Six novel pathogenic mutations in exons 3, 4, 5 and 6, in six unrelated families from 
different countries in Asia where described that same year by Hatano and colleagues 
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(Hatano, Li et al., 2004). These results indicate that pathogenic mutations in PINK1 are 
not limited to Europeans.  
To further evaluate the pathogenic role of PINK1 in early-onset PD and to find a the 
correlation between genotype and phenotype, Valente and collaborators (Valente, Salvi et 
al., 2004), performed PINK1 mutation analysis in 100 AR-JP. Two of them carried two 
mutations in PINK1, one homozygous and the other a compound heterozygous carrier. 
Interestingly, five sporadic cases carried heterozygous missense changes in PINK1. This 
supports the idea of heterozygous PINK1 mutations being a risk factor for the appearance 
of sporadic PD. 
Further mutation screenings in different populations, identified a three-nucleotide 
insertion in PINK1 (Klein, Djarmati et al., 2005) and a homozygous four-base insertion 
(Rohe, Montagna et al., 2004). Several mutations has been described since (Bonifati, 
Rohe et al., 2005; Klein, Djarmati et al., 2005; Hedrich, Hagenah et al., 2006; Ibanez, 
Lesage et al., 2006; Leutenegger, Salih et al., 2006; Tan, Yew et al., 2006). PINK1 
mutations account for approximately 1 to 7% of AR-JP in Caucasians (Healy, Abou-
Sleiman et al., 2004a; Rohe, Montagna et al., 2004; Valente, Salvi et al., 2004), about 
8.9% in Japanese AR-JP families (Li, Tomiyama et al., 2005), and 2 to 3% in sporadic 
and familial PD of Chinese origin (Tan, Yew et al., 2005; Tan, Yew et al., 2006). 
The clinical phenotype in families with homozygous PINK1 mutations are similar to 
those in PARK2-positive cases with an early onset of disease (later than PARK2-positive 
cases), excellent and sustained response to L-dopa, slow progression, frequent L-dopa-
induced motor fluctuations and dyskinesias. However, distinguishing features at onset 
such as dystonia, sleep benefit, or psychiatric disturbances, are absent. 
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• DJ-1, PARK7: Duijn and colleagues, linked PD in a consanguineous family to 
chromosome 1p36 (Van Duijn, Dekker et al., 2001). After saturating the region with 
additional markers and performing multipoint linkage analysis, they mapped the disease 
in this family to a 16 cM region in chromosome 1p36, 25 cM away from PARK6 locus. 
This locus was given the name of PARK7. 
In four families with early-onset parkinsonism from Italy, Uruguay and the Netherlands, 
Bonifati and colleagues found two with linkage to PARK7 (Bonifati, Breedveld et al., 
2002). Fine mapping reduced the critical region to a 5.6 Mb region, containing 90 genes. 
Sequencing of obvious candidate genes did not reveal any mutation in either of the two 
families analyzed. By means of systematic screening of transcripts in the region, they 
found a 14,082 bp homozygous genomic deletion in DJ-1 segregating with the disease on 
the Dutch family (Bonifati, Rizzu et al., 2003). Sequencing of the DJ-1 cDNA revealed a 
homozygous point mutation in the Italian family. That same year, Hague and colleagues 
(Hague, Rogaeva et al., 2003) found a frameshift and a splice site mutation in a 24 year 
old hispanic woman with PD. 
Abou-Sleiman et al (Abou-Sleiman, Healy et al., 2003) studied the prevalence of DJ-1 
mutations (including the 14,082 bp deletion previously reported) in a large cohort of PD 
patients. They found a homozygous missense mutation and a compound heterozygous 
mutation in two early onset PD patients. In addition, five other heterozygous variants 
were identified in patients with a later age of onset PD. This suggests either that these DJ-
1 variants are non-causal or that, as previously discussed, mutations in AR-JP-related 
genes in a heterozygous state, confer susceptibility for later onset PD. The reported 14 Kb 
deletion was not found in any of the samples assayed. 
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Since the proportion of AR-JP families with DJ-1 mutations was still unknown, Ibanez et 
al (Ibanez, De Michele et al., 2003) evaluated its frequency in a large set of 
consanguineous and non-consanguineous families with AR-JP, not linked to PARK2. No 
mutations were found in either of the families assayed. Hedrich’s group (Hedrich, 
Djarmati et al., 2004) also failed on finding any homozygous DJ-1 mutations in the 
cohort they studied. However, two carriers of single heterozygous mutations, including a 
heterozygous deletion of exons 5 to 7 and an 11 base pair deletion were found. Since 17 
cases of these same cohort harbored mutations in PARK2, the authors concluded that 
mutations in DJ-1 are less frequent than mutations in PARK2 in AR-JP. 
In aggregate several groups concluded that DJ-1 mutations are a very rare cause of early 
onset PD. (Hague, Rogaeva et al., 2003; Clark, Afridi et al., 2004; Healy, Abou-Sleiman 
et al., 2004c; Lockhart, Bounds et al., 2004; Lockhart, Lincoln et al., 2004; Tan, Tan et 
al., 2004).  
DJ-1 encodes a 189 aminoacid highly conserved protein that belongs to the DJ-
1/ThiJ/PfpI superfamily. Crystal structure analyses revealed that, at least in vitro, DJ-1’s 
native structure is a homodimer (Moore, Zhang et al., 2003). Its distribution is mainly 
cytoplasmatic with a slight proportion localized in the mitochondria (Zhang, Shimoji et 
al., 2005). It appears to have several cell functions, such as RNA stabilization and 
protection against oxidative stress. DJ-1 can also directly act against Reactive Species of 
Oxygen (ROS) such as hydrogen peroxide, which he can eliminate by auto-oxidation 
means (Taira, Saito et al., 2004). However its function remains unclear and further 
studies are needed. The clinical symptoms in these patients seem to be similar to those 
found in parkin families with a later age at onset and a slower progression of the disease. 
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• LRRK2, PARK8: In 1997, a family with autosomal dominant PD, was reported in 
Sagamihara City, Japan. Clinical features of this family did not differ from common PD, 
however, the loss of melanin-containing cells was mild to moderate, the number of 
neurons of the locus ceruleus was maintained and LBs were not detected (Hasegawa and 
Kowa, 1997). Five years later, Funayama and colleagues (Funayama, Hasegawa et al., 
2002) performed genome-wide linkage analysis over this family and mapped the disease 
to a 13.6 cM interval of chromosome 12p11.23–q13.11. This region (PARK8) contained 
116 genes or predicted transcripts. Later, Paisan-Ruiz and coworkers (Paisan-Ruiz, Saenz 
et al., 2005), identified 4 families from the Basque region in northern Spain with 
symptoms clinically compatible with idiopathic autosomal dominant PD. After 
confirming linkage to PARK8 locus, they narrowed this susceptibility locus to a 9.35 cM 
region containing 75 genes and predicted transcripts. Sequence analysis of genes and 
predicted open frames in that region showed that all four Basque families carried a very 
rare allele within one of the candidate genes (KIF21A), indicating that these families were 
ancestrally related. Genotyping of several SNPs flanking this allele, allowed them to 
define a minimum haplotype shared by all the affected members in all four families 
spanning 2.6 Mb (11genes). By means of direct sequencing, they found a segregating 
mutation (R1441G) within a putative kinase domain containing transcript, 
DKFZp434H2111. Moreover, the change Y1699C was found within the same predicted 
transcript in an English kindred analyzed. At that same time Zimprich and colleagues 
identified four missense mutations and a putative splice site mutation in two large 
German-Canadian and Nebraskan families with autosomal dominant late-onset PD 
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previously linked to PARK8 locus by Zimprich and coworkers in 2004 (Zimprich, Biskup 
et al., 2004; Zimprich, Muller-Myhsok et al., 2004).  
The protein encoded by this predicted transcript belongs to the ROCO complex protein 
family (Bosgraaf and Van Haastert, 2003). It contains an armadillo and ankyrin repeat 
region, a leucine-rich repeat domain, a kinase domain, a ROC (Ras On Complex) GTPase 
domain, a COR domain (C-terminal Of ROC) and a WD40 domain. The gene was given 
the name of LRRK2 and the encoded protein dardarin, from the Basque word meaning 
tremor. Several mutations have been reported to date. By means of segregation analysis, 
six mutations have been proven to be pathogenic: I1122V, R1441C, R1441G, Y1699C, 
G2019S, and I2020T (Mata, Wedemeyer et al., 2006). One of them, G2019S (Kachergus, 
Mata et al., 2005), is the most prevalent and has been found at frequencies of more than 
2% in general North American clinical population and English PD Brain Bank 
specimens. Early studies have quoted the prevalence of G2019S to be about 5 to 6% for 
familial and 1 to 2% for apparently sporadic cases of PD (Di Fonzo, Rohe et al., 2005; 
Gilks, Abou-Sleiman et al., 2005; Skipper, Shen et al., 2005; Tan, Shen et al., 2005). 
However subsequent studies have shown that this frequency depends on the ethnicity of 
the cohorts tested being at remarkably high frequencies in clinic-based Portuguese, 
Ashkenazi Jewish, and North African Arabian patients, even in the absence of a clear 
family history of disease (Bras, Guerreiro et al., 2005; Lesage, Durr et al., 2006; Ozelius, 
Senthil et al., 2006; Ferreira, Guedes et al., 2007b). Interestingly, a neurologically 
healthy octogenarian with the LRRK2 G2019S mutation has been reported, suggesting 
that environmental epigenetic and other genetic factors may be implicated in expression 
of the disease phenotype (Kay, Kramer et al., 2005). 
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• ATP13A2, PARK9: In 1994 Al-Din and co-workers (Najim Al-Din, Wriekat et al., 
1994), reported an unusual neurological syndrome in an Arab family with five affected 
siblings. The affected subjects had clinical signs and symptoms of severe parkinsonism 
but the age at onset was early (11-16 years) and the disease was rapidly progressive. 
Additional features of these affected individuals were spasticity resulting from 
corticospinal tract degeneration, supranuclear up gaze paresis, and the development of 
dementia. They also showed significant atrophy of the globus pallidus and the pyramids, 
as well as generalized brain atrophy in later stages. Therapy with levodopa resulted in 
significant improvement in extrapyramidal dysfunction. Since there were multiple 
affected sibilings born from phenotypically normal consanguineous parents, an autosomal 
recessive inheritance was suggested. This syndrome was given the name of Kufor-Rakeb 
Syndrome (KRS), since this was the name of the village were the individuals were 
originally from. By means of autozygosity mapping, a common region of homozygosity 
in all affected subjects on chromosome 1p was identified (Hampshire, Roberts et al., 
2001).The disease was fine mapped to a 9 cM region on chromosome 1p36. In 2006, two 
different compound heterozygous mutations were found in ATP13A2 within a Chilean 
family with autosomal-recessive PD that resembled the original KRS. A 22 bp 
duplication leading to a frameshift that causes a stop codon, was found in all affected 
members of the original Kufor-Rakeb syndrome family (Ramirez, Heimbach et al., 
2006).  
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1.6.3. Other genetic factors related to PD 
In addition to these genes, candidate sequencing analysis and whole-genome linkage 
approaches have suggested a relationship between other genes and PD. We briefly 
mention some of these here: 
 
• UCH-L1, PARK5: Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) is one of 
the most abundant proteins in the brain and it has been found in LBs (Lowe, Mcdermott 
et al., 1990). It belongs to a family of deubiquitinating enzymes, and its role is to 
hydrolyze small C-terminal adducts of ubiquitin to generate ubiquitin monomers. Thus it 
is a perfect candidate gene to be implicated on the ethiology of PD. In 1998 Leroy and 
collaborators (Leroy, Boyer et al., 1998), sequenced the coding region of UCHL-1 in 
probands from 72 families with PD, and identified a missense mutation (I93M) in the 
fourth exon of UCHL-1 in a German pedigree. They showed that this mutation caused a 
partial loss of the catalytic activity of the protease which could lead to aberrations in the 
proteolytic pathway and aggregation of proteins. Mutation analysis of the affected brother 
showed that he also carried this mutation. In both patients the phenotype was that of 
idiopathic PD with a slightly younger age at onset. The father of the affected sibling was 
not diagnosed with PD, indicating incomplete penetrance of this mutation in this family. 
Whether the I93M mutation is truly pathogenic is still an area of controversy. To date, no 
further mutations have been observed in follow-up studies (Harhangi, Farrer et al., 1999; 
Lincoln, Vaughan et al., 1999; Maraganore, Farrer et al., 1999; Wintermeyer, Kruger et 
al., 2000; Shi and Tao, 2003). Thus, on a pure genetic basis, the evidence of this mutation 
as a cause of PD is very weak. 
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In 1999 Lincoln and colleagues (Lincoln, Vaughan et al., 1999), failed to find any 
mutations in UCH-L1 in familial and sporadic PD. However they described a coding 
polymorphism (S18Y) within this gene. That same year, Maraganore and colleagues 
reported that S18Y is underrepresented in PD in European population, thus indicating a 
protective effect. Again, lot of controversy has been reported around this issue. Besides 
Maraganore’s report several groups have supported the protective effect of S18Y 
(Wintermeyer, Kruger et al., 2000; Satoh and Kuroda, 2001; Momose, Murata et al., 
2002; Facheris, Strain et al., 2005; Tan, Puong et al., 2006; Carmine Belin, Westerlund et 
al., 2007). On the other hand, several studies failed on finding any association between 
S18Y and PD (Mellick and Silburn, 2000; Zhang, Hattori et al., 2000; Levecque, Destee 
et al., 2001; Savettieri, De Marco et al., 2001; Wang, Zhao et al., 2002; Elbaz, Levecque 
et al., 2003). Interestingly, two of these studies (Wang, Zhao et al., 2002; Elbaz, 
Levecque et al., 2003) showed a protective effect when analysis was restricted to early 
onset PD patients. 
Given this controversy, Maraganore et al performed a collaborative pooled analysis of all 
the association studies performed to date (the original plus 10 additional studies) to 
determine whether S18Y is actually associated with PD (Maraganore, Lesnick et al., 
2004). This meta-analysis confirmed an inverse association between S18Y variant and 
PD, particularly in younger subjects. However, although association findings were 
positive overall, they only considered one polymorphism. It is possible that this variant is 
only a marker for genetic association of PD with another UCH-L1 variant or a variant 
within another gene.  
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Tan and colleagues (Tan, Puong et al., 2006) believed that independent replication in 
Asian cohorts would further contribute to the debate of the protective effect of S18Y 
variant in PD. Thus, they performed a large case-control study of the UCHL-1, 
confirming the protective effect of S18Y against PD amongst the younger Chinese 
subjects. 
 
• NR4A2: This gene encodes a member of the steroid-thyroid hormone-retinoid 
receptor superfamily called Nurr1. Encouraged by the fact that Nurr1 is critical for the 
midbrain dopaminergic cell development and survival, Xu and coworkers targeted it for a 
case-control association study they performed in 2002 (Xu, Liang et al., 2002). As a 
result they found that the homozygous form of an insertion in intron 6 of this gene is 
significantly higher in both familial and sporadic PD compared to a control population. 
Although no statistically significant association was reported between the heterozygous 
form of this polymorphism and PD, Zheng and colleagues found it increased in both 
sporadic PD and diffuse Lewy Bodies disease (Zheng, Heydari et al., 2003). That same 
year, two heterozygous mutations within the non-coding 5′-untranslated region of the 
gene was reported in 10 familial cases were reported. These mutations were verified to 
reduce the level of Nurr1 mRNA, implying a dominant negative effect of the mutated 
allele (Le, Xu et al., 2003) 
Although these results were encouraging, no further mutations have been found in several 
follow-up reports (Carmine, Buervenich et al., 2003; Tan, Chung et al., 2003; 
Wellenbrock, Hedrich et al., 2003; Zimprich, Asmus et al., 2003; Hering, Petrovic et al., 
2004; Ibanez, Lohmann et al., 2004; Levecque, Destee et al., 2004; Nichols, Uniacke et 
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al., 2004), leading to the speculation by some authors that Nurr1 does not play a role in 
Parkinson’s disease (Hering, Petrovic et al., 2004). 
 
• PARK10: Hicks and collaborators (Hicks, Petursson et al., 2002) using a 
genomewide scan in Icelandic patients with classic late-onset PD, found linkage to 
chromosome 1p32. The authors designated this locus PARK10. Later that same year, Li 
and collaborators (Li, Scott et al., 2002) on the first genome screen for age at onset for 
both AD and PD, found linkage for PD on a region overlapping with PARK10. Although 
different traits were studied, these two studies provided strong evidence that there may be 
one or more genes of interest (PARK10 or an age at onset gene) in this region. 
Interestingly, Li’s group, has recently nominated ELAVL4 to be affecting age at onset in 
PD (Noureddine, Qin et al., 2005). The gene maps 2 Mb from the age at onset linkage 
peak on chromosome 1p32. Haugarvoll and colleagues (Haugarvoll, Toft et al., 2007), 
suggested that the association of this gene, might be explained by a celtic founder effect. 
Thus, they used Norwegian and Irish case–control series, as well as a US series, to 
examine association between ELAVL4 markers and age at onset or susceptibility to PD. 
Association was found between two markers and susceptibility to PD only in the Irish 
cases.  
Oliveira et al (Oliveira, Li et al., 2005) tested for association genes after a combined gene 
expression and linkage data, these included genes in PARK10 (Li, Scott et al., 2002). The 
eukaryotic translation initiation factor 2B3 gene (EIF2B3) showed the strongest 
association with age at onset of PD, and the HIV type 1 enhance-binding protein 3 gene 
(HIVEP3) was the only significant gene associated with the risk of developing PD. 
Javier Simón Sánchez  Introduction 
 48
Following this, Maraganore and colleagues (Maraganore, De Andrade et al., 2005) in 
their two-tiered, whole-genome association study for PD, found that the two SNPs with 
the lowest P values tagged the PARK10 late-onset PD susceptibility locus. These two 
SNPs were within LOC200008 (now CUB Domain Containing Protein 2, CDCP2) which 
encodes a protein with inferred oxidoreductase activity and potential involvement in 
cholesterol biosynthesis and electron transport. They also found association between 
HIVEP3 and PD. 
Three recent follow-up studies failed to find any significant association between CDCP2 
and different PD cohorts. (Farrer, Haugarvoll et al., 2006; Goris, Williams-Gray et al., 
2006; Li, Rowland et al., 2006). 
Considering that all the studies performed thus far had focused on unrelated cases-control 
samples, Li et al. (Li, Deng et al., 2007) increased the density of SNPs within HIVEP3 
and CDCP2 and expanded the study to a familial dataset. They concluded that HIVEP3, 
but not CDCP2, is a strong candidate gene associated with the risk of developing PD. As 
they did not find significant association with the age at onset in this cohort, they proposed 
the possibility that two different genes regulate age at onset and risk on developing PD in 
this region.  
 
• PARK11: Pankratz et al (Pankratz, Nichols et al., 2002), in an attempt to identify 
genes contributing to PD, undertook a genome-wide linkage analysis in a large sample of 
American sibling pairs. Under two different models of PD affection status the highest 
LOD score values were obtained on chromosome X and chromosome 2. After including 
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additional individuals in this cohort, evidence of linkage to a 20 cM region of 
chromosome 2q36-37 was reported (Pankratz, Nichols et al., 2003). 
Prestel and colleagues (Prestel, Sharma et al., 2005) , failed to replicate Pankratz’s results 
in an European population. In the whole-genome association study performed by 
Maraganore’s group (Maraganore, De Andrade et al., 2005), one of the SNPs with the 
lowest p values, tagged that region on chromosome 2q36-37. 
Genome-wide linkage analyses such as those performed by Scott and Hicks did not find 
linkage at this locus (Scott, Nance et al., 2001; Hicks, Petursson et al., 2002). 
 
• PARK12: As noted previously, Pankratz et al. in their two-model genome-wide 
linkage analysis (Pankratz, Nichols et al., 2002) obtained the strongest evidence of 
linkage on chromosome X. These results were confirmed after they expanded the sample 
to 754 affected individuals , consisting of 425 sibling pairs from 362 families (Pankratz, 
Nichols et al., 2003). Previous studies had noted linkage to this same locus (Scott, Nance 
et al., 2001; Hicks, Petursson et al., 2002). 
An interesting candidate gene in this chromosomal region may be in the locus for sex-
linked dystonia with parkinsonism (XDP), a disease identified at high incidence in Panay, 
Philippines. See below. 
 
• X-linked recessive dystonia with parkinsonism: X linked recessive dystonia with 
parkinsonism (XDP) is a movement disorder unique to adult Filipino men whose ancestry 
can be traced to Panay Island, Philippines. It is characterized by severe, progressive 
torsion dystonia, with parkinsonian features occurring later in the disease course. The 
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syndrome was first noted in 1970 and referred to as “dystonia musculorum deformans”, 
Lee et al (Lee, Pascasio et al., 1976), where the first on publishing an unusually high 
frequency of torsion dystonia in Panay, the sixth largest island in Philippines. Pedigree 
analysis of the 28 reported cases revealed six families with several members affected. No 
male to male transmission occurred, suggesting x-linked recessive transmission. In 
addition, it was noted that some patients had parkinsonian features and relatives with 
parkinsonism. Fahn et al confirmed the coexistence of dystonia and parkinsonism in XDP 
in these cases and called the disease “lubag” based on the local term used to describe the 
abnormal movemen (Fahn, 1988).  
In 1990 Kupke et al (Kupke, Lee et al., 1990) performed linkage analysis in seven 
Filipino families, using microsatellite markers within chromosome X. The maximum 
LOD score value was obtained for a marker located at Xq21.3. The locus was later 
refined to chromosome Xq12-13.1 from linkage analyses performed by different groups 
(Wilhelmsen, Weeks et al., 1991; Kupke, Graeber et al., 1992). Mapping of the disease to 
this locus (DYT3) was confirmed afterwards (Graeber, Kupke et al., 1992; Muller, 
Haberhausen et al., 1994). 
Later, by means of a YAC contig construction, they disease was further refined to a 1.8 
Mb region in chromosome Xq13.1 (Haberhausen, Schmitt et al., 1995) and narrowed 
down to <350 kb by Nemeth and colleagues (Nemeth, Nolte et al., 1999). Subsequently, 
Nolte and colleagues used PCR-based sequencing and screening analyses to report four 
SNPs and five disease-specific sequence changes in the “Multiple Transcript System” 
within 260 kb of the DYT3 region (Nolte, Niemann et al., 2003). Since PCR often fails to 
find large sequence variants such and brain specimens were not included in this analysis, 
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Makino and collaborators performed complete genomic DNA sequence of that region and 
detailed expression analysis of the gene in brain specimens obtained from patients with 
XDP. Their results suggest that SVA retrotransposon insertion into TAF1 may cause 
XDP by altering the expression of taf1 isoforms (Makino, Kaji et al., 2007). 
 
• Omi/HtrA2, PARK13: This gene was first linked to neurodegeneration when Gray 
and collaborators (Gray, Ward et al., 2000) showed that Omi/HtrA2 interacts with 
presenilin-1, previously related to young-onset inherited forms of Alzheimer’s disease 
(Sherrington, Rogaev et al., 1995). Further support for a role of Omi/HtrA2 in 
neurodegeneration came when Park and coworkers demonstrated that Amyloid-β, a key 
factor implicated in the pathogenesis of Alzheimer’s disease, is directly and efficiently 
cleaved by the Omi/HtrA2 serine-protease activity both in vitro and in vivo (Park, Seong 
et al., 2004). In addition Jones and colleagues (Jones, Datta et al., 2003) found a missense 
mutation (p.S276C) in the protease domain of Omi/HtrA2 of the mouse mutant mnd2 
(motor neuron degeneration 2). Loss of neurons in the striatum resulting in a 
neurodegenerative disorder with parkinsonian features was described in OMI/HTRA2- 
knockout mice (Martins, Morrison et al., 2004); these findings lead Strauss and 
colleagues to look for mutations in OMI/HTRA2 in a large sample of 518 German PD 
(Strauss, Martins et al., 2005). They identified two novel mutations in the Omi/HtrA2 
gene that resulted in defective activation of the protease activity of the protein codified by 
this gene in vitro. Moreover, these mutations induced mitochondrial dysfunction 
associated with altered mitochondrial morphology that made the cells more susceptible to 
stress-induced cell death than wild-type. These results provide a novel link between 
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mitochondrial dysfunction and neurodegeneration in PD. Interestingly, they also found 
this protein as a component of LBs in idiopathic PD patients. 
 
• Association with Gaucher’s disease: Gaucher disease (GD) is a lipid storage 
disorder due to the inherited deficiency of the lysosomal enzyme acid β-glucosidase due 
to mutations in the β-glucocerebrosidase gene (GBA). There are three subgroups within 
the GD phenotype: Type 1(OMIM #230800), 2 (OMIM #230900) and 3 (OMIM 
#231000). GD type 1 is the most common and least severe variant and has not been 
associated with neurological manifestations. Type 2 is a rapidly progressive disorder with 
death before the first year of life. Type 3 has a varying degree of systemic involvement as 
well as at least one neurological manifestation. This is not a strict classification scheme 
and particular cases can cross boundaries. Several GD type 1 cases have been reported to 
develop parkinsonian symptoms  (Vanbogaert L, 1939; Sack, 1980; Mckeran, Bradbury 
et al., 1985; Sun, 1986; Turpin Jc and Boutry Jm, 1987; Cormand, Vilageliu et al., 1995; 
Tylki-Szymanska, Millat et al., 1996). However, the first publication to clearly report the 
coexistence of PD with type 1 GD in six cases, was that by Neudorfer in 1996 
(Neudorfer, Giladi et al., 1996). These subjects suffered from relatively mild GD 
symptoms but with early onset and L-dopa refractory parkinsonian manifestations 
including tremor, bradykinesia, rigidity, and often cognitive decline. Analysis of the GBA 
gene in 57 autopsy-confirmed PD cases with broad age of onset identified 8 mutation 
carriers (Lwin, Orvisky et al., 2004). In 2005 association between GBA mutation and PD 
was reported, suggesting that heterozygous mutations in GBA might be a very rare cause 
of PD (Sato, Morgan et al., 2005). 
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The way mutations in this gene might lead to the development of PD is not known. 
However, a hypothesis would be that misfolding of aberrant glucocerebrosidase may 
affect lysosomal targeting and proteasome function, predisposing to synucleinopathies, 
leading to improper degradation of α-synuclein and contribute to aggregate formation 
(Lwin, Orvisky et al., 2004), has also been reported.  
 
• Relationship between SCA2/SCA3 and PD: Autosomal dominant spinocerebellar 
ataxias (SCAs) were first described at the end of the 19th century. (Brown, 1892; Marie, 
1893; Babinski, 1899). The phenotype was investigated in detail by Schut (Schut, 1950) 
and subclassifications were attempted by Greenfield (Greenfield, 1954) and Harding 
(Harding, 1983). 
Orozco et al. described a large cohort from the Holguin province in Cuba with autosomal 
dominant ataxia (Orozco, Estrada et al., 1989). Linkage to SCA1 locus was excluded in 
this population, providing the first evidence of locus heterogeneity for this disorder 
(Auburger, Diaz et al., 1990). Three years later the disease-causing locus was mapped to 
a 30 cM region in chromosome 12q23-q24.1 (Gispert, Twells et al., 1993). This region 
was narrowed down 2 years later thanks to he linkage results obtained by Hernandez and 
collaborators over 11 families from the same geographical region (Hernandez, Magarino 
et al., 1995). Moreover, their haplotype analysis results were consistent with the 
hypothesis of a founder effect of SCA2 mutations in Holguidn province in Cuba. 
Pulst et al. (Pulst, Nechiporuk et al., 1993) identified an Italian pedigree with linkage to 
chromosome 12q. In contrast with the Cuban pedigree, this one showed a remarkable 
degree of anticipation of age at onset. Given that (CAG)n triplet expansion had been 
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identified in ATXN-1 (Orr, Chung et al., 1993), they proposed that something similar 
could be underlying the disease in this pedigree. This was confirmed when a 150 Kda 
protein in a patient linked to SCA2, using an antibody that identifies only extended 
polyglutamine tracts, was detected (Trottier, Lutz et al., 1995). They latter found (CAG)n 
repeats in a novel gene (ATXN-2) encoding ataxin 2 (Pulst, Nechiporuk et al., 1996). 
Given that anticipation had been described on familial parkinsonism (Payami, Bernard et 
al., 1995) and that probands with parkinsonism had been reported in families linked to 
SCA2 (Gwinn-Hardy, Chen et al., 2000; Shan, Soong et al., 2001), Payami and 
collaborators decided to look for ATXN-2 mutations in patients with parkinsonism in 
which family history had been reported (Payami, Nutt et al., 2003). They found two 
probands with expanded CAG alleles of ATXN-2.  
On the other hand, Kawaguchi and collaborators, found 68-69 CAG expansions within 
ATXN-3 in patients diagnosed with Machado-Joseph disease (MJD) (Kawaguchi, 
Okamoto et al., 1994). In 2001, encouraged by the fact that parkinsonism had previuolsy 
been reported as the predominant clinical feature of some variants of MJD patients 
(Tuite, Rogaeva et al., 1995), Gwinn-Hardy and colleagues successfully screened for 
(CAG)n trinucleotide repeats in a large black family with apparent autosomal dominant 
PD (Gwinn-Hardy, Singleton et al., 2001). 
These results together, supported the hypothesis that some forms of parkinsonism with 
anticipation, may be caused by trinucleotide expansions. Several studies have further 
supported the hypothesis that ATXN-2 and ATXN-3 expansion mutations may be a cause 
of disease in patients with a history of parkinsonism. (Shan, Soong et al., 2001; Furtado, 
Farrer et al., 2002; Ragothaman, Sarangmath et al., 2004; Wilkins, Brown et al., 2004; 
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Simon-Sanchez, Hanson et al., 2005; Lim, Zhao et al., 2006; Modoni, Contarino et al., 
2007). 
 
• Microtubule-Associated Protein Tau: One of the regions giving the highest lod 
score in the genomic screen for PD Scott and collaborators performed (Scott, Nance et 
al., 2001), was on chromosome 17q21. This region contains the gene encoding 
Microtubule-Associated Protein Tau (MAPT). Tau is a neuronal microtubule-associated 
protein that plays a central role in microtubule assembly and maintenance. Pathological 
accumulations of tau, known as neurofibrillary tangles, characterize a number of 
tauopathic conditions, including AD, PSP, corticobasal degeneration, prion diseases, and 
amyotrophic lateral sclerosis/parkinsonism-dementia complex (Conrad, Andreadis et al., 
1997; Bennett, Bonifati et al., 1998; Baker, Litvan et al., 1999; Bonifati, Joosse et al., 
1999). 
Mutations in MAPT have been found to cause familial variants of frontotemporal 
dementia (Clark, Poorkaj et al., 1998; Hutton, Lendon et al., 1998; Poorkaj, Bird et al., 
1998; Spillantini, Murrell et al., 1998). Besides, there is a strong association between 
common variants in MAPT and cortical basal degeneration, Pick’s disease, PSP and AD. 
(Conrad, Andreadis et al., 1997; Conrad, Vianna et al., 2002; Zhukareva, Mann et al., 
2002). 
Pastor and colleagues first studied MAPT in a cohort of PD patients and controls (Pastor, 
Ezquerra et al., 2000). They reported association of a dinucleotide polymorphism (A0) 
with PD compared with controls. These results were confirmed in a meta-analysis 
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performed by Golbe and coworkers that included all the studies published thus far 
(Golbe, Lazzarini et al., 2001).  
Martin and colleagues in 2001 (Martin, Scott et al., 2001) underwent a positional 
association study utilizing many of the families they used in their former PD whole 
genome linkage screen (Scott, Nance et al., 2001). They found that the H1 haplotype, 
previously reported to be related to PSP (Baker, Litvan et al., 1999), was associated with 
PD. They also found allele A0 to be significantly overrepresented, and A3 to be 
underrepresented in PD patients. Kwok and colleagues (Kwok, Teber et al., 2004) 
identified a series of biallelic variants in the promoter region of the MAPT gene, which 
were in complete linkage disequilibrium and are part of haplotypes H1 and H2. They 
showed that the H1 promoter haplotype, which is the strongest at initiating transcription, 
is significantly overrepresented in idiopathic PD patients compared with normal controls, 
suggesting that increased MAPT expression confers susceptibility for PD. This suggested 
that tau protein levels are an important factor in the cause of idiopathic PD. They also 
looked for recombination events between the promoter haplotypes and the coding region 
ones. Their data strongly suggested that the promoter haplotypes form part of an extended 
haplotype with the entire MAPT gene. Since then, those polymorphisms defining H1 
haplotype have been investigated for an association with PD with conflicting results. Two 
meta-analyses support an association between haplotype H1 and PD (Healy, Abou-
Sleiman et al., 2004b; Zhang, Song et al., 2005). 
Besides association studies, other studies support the involvement of tau in PD 
pathogenesis. Hence, there is evidence that tau can co-aggregate with α-synuclein in LBs 
(Ishizawa, Mattila et al., 2003) and that these two proteins interact to promote and 
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propagate the polymerization of each other into fibrils (Ishizawa, Mattila et al., 2003). In 
addition, tau aggregation has been seen in AR-JP caused by parkin gene mutations (Mori, 
Kondo et al., 1998). 
 
•  Apoliporotein E: Apolipoprotein E is a polymorphic protein, highly expressed in the 
brain (APOE, chromosome 19q13.2). There are three major isoforms: ε2, ε3 and ε4. 
Since the ε4 isoform is a very well known genetic risk factor for familial and sporadic 
AD (Corder, Saunders et al., 1993; Saunders, Schmader et al., 1993), several studies have 
been published about a possible association between APOE and PD. Most have reported 
no association between ε4 and the development of PD itself or dementia in PD patients 
(Arai, Muramatsu et al., 1994; Marder, Maestre et al., 1994; Rubinsztein, Hanlon et al., 
1994; Ibarreta, Gomez-Isla et al., 1995; Poduslo, Riggs et al., 1995; Helisalmi, 
Linnaranta et al., 1996; Whitehead, Bertrandy et al., 1996; Bon, Jansen Steur et al., 1999; 
Kruger, Vieira-Saecker et al., 1999; Li, Hauser et al., 2004). However, in a meta-analysis 
performed by Huang and colleagues (Huang, Chen et al., 2004), an association between 
ε2 carriers and sporadic PD was found. This had been previously prompted by Harhangi 
and collaborators (Harhangi, De Rijk et al., 2000).  
The effect of APOE variants on age of onset of PD has also been investigated. Thus, 
Zareparesi and colleagues (Zareparsi, Camicioli et al., 2002) presented data that 
suggested that patients with ε3/ε4 and ε4/ε4 genotypes had an age at onset much earlier 
that those with ε3/ε3 genotype. Moreover, they saw a trend of earlier onset of PD in ε2/ε3 
patients than in ε3/ε3. Interestingly, Maraganore et al (Maraganore, Farrer et al., 2000) 
had previously described an earlier age at onset of those PD patients with the ε2/ε3 APOE 
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genotype. Hoewver, this is still a controversial issue (De La Fuente-Fernandez, Sellers et 
al., 1998; Inzelberg, Schechtman et al., 2002; Parsian, Racette et al., 2002; Li, Hauser et 
al., 2004; Pankratz, Byder et al., 2006). APOE has also been related to other features 
related with PD like appearance of drug-induced hallucination or psychosis along the 
course of PD (De La Fuente-Fernandez, Nunez et al., 1999; Goetz, Burke et al., 2001; 
Feldman, Chapman et al., 2006). 
 
1.6.4. Genome-wide association studies (GWAS) and PD. 
Although six monogenic forms of PD have been identified, ∼ 95% of the PD cases are 
apparently sporadic variant in which both genes and environmental risk factors are 
thought to play an important role. In this variant of the disease, genetic variability, unlike 
that causing familial disease, refers to common variants more or less extended in normal 
population and only exerting adverse or protective effects when appearing in combination 
with other genetic or environmental factors. This grouping into two apparently separate 
variants does not imply that these two types of the disease should be considered as 
different entities. In fact, because of the clinical and pathological similarities existing 
between familial and non-monogenic PD, knowledge of the genes causing the familial 
disease could bring new ideas for the research of sporadic forms of the disease.  
Before the advent of GWAS the search for genetic variants that alter risk for disease was 
dominated by candidate gene association studies, usually focused on genetic variants that 
altered the coding sequence of a gene. Generally, positive associations would be reported 
and negative associations, unless a refutation of a previous report would go largely 
unpublished. Genuine success required sufficient understanding of the disease process to 
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allow selection of the correct gene, the right variants to type within the gene and most 
importantly the presence of variability within the gene that altered function/expression. If 
we assume there are ~30,000 genes and a couple of million common variants, the odds 
are clearly stacked against being successful. GWAS attempts to solve this inherent bias 
by offering association across the entire genome, including both regions containing genes 
and those between genes. This approach has been made possible by three primary 
developments. The first, the inception and execution of the International Haplotype Map 
Project (http://www.hapmap.org), a study designed to catalog and correlate genetic 
variability in the genome in a population specific manner (Frazer, Ballinger et al., 2007). 
This project allows the use of SNP genotypes to infer genotype information about 
neighboring SNPs; thus a large proportion of the information content in several million 
SNP variants can be inferred using a smaller set of several hundred thousand informative 
tagging SNPs. The second is the development of reliable high-throughput genotyping 
methodologies, which allow cost-effective typing of millions of SNP loci in parallel. The 
third is the existence of repositories harboring DNA from well-characterized cases and 
controls. This is especially relevant in case of heterogeneous disorders such as 
Parkinson’s or Alzheimer’s disease, in which many clinical phenotypes have been 
described. A good example of such a repository is the NINDS-funded Coriell Institute for 
Medical Research, which banks DNA from subjects with a variety of diseases as well as 
controls (http://ccr.coriell.org/). The intersection of these three developments allows the 
application of genome wide SNP association studies to understand the genetic basis of 
complex disease. 
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Given the technical demands, it was not until 2002 that the first whole-genome 
association study was published (Ozaki, Ohnishi et al., 2002). In this study, by means of 
genotyping 92,788 gene-based SNPs, they identified a candidate locus on chromosome 
6p21 associated with susceptibility to myocardial infarction. Three years later 
Maraganore and colleagues performed the first whole-genome association study for PD 
(Maraganore, De Andrade et al., 2005). On tier 1 of their study, they genotyped 198,345 
uniformly spaced SNPs in 443 sibling pairs discordant for PD. Those SNPs that presented 
a P value below 0.1 (1,793) were genotyped in 332 case-control unrelated pairs (tier 2a). 
This way they found 11 SNPs associated with PD. The lowest combined P value was 
found on a SNP located on a gene encoding a protein with an important role on 
neurogenesis and neural apoptosis, SEMA5A. A second SNP was located at the PARK11 
locus. They also performed a tier 2b in which they genotyped SNPs with borderline P 
values but located in biologically interesting targets. This way, the SNP with lowest P 
value was found at the PARK10 locus. 
In genetic research, almost as important as an initial description of an association 
between a certain trait and a location in the genome related to that trait, is the replication 
of that particular finding. Although the results obtained by Maraganore’s group appeared 
to be exciting, several groups have failed to confirm these findings in different cohorts 
(Clarimon, Scholz et al., 2006; Elbaz, Nelson et al., 2006; Farrer, Haugarvoll et al., 2006; 
Goris, Williams-Gray et al., 2006; Li, Rowland et al., 2006). The results from these 
studies, along with the fact that SNCA (the most common causes of PD) was not 
identified in Maraganore’s experiments (Maraganore, De Andrade et al., 2005), were 
both disappointing and discouraging. However, since sporadic PD is likely caused by an 
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interaction of genetic and environmental risk factors, the chances of discovering a 
causative gene, depends on its relative effect on disease risk (penetrance) and the 
frequency of the disease-associated allele. Thus, a larger number of both PD cases and 
control subjects would allow minimizing the bias created by this phenomenon. 
An interesting point extracted from Perez-Tur comment in 2006 (Perez-Tur, 2006), is that 
related to data sharing. Since we are about to witness an explosion in the number of 
genome-wide association studies aimed at uncovering genetic variability related to 
common diseases, implementation of an open access policy regarding the availability of 
data to all researchers, is important. This way, other groups are allowed to interpret data 
produced in a different way, possibly selecting groups of patients on the basis of certain 
clinical characteristics and selecting genotypes within specific genes in order to perform 
independent association studies.  
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2. OBJECTIVES 
 
As can be observed from this introduction, PD is a very heterogeneous disorder in which 
genetic factors play an important role. In the last 12 years, six distinct genetic loci have 
unequivocally been linked with familial forms of PD, and several others related to both 
sporadic and familial forms of the disease.  
In the current study we aim to identify the responsible genetic factors representing a 
risk of PD in both familial and sporadic forms of parkinsonism. To achieve this 
purpose different strategies have been utilized including family-based and population 
approaches in both single genomic locations and genome-wide. 
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3. METHODS 
 
3.1. GENETIC ANALYSIS OF PARK8-LINKED PARKINSON’S DISEASE 
PATIENTS. 
 
3.1.1. Basque late-onset PD families 
DNA samples were collected from PD patients with a positive family history of late onset 
PD. All patients were examined by Drs. Jose Félix Martí-Massó and Dr. Angel Martinez 
Gil. A total of 4 families were identified, of which 3 presented PD with a mode of 
inheritance clearly resembling apparent autosomal dominant disease (UGM03, UGM05 
and UGM06). Limited genealogical information in the fourth family (UGM04), did not 
allow assignment of any particular mode of inheritance. DNA samples from a total of 75 
individuals (15 affected and 60 unaffected) were collected, all belonging to one of these 
four families (figure 6). Age at onset in all four families ranged from 50 to 80 with an 
average of 61. Disease duration is known for only 2 of the four families, UGM03 and 
UGM05, with mean disease duration of 18 and 10 years respectively. All affected 
members respond well to L-Dopa (table 2). 
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Figure 6: Families UGM003, UGM004, UGM005 and UGM006. Affected members are shaded, 
and those whose DNA was available are denoted by a plus sign.
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Kindred Person Gender Age at onset Initial Symtom Response to L-Dopa Duration (years) Disease complications 
III:1 F 62 Leg tremor, clumsiness Good response 18 Dyskinesias, falls 
III:10 F 66 Unilateral tremor Good response 22 Dyskinesias and motor oscillations 
III:12 F 80 Unilateral tremor, severe gait disorder Good response 9 
Dyskinesias, motor oscillations 
and severe gait disorder 
III:16 F 69 Unilateral hand tremor Good response 7 
Dyskinesias and motor 
oscillations 
III:18 F 69 Gait disorder clumsiness Good response 10 
Dyskinesias and motor 
oscillations 
IV:7 F 51 Unilateral tremor Good response 17 Dyskinesias and motor oscillations 
UGM03 
IV:27 M 51 Unilateral tremor Good response 5 - 
II:3 F 59 Unilateral tremor Good response 5 - 
II:5 F 67 Unilateral leg tremor Good response 4 - UGM04 
II:7 F 63 Unilateral tremor Good response 5 - 
II:14 M 57 Clumsiness, unilateral tremor Good response 2 - 
III:1 M 58 
Global clumsiness, 
unilateral tremor, 
foot dystonia 
Good response 7 - 
III:2 M 58 
Unilateral 
clumisiness, 
unilateral tremor, 
foot dystonia 
Good response 2 - 
UGM05 
III:4 F 60 Unilateral tremor Good response 11 Severe gait disorder 
III:1 M 65 Unilateral leg tremor Good response 17 Dyskinesias and motor oscillations 
III:2 M 60 Unilateral leg tremor Good response 6 - 
III:5 M 62 Clumsiness, unilateral tremor Good response 14 Dyskinesias 
III:6 F 60 Unilateral leg tremor Good response 12 Dyskinesias, motor oscillations, gait ignition failure 
UGM06 
III:7 F 60 Unilateral leg tremor Good response 7 - 
Table 2: Summary of clinical features of affected members of autosomal dominant PD from families UGM3, UGM4, UGM5 .and UGM6.
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3.1.2. Minimal haplotype shared by UGM03, UGM04, UGM05 and 
UGM06. 
After linkage analysis showing linkage to PARK8 was performed in these four families 
(Paisan-Ruiz, Saenz et al., 2005) and a large kindred from the United Kingdom (Khan, 
Jain et al., 2005), identification of a rare polymorphism within KIF21A in three of the 
four Basque families suggested that they were ancestrally related and might share a 
minimal interkindred disease haplotype. In order to define this common minimum 
haplotype, 23 SNPs were selected from the region with strongest linkage to PD in these 
families (D12S331 to D12S1668). These SNPs were selected from dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) choosing those most likely to be 
informative. In order to maximize our ability to obtain phase, all available family 
members were genotyped. 
These SNPs were genotyped by means of PCR amplification and direct sequencing 
(primer sequences shown in table 3). To ensure maximum accuracy on these SNPs 
genotypes, these assays were performed twice by two differnts researchers (Coro Paisán-
Ruiz and Javier Sim´n Sánchez). Amplification of each SNP was carried out with 
Eppendorf’s Taq DNA polymerase using a Mastercycler thermal cycler 
(http://www.eppendorf.com) as shown below: 
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Taq DNA Polymerase:………………….. 0.15 μl 
Primer F (20 μM):…………………....……1.5 μl 
Primer R (20 μM): ……………….…...…..1.5 μl 
dNTP mix (10μM)…………….……..……1.5 μl 
10x PCR Buffer: ……………...….…...…….5 μl 
H2O: ……………………………...…….40.85 μl 
DNA (20 ng/μl): ……………………....……1 μl 
 
 
SNP ID Forward primer (5'-3') Reverse primer (5'-3') 
rs1523118 TAACTGATCTGTATGTGAAAGC TGTGTACAGGATTCTGCTTG 
rs11169992 AAAATATCTAGTTCTTTTCC CATTATAACTATGCCTTGCA 
rs10876410 CTTAGATATGAGCAGGAACAAC TCACCTCCAGTCAACTATCAG 
rs10876646 GACAGAGATTCAAACCCAAG GAAATGCTTATCATAGGATT 
rs10876876 CATTGTGAAAATTAAGTGAG TTGCATGCTGAGAAATTTCT 
rs11171789 TATACTAGGACTGCTGATTT AACCACCTAGAAAGAACTCT 
rs10876886 GGAAATAAGCACTAGTCAAGC TGTTGAGAGTACTGTTCCCTG 
rs11172282 TGACAATAGATTAGAATGCAG TTTACTCATACCTAAGGCTG 
rs11172541 ATATTGGGTCACAAGTACTG TTCAAGACAACATGCTAAAT 
rs10877201 GCATATTTGAGTAACTGAGGC TGCACTCGAGAATTATAGCC 
rs4548690 GTCTAATTGCTCTTGCCTTG GTGAACTTGAAAGACGGATATG 
rs7294916 CACAAGAAGGCTTTAGCTG GGGATAGCAGACGTAATTG 
rs4423249 ACATTACTCTGGTGAGAGCC GTAATTTGTCATGGCAGCA 
rs515205 AGTTTAAAGGGATGGACTAG CAAAGGGAGGCTGAATTTAT 
rs515291 CATGCATTATGATACTATTACC GTACTCCAGCCTAGGTGAC 
rs937110 GAAGCCTCTTGGAGTCTATC GTCTTTGCTTCCTTAATATTG 
rs7399259 GTAGAGACGGGGTTTCACCA AATCATGGCAGAAGGCAAAG 
rs4768224 GATACCAGCATTGTGAACATAG CATTTTCCTCAACCATGATG 
rs1820544 CAAGAAATGGCTGTAATCAAG GAAGAGAAAAACAACAGCATG 
rs10784800 CCAATCATCTCCCACCAG GAAGTGTTAAAGAGGCTATGTG 
rs10879192 GCTTAACCCATGTCATTGTC ATTTATTAGCTCTGTGCACAAG 
rs10747736 TGAGGGTAACTTGTTTCACAGC ATGCTTTGGAGGGTCATTTG 
rs12423567 CCTCAGTTTGGTCTGGGAAC GTGTTTAAAGGTGGCTGTGGTC 
rs10784616 GTATTGCCTCTCCTGTTTATGG GGCAAGAATGTTCTGTTGGTAC 
Table 3: Forward and reverse primer sequences used for genotyping 23 SNPs in the region flanked by D12S331 and D12S1668. 
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Thermocycling programs used were 60TD50 for rs10876410, rs11169992, rs10876886, 
rs10877201, rs4548690, rs11171789, rs7294916, rs4426249, rs9371100, rs7399259, 
rs10876876, rs1820544, rs10879192 and rs12423567 (table 4); 57TD52 for rs1523118, 
rs10876646, rs11172282, rs11172541, rs515291 and rs4768224 (table 5); 62x35 for 
rs10784800 and rs10784616 (table 6); and 55x35 for rs10747736 (table 7). 
 
 
 
 
 
 
 
 
 
 
 
 Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 
             
 1 Cycle 8 Cycles 20 Cycles 12 Cycles 1 Cycle 
Temperature 94ºC 94ºC 60ºC 72ºC 94ºC 60ºC 72ºC 94ºC 50ºC 72ºC 72ºC  ºC 
Time 5 min 30 seg 30 seg 45 seg 30 seg 30 seg 45 seg 30 seg 30 seg 45 seg 5 min HOLD 
Temperature 
increase 
0 0 0 0 0 - 0.5ºC 0 0 0 0 0 0 
 Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 
             
 1 Cycle 15 Cycles 10 Cycles 14 Cycles 1 Cycle 
Temperature 94ºC 94ºC 57ºC 72ºC 94ºC 57ºC 72ºC 94ºC 52ºC 72ºC 72ºC  ºC 
Time 5 min 30 seg 30 seg 45 seg 30 seg 30 seg 45 seg 30 seg 30 seg 45 seg 5 min HOLD 
Temperature 
increase 
0 0 0 0 0 - 0.5ºC 0 0 0 0 0 0 
 Stage 1 Stage 2 Stage 3 
       
 1 Cycle 35 Cycles 1 Cycle 
Temperature 94ºC 94ºC 62ºC 72ºC 72ºC  ºC 
Time 5 min 30 seg 30 seg 45 seg 5 min HOLD 
Temperature 
increase 
0 0 0 0 0 0 
Table 5: Thermocycling conditions corresponding to program 57TD52. 
Table 6: Thermocycling conditions corresponding to program 62x35. 
Table 4: Thermocycling conditions corresponding to program 60TD50. 
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 Stage 1 Stage 2 Stage 3 
       
 1 Cycle 35 Cycles 1 Cycle 
Temperature 94ºC 94ºC 55ºC 72ºC 72ºC  ºC 
Time 5 min 30 seg 30 seg 45 seg 5 min HOLD 
Temperature 
increase 
0 0 0 0 0 0 
 
 
PCR products were verified in a 2% agarose-TBE gel with ethidium-bromide, and 
visualized with ultraviolet transillumination. Before loading each PCR product on a gel, 5 
μl were mixed with 6X Orange G Loading Dye Solution (10 mM Tris-HCl (pH 7.6), 
0.15% orange G, 60% glycerol, 60mM EDTA).  
After verification, PCR products were purified with MultiScreen 96-Well Filter Plates 
(Millipore, http://www.millipore.com) following the protocol below: 
 
• Add 80 μl of di H20 to 15 μl of PCR product and transfer to a MultiScreen 96-Well 
Filter Plate. 
• Apply vacuum at 20 inches Hg until wells are dry. 
• Add 20 μl of distilled, deionized H20 (Molecular Grade Water, Mediatech, 
http://www.cellgro.com) to each well containing sample 
• Vortex at 1000 rpm for 10-15 minutes. 
• Collect samples. 
 
Table 7: Thermocycling conditions corresponding to program 55x35. 
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Each purified product was sequenced using thermocycling conditions shown in table 8, 
using the same forward or reverse primers as in the PCR reaction and with Applied 
Biosystems BigDye terminator v3.1 sequencing chemistry as below: 
 
BigDye v3.1:……………………... 0.5 μl 
5x Sequencing buffer:…………….…2 μl 
Primer F or R (5μM) ……………...0.5 μl 
H2O: ……………...….…...………….5 μl 
Purified PCR product: ……………….1 μl 
 
 
 
 
 
 
 
 
Sequencing products were then purified with MultiScreen 96-Well Filter Plates 
(Millipore, http://www.millipore.com) following the protocol below: 
 
• Add 20 μl of Molecular Grade Water to 10 μl of sequencing product and transfer to a 
MultiScreen 96-Well Filter Plate. 
• Apply vacuum at 20 inches Hg until wells are dry. 
 Stage 1 Stage 2 
     
 25 Cycles 1 Cycle 
Temperature 96ºC 50ºC 60ºC 4ºC 
Time 30 seg 15 seg 4 min HOLD 
Temperature 
increase 
0 0 0 0 
Table 8: Thermocycling conditions used for sequencing with Applied Biosystems BigDye terminator v3.1. 
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• Add 20 μl of di H20 to each well containing sample 
• Apply vacuum at 20 inches Hg until wells are dry. 
• Add 20 μl of Molecular Grade Water to each well containing sample 
• Vortex at 1000 rpm for 10-15 minutes. 
• Collect samples. 
 
Purified  sequencing  reactions  were  then  electrophoresed  on  an  ABIPrism 3100 
Genetic Analyzer (Applied  Biosystems,  http://www.appliedbiosystems.com)  and 
analyzed with Staden sequence analysis package (http://staden.sourceforge.net).  
 
3.1.3. Analysis of p.R1441G mutation in a Basque PD cohort. 
Given that p.R1441G was not only found in those families presented in section 3.1.1, but 
also in apparently sporadic cases with Basque ancestry (Paisan-Ruiz, Jain et al., 2004), 
we proceeded to determine its frequency in a larger population from this same region in 
Spain. Thus, blood from 238 individuals was drawn from the clinical practice of three 
public hospitals of San Sebastián. Patients were diagnosed according to the Gelb criteria 
for PD (Gelb, Oliver et al., 1999). All study participants provided their informed consent, 
and the study was approved by the Ethics Committee of the Hospital Donostia (San 
Sebastián). Study participants were classified according to either the presence or absence 
of family history of PD (61 familial patients; 177 sporadic patients). Family history was 
considered positive when at least one first-degree relative of the patient was reported to 
suffer from PD. The information about familial history was obtained from the patients or 
their proxies; thus, it is possible that there may be under-reporting of positive family 
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historty. Unfortunately, it was not possible to analyze the family members of the 
probands; therefore, no estimates of penetrance are provided.  
Since 30% of Guipuzcoa inhabitants (730,000 total inhabitants) do not have Basque 
origin, the ethnicity of patients was assessed during the personal interview. Spanish 
handling of surnames makes it reasonably easy to know immediate ancestry of a patient 
by simply examining his or her surnames. Upon this basis, we classified patients as being 
of Basque descent when at least one of the patient’s surnames was of Basque origin and 
as non-Basques when none of their surnames could be considered as ethnically Basque 
(table 9). 
 
UT: Unilateral tremor. 
 
The presence of the p.R1441G mutation was determined in all cases by the use of allele-
specific PCR (ARMS) (Newton, Graham et al., 1989). This technique allows 
amplification and discrimination of specific alleles or DNA sequence variants at the same 
locus. Specificity is achieved by designing PCR primers so that they partially overlap the 
site of sequence difference between the amplified alleles. For each change, we designed a 
common primer, distal to the tested variant, and two allele-specific primers whose 3’ end 
was specific of the alleles of that locus. For a given variant, each sample is PCR-
amplified in two different PCR reactions containing one of the allele specific primers and 
  Positive familial history  Sporadic 
 
Whole sample Basque origin Non Basque 
Basque Non Basque  Basque Non Basque 
N 238   41 20  117 60 
Mean aget at onset 64.6±10.2 65.4±10.2 63.0±10.3 65.1±10.9 62.3±9.4  65.4±10.0 63.3±10.6 
Sex ratio (% men) 57.7%% 0.544 0.588 0.634 0.75  0.513 0.533 
Years of evolution 8.1±6.4 8.0±6.5 8.4±6.0 6.6±4.9 9.1±7.7  8.4±7.0 8.1±5.4 
UT UT UT UT UT  UT UT Main presenting 
symptom 60.0% 53.6% 66.7% 52.6% 72.7%  63.1% 62.7% 
Table 9: Clinical and demographic characteristics of the analyzed population. 
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the common primer. Absence/presence of the expected band in an agarose-TBE gel 
indicates absence/presence of that particular allele in that sample’s genotype. Thus, if 
only one of the reactions produces a visible band in an agarose-TBE gel, that sample is 
considered as homozygous for the allele recognized by the specific-allele primer used in 
that reaction. Otherwise, if amplification is achieved after both separate reactions, a 
heterozygous genotype is suspected. 
 In this case, this technique was carried out using common primer: hiLRRK2-X31-
ARMS-F (5’-CCTTGTGATTGAATCACCAC-3’) and an allele-specific primer: 
heLRRK2-X31-ARMS-R-C (5’-GTGTCTTTCCCTCAGGCTC-3’), that detects the wild-
type allele, or heLRRK2-X31-ARMS-R-G (5’-GTGTCTTTCCCTCAGGCTG-3’) to 
detect the mutant allele. PCR amplification was carried out with Qiagen’s Taq 
polymerase chemistry (www1.qiagen.com), using the following protocol: 
 
Taq DNA Polymerase:…………….…..…0.08 μl 
hiLRRK2-X31-ARMS-F (20 μM): ……….0.6 μl 
heLRRK2-X31-ARMS-R (20 μM): ……...0.6 μl 
dNTP mix (10 mM): ………………..…….0.6 μl 
10x PCR Buffer:.........................................1.5 μl 
H2O: .......................................................11.92 μl 
DNA (20 ng/μl): ………………..………..0.3 μl 
 
The thermal cycling program used was a 60x27 program, which consists of the steps 
displayed in table 9. 
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After resolving the PCR product on a 2% agarose-TBE gel, a band of 571 bp indicates the 
presence of the allele corresponding to the allele-specific primer used in that reaction. 
Every allele-specific PCR was performed along with both a negative and a positive 
control whose genotype had previously been verified by means of direct sequencing. 
Positive results were also verified by direct sequencing. 
 
3.1.4. Haplotype analysis of Basque p.R1441G carriers. 
To explore the possibility that all mutation carriers inherited their disease allele from a 
common ancestor, the 11 SNPs that defined a common haplotype in our previous study in 
the four Basque families (Paisan-Ruiz, Jain et al., 2004), were directly sequenced after 
PCR amplification in all carriers of p.R1441G (see section 3.1.2 for conditions). 
In order to determine the haplotype frequency in general population, 80 healthy 
individuals from the Basque country and 82 non-Basque Spanish healthy individuals, 
were typed at each SNP. Haplotypes were determined with fast-PHASE (Scheet and 
Stephens, 2006) and HapAnalyzer (http://hap.ngri.re.kr). The standardized coefficients of 
disequilibrium r2 and D’ between all combinations of SNP pairs was calculated using the 
 Stage 1 Stage 2 Stage 3 
       
 1 Cycle 27 Cycles 1 Cycle 
Temperature 94ºC 94ºC 60ºC 72ºC 72ºC ºC 
Time 5 min 30 seg 30 seg 45 seg 5 min HOLD 
Temperature 
increase 
0 0 0 0 0 0 
Table 9: Thermocycling conditions corresponding to program 62x27. 
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EMLD software, developed in the University of Texas by Drs. Huang and Andreson 
(http://cge.mdanderson.org/qhuang/software/pub.htm). 
These Basque controls comprised 46.25% males with mean age at sampling of 68.66 
years (range, 21-87 years) and 52.75% females with a mean age at sampling of 75 years 
(range, 44-89 years). The non-Basque Spanish controls comprised 63,64% males with 
mean age at sampling of 37 years (range, 23-67 years) and 36,36% females with mean 
age at sampling of 42 years (range, 24-67 years). 
In order to determine the copy number of a chromosomal region of individual 01-407 
between SNPs rs937110 and rs10747736, a semiquantitative PCR analysis was 
performed. For this purpose each SNP was amplified along with an endogenous control 
located on the first intron of the MAPK81P1 on chromosome 11p11.2, using fluorescent-
labeled oligonucleotides MAPK8IP1-I1-F (5’-GCAGTGCCTCTTTAATAGGC-3’) and 
MAPK8IP1-I1-R (5’- GTGCAATATCATCCTGGGGA-3’). Fluorescent labels were 
HEX for rs10747736 in its forward primer, TAMRA for rs937110 in its forward primer, 
and FAM for the endogenous control in its reverse primer (primer sequences for 
rs10747736 and rs937110 shown in table 3) 
PCR products were electrophoresed on an ABIPrism 3100 Genetic Analyzer (Applied 
Biosystems) with an internal standard molecular weight (GeneScan 350-ROX; Applied 
Biosystems). Data was analyzed using GeneScan v3.6 (Applied Biosystems) to produce 
electrophoregrams showing the sizes of the peaks in base pairs and areas under the peaks 
representing the amount of PCR product present. To determine gene dosage for each 
amplicon the samples were first compared to the endogenous control on chromosome 
11p11.2 to obtain a ratio. The resulting ration was then compared to the ratio obtained 
Javier Simón Sánchez  Methods 
 76
from a control subject run in parallel. Thus, a ratio of 0.6 or less is indicative of 
heterozygous deletion, a ratio ranging from 0.8 to 1.2 is indicative of normal and ratios 
between 1.2 and 1.8 as heterozygous dupication. 
The number of cycles of these PCR reactions was calculated previously so that when the 
reaction finishes, it is still on the log-linear range of the PCR (see section 3.7.7.2). This 
way, the amount of amplified product is directly proportional to the genomic DNA used 
as a template in the reaction. For this purpose, a control DNA was PCR-amplified in 11 
different reactions for a certain number of cycles ranging from 20 to 40, with the 
thermocycling program shown in table 10. After electrophoresing the amplified products 
on a 10% polyacrylamide gel and resolving with silver staining (protocol below), PCR-
reaction kinetics were calculated with Kodak digital Science 1D v.3.0.1 software (figure 
7). 
The protocol used for silver staining samples electrophoresed on a 10% polyacrilamide 
gel is: 
 
• Cover the gel with fixer solution containing 7.5% of acetic acid, glacial in diH20. This 
solution immobilizes the DNA molecules in the acrylamide gel matrix to avoid 
diffusion and subsequent image blurring. 
• Rock the staining tray continuously on a platform rocker for 5-10 minutes. 
• Following fixation, carefully decant the solution, taking care not to damage the gel or 
touch the gel surface. 
• To wash the gel, cover the gel with diH20  
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• Rock the staining tray continuously on a platform rocker for 2 min. This step removes 
acid and other trace substances that may interfere with staining, and provides a clear 
background to the final stain. 
• Repeat the wash step twice. 
• Cover the gel with fresh formaldehyde solution containing 15% formaldehyde in 
diH20 and gently rock for 5-10 minutes. This treatment is important for stain 
sensitivity and maximum image contrast. 
• Carefully decant solution, taking care not to damage the gel or touch the gel surface. 
• Cover the gel with fresh silver solution containing 0.1% AgNO3 in diH20 and gently 
rock for 10-20. A careful examination of silver impregnation times showed that 
optimal staining was achieved after 20 minutes. However, as little as 10 minutes is 
sufficient for high-quality staining without significant loss of sensitivity. 
Impregnation times can be increased up to 60 minutes, but greater than 90 minutes 
can cause severe image loss. 
• Following silver impregnation, carefully decant the solution, taking care not to 
damage the gel or touch the gel surface. 
• Briefly rinse residual silver solution from the surface of the gel by covering it with 
diH20 for 5–10 s. Do not rinse the gel longer than 15 s, as this step removes silver 
from the gel.  
• Cover gel with cold (4-10°C) developer solution containing 3% Na2CO3. Agitate the 
staining tray throughout image development so the developer solution is not stagnant. 
Image development begins as soon as the developer solution is added. Image 
development typically takes about 3 min depending on gel thickness, the reagents 
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used and the temperature of the reagents. Alternatively, you can add 600 ml of 
formaldehyde solution per 100 ml of final developer solution to improve image 
contrast. 
• Decant the developer solution carefully, avoiding damage to the gel or touching the 
gel surface.  
• Cover gel with cold (4°C) developer stop solution containing 7.5% of acetic acid, 
glacial in diH20 and incubate for 5-10 minutes. 
• Decant the developer stop solution and rinse the gel with diH20.  
• Photograph the gel and dry overnight.  
 
 
 
 
 
 
 Stage 1 Stage 2 Stage 3  
      
 1 Cycle 20-40 Cycles 1 Cycle  
Temperature 95ºC 94ºC 60ºC 72ºC 4 ºC 
Time 15 min 30 seg 90 seg 60 seg HOLD 
Temperature 
increase 
0 0 0 0 0 
Table 10: Thermocycling conditions used to amplify chromosomal region between SNPs rs937110 and rs10747736. 
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3.1.5. Haplotype analysis of p.R1441G carriers from Asturias 
Five p.R1441G carriers (PE008, PE155, PE040, PE066 and PE139) derived from a study 
performed by Mata and collaborators (Mata, Ross et al., 2006) in a population of 225 
patients from Asturias were typed for SNPs rs4768224, rs12423567, rs1820544 and 
rs10784616 (minimal common haplotype of p.R1441G carriers without taking into 
account individual 01-407. See section 4.1.1) 
These 5 samples represent 2.7% of the original 225 samples selected by Mata and 
coworkers from three hospitals (Hospital Universitario Central de Asturias, Oviedo; 
Hospital Alvarez Buylla, Mieres; and Hospital de Cabueñes, Gijón) within Asturias. 
These 5 patients (2 females and 3 males) presented typical late-onset PD with at least two 
of the three cardinal signs tremor, rigidity and bradykinesia, and with a positive response 
to levodopa therapy when administered. Only one patient noted a family history of PD at 
Figure 7: Band intensity (proportional to DNA concentration) versus number 
of PCR cycles of amplification of rs10747736 in three different control 
samples represented herein in three different colors. 
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the time of diagnosis. The mean age at onset was 63.2 years (range, 46-74) and at the 
time of diagnosis they did not present any atypical disease signs. All patients gave their 
consent to participate in this study, which was approved by the Ethical Committee of all 
three hospitals. 
 
 
3.2. IN SITU HYBRIDIZATION OF LRRK2 mRNA IN ADULT MOUSE 
BRAIN  
 
This work is based on five B2B6 adult male mice. All animal manipulations were 
approved by the Animal Care Ethics Committee of the C.S.I.C. and the School of 
Medicine of the University of Valencia. This technique can mainly be divided on two 
steps: Probe synthesis and in situ hybridization. 
 
3.2.1. Probe synthesis 
LRRK2 cDNA fragments from codon 1004 to codon 1172 (probe 1) and 2013 to 2171 
(probe 2) were PCR-amplified from a mouse cDNA library (Invitrogen). Primers used for 
this stage along with size of the corresponding probe is shown in table 11. 
 
Non-complementary tails of the primers are shown in grey including the corresponding restriction site for enzyme. 
Probe 
name Forward primer (5’-3’) Reverse primer (5’-3’) 
5’ Restriction 
site 
3’ Restriction 
site 
Probe size 
(bp) 
LRRK2-
PROBE1 ATCATCTAGAGTTGCCTCAGTAGCCACC ATCAGTCGACAAGGTAAGGCAGGCATTG XbaI SalI 531 
LRRK2-
PROBE2 TACGTCTAGAGCGAAGATTGCGGACTAC CACAGATATCCCAACCAGAGAGTCGCAC XbaI EcoRV 554 
Table 11: Primers and restriction sites used for cloning the different probes designed for the in situ hybridization. 
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The first 18 nucleotide of the primers used (3´-5´) were sequence specific, the next 6 
contain the restriction site in further steps, and the last 4 were randomly assigned and 
provided a physical site for the restriction enzyme (table 11). Pfu turbo polymerase from 
Stratagene (http://www.stratagene.com) was used for these amplifications following the 
protocol below: 
 
dNTPs 2.5m mM:…………………………4μl 
Primer F (20ng/ul):………………………..2μl 
Primer R (20ng/ul):………………………..2μl 
Buffer 10X:………………………………..5μl 
Pfu turbo polymerase:…….……………….1μl 
cDNA:……………………………………..1μl 
H2O:……………………………………...35μl 
 
The PCR conditions used were 2 minutes at 95ºC followed by 35 cycles of 30 seconds at 
95ºC, 30 seconds at 58ºC and 1 minute at 72ºC. After these 35 cycles, a 10 minutes 
extension at 72ºC was performed. 
The amplified PCR products (probes 1 and 2) were resolved on a 1% agarose-TBE gel. 
The band corresponding to the expected fragment size was isolated and purified with 
Minelute gel extraction kit (Qiagen, http://www.qiaquen.com).  
Minelute-purified products were next digested with XbaI and SalI (probe 1); or XbaI and 
EcoRV (probe 2) for 3 hours at 37ºC as displayed in table 12. All restriction enzymes 
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used were from Fermentas (http://www.fermentas.com). The digested product was 
purified with minelute kit afterwards. 
Meanwhile, 8 μg of pBluescript KSII- vector (Strategene, http://www.stratagene.com) 
were also digested first with XbaI and then with either SalI or EcoRV for 3 hours at 37ºC 
as displayed in table 13. 
 
 
 
 
 
 
 
 
 
 
 
 
QIAquick PCR Purification kit (Quiagen, http://www.qiagen.com) purification was 
performed after each digestion. 
The entire digested vector was dephosphorylated for 1 hour at 37ºC with Roche’s 
Alkaline phosphatase (http://www.roche.com). For this purpose, 5 μl of alkaline 
phosphatase with to 6 μl of 10X buffer was utilized for each reaction. Purification with 
Component Probe 1 Probe 2
PCR Product 9 μl 9 μl 
Y+Tango 2X 4 μl 4 μl 
XbaI 0.7 μl 0.7 μl 
Sal/EcoRV 0.7 μl 0.7 μl 
H2O 5.6 μl 5.6 μl 
    First digestion        Second digestion 
Component Amount Component Amount 
Y+Tango 2X 5 μl O+/R 6 μl 
XbaI 1.5 μl SalI/EcoRV 1.5 μl 
H2O 35.5 μl H2O 4.5 μl 
pBluescript KSII- 8 μl Digested pBluescript KSII- 48 μl 
Table 12: Reaction mixture for the digestion of the Minilute-purified PCR products prior to ligation. 
Table 13: Reaction mixtures for the digestion of pBluescript KSII- prior to ligation. 
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QIAquick PCR Purification kit (Quiagen, http://www.qiagen.com) was performed 
afterwards. 
After these digestions both PCR products (inserts) and pBluescript KSII- plasmid 
(vector), were ready for ligation (Roche’s Rapid ligation kit). In order to estimate how 
much insert and vector we had to use for this step we ran 1 μl of each sample through a 
0.8% agarose-TBS gel, along with REAL SCALA 1 DNA ladder (Durviz, 
http://www.durviz.com). This DNA ladder allows an estimation of the DNA 
concentration we ran in the gel. Thus, according to the formula [Insert ng = (3*Vector ng 
* Insert bp)/ Vector] we concluded that the amount to be used of each product for the 
ligation reaction should be that shown in the table 14: 
 
 
 
 
 
 
 
After incubating for 10 minutes at room temperature, Roche’s High Pure PCR Product 
Purification Kit (http://www.roche.com), was used to purify each reaction mix.  
The samples were then transfected into DH5-α electrocompetent bacteria. For this 
purpose 40 μl of electrocompetent bacteria, 10 μl of ligation product, and 950 μl of SOC 
medium were exposed to 1700 V in a Eppendorf Electroporator 2510 (Eppendorf, 
Component Probe 1 Probe 2 
Digested pBluescript KSII- 6 μl 6 μl 
Digested PCR Product 1.2 μl 1.1 μl 
Buffer 2 2 μl 2 μl 
Buffer 1 20 ul 20 ul 
Ligase 1 ul 1 ul 
Table 14: Reaction mixtures for ligation of pBluescript KSII- with the corresponding digested PCR product. 
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http://www.eppendorf.com). After electroporation, bacteria were allowed to recover for 1 
hour at 37ºC.  
SOC is a nutrient-rich medium usually utilized at the end of a transformation process. It 
is mainly composed of 1) tryptone and yeast extract which serve as rich nutrients to allow 
good growth of bacteria after transformation (Pronadisa, http://www.condalab.com); 2) 
sodium and potassium chloride to achieve optimal osmotic conditions; and 3) a 
magnesium source, needed in many enzyme reactions, such as those involved on DNA 
replication. The exact composition of every 100ml of this medium is as follows: 
 
Tryptone:………………..…………………………………… 2.0g 
Yeast extract: ………………….………………….……...…..0.5g 
NaCl (1M): ………………..............................………….……1ml 
KCl (1M):………………………..…..…….……………….0.25ml 
Filter-sterilized Mg2+ stock (CL2Mg 1M + Mg SO4 1M): ……1ml   
Filter-sterilized glucose 2M: …………………………………1ml  
 H2O: …………………………………………………Up to 100ml  
 
The completed medium had to be filtered through a 0.2 μm filter unit (Millipore, 
http://www.mlilipore.com). The pH was 7.0. 
In order to check the integrity of our construct, 100 μl of the transfected cells were grown 
overnight at 37ºC on an agar plate with ampicilin at a final concentration of 100 mg/ml. 
Two single colonies from each construct were grown in 200 μl of LB-ampicilin (10 g/l 
tryptone, 5g/l yeast extract, 5g/l NaCl and 100 μg/ml ampicilin) overnight at 37ºC. After 
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extracting plasmid DNA from the bacterial cultures using QIAprep Spin Miniprep Kit 
(Qiagen, www1.qiagen.com), 5 μl of the final product were sequenced with BigDye v3.1 
chemistry as shown below. (Thermocycling conditions shown in table 8). 
 
BigDye v3.1:……………………... 0.5 μl 
5x Sequencing buffer:…………….…2 μl 
T3/T7 Promoter primer (5ng/ul)…...0.5 μl 
H2O: ……………...….…...……….....2 μl 
Construct: ……………………...…….5 μl 
 
To further confirm that our inserts had successfully been cloned into pBluescript KSII-, 
each construct was digested with a different restriction enzyme. The digested product was 
then run in a 1% agarose-TBE gel, to see whether we could visualize bands with the 
expected size (table 15). 
 
 
 
 
 
 
The bands expected after digestion were of 19, 692, 1351 and 1405 bp (probe 1 
construct), and 166, 409, 540, 821 and 1499 bp (probe 2 construct). 
Both sequencing and restriction digestion, confirmed the integrity of the two constructs.  
Component Probe 1 constuct Probe 2 construct 
B+ 2X/H 2X 6 μl 6 μl 
DraI/DdeI 1.2 μl 1.1 μl 
H2O 2 μl 2 μl 
Construct 20 μl 20 μl 
Table 15: Reaction mixture to confirm probe 1 and 2 construct integrity. 
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In order to linearize our constucts so that further reactions could be performed, 20 μg of 
each construct was digested with each of the enzymes we used prior to the ligation step. 
Thus, the probe 1 construct was digested with XbaI (for antisense probe synthesis) and 
SalI (for sense probe synthesis), and the probe 2 construct with XbaI (antisense probe 
synthesis) and EcoRV (sense probe synthesis) as follows (table 16). 
 
 
 
 
 
 
After checking the results of these digestions in a 2% agarose-TBE gel, samples were 
purified by phenol purification following the protocol below: 
 
• In order to remove proteins, add 1 volume of phenol: chloroform: iso-amyl alcohol 
(25: 24: 1). 
• Vortex. 
• Spin 5 minutes at 13000 rpm at 4ºC. 
• Transfer supernatant to a new tube avoiding aspiration of the interlayer or organic 
phase. 
• In order to remove phenol, add 1 volume of chloroform: iso-amyl alcohol (24: 1). 
• Vortex. 
• Spin 5 minutes at 13000 rpm at 4ºC. 
  Probe 1 construct     Probe 2construct 
Component Amount Component Amount 
Y+Tango 2X/ O+2X 8 μl Y+Tango 2X/ R+2X 8 μl 
XbaI/SalI 2 μl XbaI /EcoRV 2 μl 
H2O 60 μl H2O 60 μl 
Constuct (2000ng/μl) 10 μl Constuct (2000ng/μl) 10 μl 
Table 16: Reaction mixture used to linearize probe 1 and probe 2 constructs 
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• Transfer supernatant to a new tube avoiding aspiration of the interlayer or organic 
phase. 
• In order to precipitate DNA, add 2.5 volumes of ethanol 100% at -20ºC and 0.1 
volumes of sodium acetate 3M. 
• Vortex. 
• Incubate 30 minutes at -80ºC. 
• Spin 30 minutes at 13000 rpm at 4ºC. 
• Carefully pour out supernatant without loosing DNA pellet. 
• Add 1 ml of ethanol 70% (do not vortex). 
• Spin 15 minutes at 13000 rpm at 4ºC. 
• Carefully pour out supernatant without loosing DNA pellet 
• Air dry pellet at room temperature being careful of not overdrying it. 
• Resuspend in 12 ul of DEPC-treated H2O. 
 
Once samples were purified, probes were synthesized by means of in vitro transcription 
with digoxigenin-labeled nucleotides using the PCR DIG Probe Synthesis Kit (Roche, 
http://www.roche.com) as shown in table 17. 
 
  Probe 1   Probe 2 Component Antisense Sense Antisense Sense 
Construct concentration ng/ml 624 306 1806 930 
Construct volume used 2.4 μl 4.9 μl 0.83 μl 1.61 μl 
10X digoxigenin RNA labeling mix 2 μl 2 μl 2 μl 2 μl 
10X transcription buffer 2 μl 2 μl 2 μl 2 μl 
RNA polymerase 2 μl 2 μl 2 μl 2 μl 
RNAse inhibitor 0.5 μl 0.5 μl 0.5 μl 0.5 μl 
Table 16: Reaction mixture used for in vitro transcription reactions. 
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Incubation for 2 hours at 37ºC is required. The obtained product was now precipitated 
following the protocol below:  
 
• Precipitate RNA with 2 μl of sodium acetate 3M and 40 μl of ethanol 100% at -
20ºC. 
• Vortex. 
• Incubate 30 minutes at -80ºC. 
• Centrifuge for 30 minutes at 1,3000 rpm and 4ºC. 
• Remove supernatant 
• Air dry pellet at 4ºC to avoid temperature rising 
• Resuspend pellet on 12.5 μl of DEPC-treated water 
 
1 μl of the purified RNA was then resolved on a 1% agarose-TBE gel and the rest was 
stored at -80ºC with 50% formamide to avoid the formation of secondary structures. 
 
3.2.2. In situ hybridization 
In order to avoid the action of ribonucleases, all material was washed with ethanol and 
heated for at least two hours at 200ºC, prior to in situ hybridization. In addition, all 
solutions were treated with 1:104 diethyl-pyrocarbonate (DEPC, Sigma-Aldrich, 
http://www.sigmaaldrich.com) and autoclaved. All steps are performed at 4ºC if not 
otherwise specified. 
Subcervical dislocation was performed on five B2B6 adult male mice. After decapitation, 
brains were quickly removed, washed on 0.1M PBS (0.137M NaCl, 2.68mM KCl, 6.48 
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mM Na2HPO4, 647mM KH2PO4) and immersed overnight in a fixative solution 
containing 4% paraformaldehyde in 0.1M PBS at 4ºC. Brains were then washed for 30 
minutes with 0.1M PBS and immersed in gelatine glutaraldehyde for 30-60 minutes, 50 
μm thick coronal sections were prepared using a vibratome VT1000M (Leica, 
http://www.histo-solutions.com). Coronal sections were refixed in PBS-DEPC overnight.  
In order to remove the residual paraformaldehyde, sections were washed twice with 
PBST (PBS with 0.1% of Tween 20) before gradual dehydration and rehydration with 
25%, 50%, 75%, 100% methanol in PBST, and vice-versa. All washes were 5 minutes 
long. Next, sections were washed with PBST and bleached with 1% H2O2 in PBST for 10 
minutes. Afterwards, sections were washed again with PBST, treated with 5μg/ml of 
proteinase K for 7 minutes and post-fixed with 4% paraformaldehyde-PBS for 20 
minutes. Sections were next washed for at least 2 hours with a hybridization solution 
containing 50% dionized formamide, 5XSSC, 2% Blocking powder (Roche, 
http://www.roche.com), 0.1% Triton X-100, 1mg/ml yeast tRNA, 5mM EDTA and 
50μg/ml heparin at 57ºC. After removing this solution, fresh one was added containing 
the digoxigenin-labeled RNA probes at a final concentration of 1 μg/ml. The probes were 
left to hybridize overnight at 57ºC. The next day, five high stringency washes were 
carried out for 30 minutes with CHAPS 0.1% and SSC 2X in DEPC-treated H2O at 57ºC. 
After blocking the sections with 20% fetal calf serum in KTBT (50mM Tris-HCl pH7.5, 
150 mM NaCl, 10mM KCl, 0.3% Triton X-100) for 3 hours, sections were incubated 
with the anti-DIG antibody (Roche, http://www.roche.com) overnight. We pre-absorbed 
the anti-DIG antibody with brain powder (see next paragraph). The next day 5 one-hour 
washes were performed with KTBT at room temperatures. An alkaline phosphatase-
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mediated color reaction was subsequently carried out using 333 mg/ml of 4-nitroblue 
tetrazolium chloride (Boehringer Mannheim) and 165 mg/ml 5-bromo-4-chloro-3-indolyl 
phosphate (Boehringer Mannheim) in NTMT buffer (100mM Tris-HCl pH 9.5, 50mM 
MgCl, 100mM NaCl, 0.1% Tween 20). When the desired level of signal was observed, 
the reaction was stopped by gently washing with KTBT for two hours with a final wash 
in PBS prior to mounting the sections. 
Brain powder previously mentioned was obtained by homogenizing several frozen mouse 
brains in a minimal volume of PBS. Following centrifugation at 3000g for 30 minutes, 
the pellet was washed with ice-cold acetone, dried, and crushed to a fine powder 
 
3.2.3. Relative regional expression 
To determine the level of the LRRK2 expression in different areas of the brain we 
performed several experiments with different image development times (from 2 to 16 h). 
The level of expression was then correlated with the time needed to obtain clear staining 
in each of the areas shown in table 25. When clear staining was observed in a particular 
area during the first two hours of developing, it was assigned a +++ mark, those areas that 
were clearly stained after nine hours of chromogenic reaction were assigned as ++ 
whereas those stained after sixteen hours of staining were designated with +. Those 
which revealed no staining after sixteen hours were considered as having LRRK2 
expression too low to be detectable with this particular technique. 
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3.2.4. Image handling 
Brightfield microscopic images were captured using a Nikon DMX-2000 camera (Nikon, 
http://www.nikoninstruments.com). The camera was attached to a Nikon Eclipse E600 
microscope (Nikon, http://www.nikoninstruments.com) and connected to a computer. 
The captured images were automatically adjusted for brightness and contrast with Adobe 
Photoshop. 
 
3.2.5. Quality-control procedures 
We carried out control experiments for all the probes using the sense sequence, always at 
the same concentration as the respective antisense probe, to check possible non-specific 
hybridization. 
 
3.2.6. Nomenclature 
The nomenclature used in this report follows that of the atlas the adult mouse brain by 
Paxinos and Franklin (Paxinos G, 2001). 
 
 
3.3. SCREENING FOR MUTATIONS IN OMI/HTRA2 
 
3.3.1. Subject collection 
All samples were taken directly from pre-compiled panels from the National Institute of 
Neurological Disorders and Stroke (NINDS) funded Neurogenetics repository hosted by 
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the Coriell Institute for research (http://ccr.coriell.org). All participants provided written 
informed consent. 
Neurologically normal Caucasian control subjects were derived from 9 panels of DNA: 
NDPT002, NDPT006, NDPT009, NDPT019, NDPT020, NDPT021, NDPT022, NDPT023 
and NDPT024 (see section 3.5.1.1). These contain DNA from 828 unrelated individuals 
from North America, 340 males and 488 females. Each panel contains 5 micrograms of 
DNA from 92 unrelated Caucasian individuals without history of Alzheimer’s disease, 
amyotrophic lateral sclerosis, ataxia, autism, bipolar disorder, brain aneurism, dementia, 
dystonia, or Parkinson’s disease. None had any first-degree relative with a known 
primary neurological disorder and the mean age of participants was 74 (range, 55-88), 67 
(range, 55-84), 68 (range, 55-84), 28 (range, 15-35), 40(range, 36-48), 49(range, 46-53), 
67(range, 56-91), 68 (range, 56-94) and 67(range, 56-95) for panels NDPT002, 
NDPT006, NDPT009, NDPT019, NDPT020, NDPT021, NDPT022, NDPT023 and 
NDPT024 respectively. The mean age at onset of all controls was 58 years.  
PD cases were taken from 7 panels of DNA: NDPT001, NDPT005, NDPT014, NDPT015, 
NDPT016, NDPT017 and NDPT018 (for more details see section 3.5.1.2). 
These panels contain 5 micrograms of DNA from 644 unrelated Caucasian individuals 
from North America with PD, including 363 males and 281 females. The mean age at 
onset was 70 (range, 55-70), 67 (range, 55-81), 32 (range, 7-40), 43 (range, 40-47), 49 
(range, 47-52), 66 (range, 56-84) and 66 (range, 56-87) respectively. 
Here we have defined young-onset PD (YOPD) as onset of a parkinsonian syndrome at or 
before age 40 (≤ 40); only those samples from NDPT014 and 14 samples from NDPT015, 
were considered as YOPD. These samples (a total of 106 including 63 males and 43 
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females) had a mean age at onset of 31 (range 7-40), defined as when symptoms were 
first noted, including at least one of the following: resting tremor, rigidity, bradykinesia, 
gait disorder and postural instability. 
The remaining samples comprise 538 samples, including 302 males and 236 females with 
late-onset PD. The mean age at onset is 59 years (range 41-87) and they all show at least 
one of the main clinical signs of PD such as resting tremor, rigidity, bradykinesia, gait 
disorder and postural instability at the disease onset. 
All subjects (from both young- and late-onset panels) were questioned regarding family 
history of parkinsonism, dementia, tremor, gait disorders, and other neurological 
dysfunction. Subjects both with and without a reported family history of Parkinson's 
disease were included. None were included who had three or more relatives with 
parkinsonism, nor with clear Mendelian inheritance of PD. The mean age at onset of all 
PD cases was 55 years.  
A more detailed description of both case and control samples, can be found at 
http://ccr.coriell.org/Sections/Collections/NINDS/DNAPanels.aspx?PgId=195&coll=ND. 
 
3.3.2. Sequence analysis of OMI/HTRA2 
The entire coding region of OMI/HTRA2 (RefSeq NM_013247) was sequenced in all 
samples. PCR was performed with thermocycling program 57TD52 (table 5) in a final 
volume of 15 μl with Roche´s FastStart PCR Master Mix, and forward and reverse 
primers listed on table17. 
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Master Mix:……………………... 10 μl 
Primer F (5μM):…………….……..2 μl 
Primer R (5μM):…………………...2 μl 
DNA (10ng/μl): ……………...…....1 μl 
DMSO: ……………………...…….….* 
* 1μl of Dimethylsulfoxide (American Bioanalytical) was added for PCR reactions of exons 2 and 4. 
 
 
 
PCR products were verified in a 2% ethidium-bromide-containing agarose-TBE gel and 
visualized via ultraviolet transillumination. Prior to loading each PCR product on a gel, it 
was mixed with 6X Orange G Loading Dye Solution (10 mM Tris-HCl (pH 7.6), 0.15% 
orange G, 60% glycerol, 60mM EDTA).  
 
 
In order to remove unincorporated primers, dNTPs, DNA polymerase and salts used 
during PCR amplification that can interfere with downstream applications such as 
sequencing, the Agencourt AMPure PCR Purification system (Agencourt, 
http://www.agencourt.com) was utilized. This system utilizes Agencourt’s AMPure solid-
phase paramagnetic bead technology for high-throughput amplification of PCR 
amplicons. Agencourt AMPure utilizes an optimized buffer to selectively bind PCR 
Exon Forward primer (5’-3’) Reverse primer (5’-3’) 
Exon 1_1 GTCCTACTGTCCGCCTG TTCCAGAGTTCTCTGAGGC 
Exon 1_2 GGTTGTCTGTTGGGGTC ACAGATAAGAGGAGGCTCTG 
Exon 2 CTATATCGAGATCCTGGACC GACCTGTCATCTGAGATGC 
Exon 3 CTTATTTGCTCGCATCTTCAG GCTCTATATAGGCTCATCCACC 
Exon 4 AGAAAGTACCTACATCCTGG CTTCCCCTATTTCCACC 
Exon 5-6 CTATCTCTCAATATTCCAACCAG ATTACACTGGTCACATTACATGT 
Exon 7 AATGTGTTGATGAGAGACTTGAG GGAGTACAAAGCCTAGTTCAAG 
Exon 8 GATGTTCAGCATGGTGTACTC GTGATTCTTCAGAGCCCAG 
Table 17: Forward and reverse primer sequences used for amplification and direct sequencing of the coding region of OMI/HTRA2. 
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amplicons 100bp and larger to paramagnetic beads. Excess oligos, nucleotides, salts, and 
enzymes can be removed using a simple washing procedure. The resulting purified PCR 
product is essentially free of contaminants and can be used in downstream applications 
such as sequencing. 
Each purified product was sequenced using forward or reverse primers with Applied 
Biosystems BigDye terminator v3.1 sequencing chemistry as explained in section 3.1.2.  
In order to efficiently purify the sequencing products to deliver superior quality 
sequencing data, Agencourt CleanSEQ technology was used. 
Purified sequencing reactions were then electrophoresed on an ABI3730 XL genetic 
analyzer (Applied Biosystems, http://www.appliedbiosystems.com) and analyzed with 
Sequencher software v4.1.4 (Gene Codes, http://www.genecodes.com). All changes that 
derived from the wild type sequence were verified by PCR amplification of a fresh DNA 
aliquot and sequencing in both forward and reverse directions. 
 
3.3.3. Statistical analysis. 
Power calculations were performed using the program PS v2.1.30 (Dupont and Plummer, 
1990). For variant p.A141S, based on the minor allele frequency we obtained after 
sequencing 828 control samples (0.02991), our series possesses sufficient power (98.5%) 
to detect a difference in allele frequency (p = 0.05) with an effect of OR = 2.15. This is 
the OR that Strauss and coworkers obtained in their study for this same variant (Strauss, 
Martins et al., 2005). 
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For p.G399S based on a minor allele frequency of 0.0036 (according to our control 
population), our study posses enough power (80%) to detect a difference in allele 
frequency (p = 0.05) with an effect of OR = 3.59. 
Plink v0.99s (http://pngu.mgh.harvard.edu/~purcell/plink/) (Purcell, Neale et al., 2007) 
was used to perform Fisher’s exact test of association between all identified variants and 
PD. Haploview v4.0RC2 (http://broad.mit.edu/mpg/haploview/) was used to verify the 
results obtained. (Barrett, Fry et al., 2005). 
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3.4. ANALYSIS OF SCA-2 AND SCA-3 GENES IN PARKINSONISM 
 
3.4.1. Subject collection. 
280 probands with PD with and without family history with different ethnic background 
(African American, Asian, Caucasian, Hispanic, Native American and Pacific Islandic) 
were selected for these experiments (table 18). Probands underwent a neurological 
history and physical examination and were diagnosed with parkinsonism by Drs. Katrina 
Gwinn-Hardy, Roberto Weiser, or Marisol Gallardo. Family history was based on a 
questionnaire completed by the proband prior to the clinic visit. This questionnaire elicits 
the medical history of first and second-degree relatives. Enrollment of other family 
members was carried out as follows: the proband was informed that those relatives 
wishing to participate should call the investigators in order to be considered for the study. 
If those individuals came forward and wished to enroll, informed consent was obtained 
and subsequently these additional family members were evaluated according to the above 
procedures. The diagnosis of Parkinson’s disease was made based on Hughes’ criteria 
(Hughes, Daniel et al., 1992) for all 280 subjects.  
In 114 cases with a positive family history of parkinsonism, additional diagnoses of 
dementia, dystonia, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), restless 
legs syndrome (RLS), essential tremor and epilepsy were noted in other members of the 
kindred. Several of these diagnoses may have been present in the proband in addition to 
PD, these include: dementia, dystonia, essential tremor, and RLS. 
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Here we present a brief clinical description of members of the family 374, in which 
pathogenig ATXN-2 expansions were identified (see results, section 4.4): 
 
• 374-1: This Caucasian woman, evaluated by us at age 
59 years, was first diagnosed with Parkinson’s disease at age 55 years. Her initial 
symptoms were shuffling gait and 4–6 Hertz resting tremor. On evaluation in our clinic, 
she had rare right lower extremity resting tremor while “on”, en bloc turns, small steps, 
and stooped posture. She had markedly decreased right arm swing when walking. There 
was right sided rigidity in both upper and lower extremities. She had no cerebellar 
findings. She responded well to carbidopa/levodopa therapy, which she stated made her 
feel “normal”. In addition to her symptoms of Parkinson’s disease, she suffered from 
symptoms consistent with periodic leg movements of sleep, and restless legs syndrome, 
which responded to the dopamine replacement therapy. A sleep study has not been done. 
 
• 374-5: This 36-year old Caucasian woman’s symptoms began at age 29 
years, when she noted difficulties with “internal trembling”. Resting tremor in the right 
upper extremity became apparent to her at age 30 years, and involved the right lower 
extremity within the next several years. An extensive evaluation by a neurologist revealed 
no secondary cause for her symptoms. She was diagnosed with Parkinson’s disease and 
responded well to carbidopa/levodopa therapy. Examination when “on” was remarkable 
for normal eye movements, mild dystonic posturing in the right foot, and no resting nor 
activation tremor. No retropulsion was noted on pull test. Gait was apparently normal. 
There were no cerebellar or other atypical signs. 
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• 374-9: This patient is a 53-year old female sibling of the proband with 
essential tremor onset at age 49 years affecting both upper extremities. Additional 
diagnoses include vertigo consistent with peripheral vestibular disease, migrane and left 
hand paresthesias, possibly carpal tunnel syndrome. 
 
 
 
 (n = 280) 
  
Age, median, mean, range  61, 61±15, [22–91] 
Age at onset median, mean, range  50, 51±15, [16–89] 
Gender (n, freq)  
Male  152 (0.54) 
Female  98 (0.35) 
Unknown  30 (0.11) 
Dopamine replacement therapy (n, freq)   
Responsive  149 (0.53) 
Unresponsive  8 (0.03) 
Unknown  123 (0.44) 
Other features (n, freq)  
Dystonia  13 (0.05) 
Dementia  16 (0.06) 
Essential tremor  8 (0.03) 
Family history  
Sporadic  166 (0.59) 
First degree relative  57 (0.20) 
Second degree relative 1 4 (0.05) 
Extended (first and second degree)  40 (0.14) 
Distant relative only  3 (0.01) 
Mode of inheritance (n, freq)  
Autosomal dominant  66 (0.58) 
Autosomal recessive  41 (0.36) 
Unclear  7 (0.06) 
Ethnic origin (n, freq)  
African American  21 (0.08) 
Asian  10 (0.03) 
Caucasian  165 (0.59) 
Hispanic  81 (0.29) 
Native American  2 (0.01) 
Pacific Islander  1 (0.004) 
Table 18: General Characteristics of parkinsonism patients. 
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3.4.2. Genomic DNA extraction. 
Genomic DNA was isolated from whole blood using the Wizard Genomic DNA 
purification kit (Promega Corporation, http://www.promega.com) as per the 
manufacturer’s instructions. Briefly, purification is based on a four-step process. The first 
step in the purification procedure lyses the cells and the nuclei. For isolation of DNA 
from white blood cells, this step involves lysis of the red blood cells with the Cell Lysis 
Solution, followed by lysis of the white blood cells and their nuclei in the Nuclei Lysis 
Solution. The cellular proteins are then removed by a salt precipitation step using the 
Protein Precipitation Solution, which precipitates the proteins but leaves the high 
molecular weight genomic DNA in solution. Finally, the genomic DNA is concentrated 
and desalted by isopropanol precipitation. 
 
3.4.3. Genotyping 
PCR amplification was performed in a 25 μl reaction containing 25ng of genomic DNA, 
10 pmol of both forward and reverse oligonucleotide custom primers (table 19), 
manufacturer’s buffer, Q solution (Qiagen, http://www.qiagen.com), 200 μmol/L 
deoxynucleotide trisphosphates (Amersham Pharmacia Biotech Inc, 
http://www.amersham.com), and 0.2 U of TaqDNA polymerase (Qiagen, 
http://www.qiagen.com). For PCR amplification either the forward or the reverse primer 
utilized was labeled with 6-FAM (table 19). PCR reaction were run on a Touchdown 
Hybaid thermocycler (Hybaid, http://www.thermo.com) using the conditions in table 4. 
Five microliters of each reaction were then run on a 2% agarose-TBE gel and visualized 
via ultraviolet transillumination to confirm amplification and to exclude the possibility of 
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pathogenic extensions beyond the ladder size (500 bp) used on the automated sequencer. 
Prior to loading each PCR product on a gel, it was mixed with 6X Orange G Loading Dye 
Solution. 
Two microliters of each PCR product along with 8 microliters of a solution 1:20 of 
GS500LIZ size standard (Applied Biosystems, http://www.appliedbiosystems.com) and 
doubly deionyzed formamide were analyzed on an ABIPrism 3100 Genetic Analyzer 
(Applied Biosystems, www.appliedbiosystems.com). All samples were amplified and 
analyzed on at least two separate occasions. Product size was used to calculate triplet 
repeat sizes for all samples; this calculation was based on the product size relative to 
samples run in parallel with a known repeat number. To identify these samples with 
known repeat sizes for each repeat, three samples with homozygous repeat size were 
sequenced with BigDye terminator chemistry (Applied Biosystems, 
http://www.appliedbiosystems.com) using unlabeled primer pairs identical in sequence to 
those used for amplification (see section 3.1.2 for conditions). The observed number of 
repeats at each locus was then used to calculate repeat numbers for all other cases. 
 
 
 
 
 
 
 
Gene/Exon Forward primer (5’-3’) Reverse primer (5’-3’) Label 
ATXN-2/Exon 1 TTCCAGACCCTTCCATCC ACGATGGATAACTAATTGGAGC 6-FAM 
ATXN-3/Exon 9 CCAGTGACTACTTTGATTCG TGGCCTTTCACATGGATGTGAA 6-FAM 
Table 19: Forward and reverse primer sequences used for amplification and direct sequencing of the region containing cag repeats 
within ATX2 and ATX3 genes.  
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3.5. WHOLE-GENOME SNP GENOTYPING IN PARKINSON’S DISEASE 
AND NEUROLOGICALLY NORMAL CONTROLS. STAGE 1. 
 
3.5.1. Subject collection. 
All samples utilized in this study were derived from the National Institute of Neurological 
Disorders and Stroke (NINDS) funded Neurogenetics repository hosted by the Coriell 
Institute for Medical research (http://ccr.coriell.org). The NINDS banks lymphoblast cell 
lines (LCLs) with DNA from subjects with cerebrovascular disease, epilepsy, motor 
neuron disease, Parkinsonism and Tourette syndrome as well as controls. Six 
precompiled panels each consisting of 92 cases or controls were selected for the analysis. 
The panels that contained samples from patients with Parkinson’s disease were 
NDPT001, NDPT005, and NDPT007; these included DNA from 273 unique participants 
and three replicate samples. The panels that contained samples from neurologically 
normal controls were NDPT002, NDPT006, and NDPT008; these comprised DNA from 
275 unique participants and one replicate sample. 
DNA was extracted using a modification to the procedure developed by Miller et al. 
(Miller, Dykes et al., 1988) as previously reported and transfected to Epstein-Barr virus 
immortalized LCLs. Epstein-Barr virus immortalization was performed aspreviously 
described (Miller, Shope et al., 1972; Tumilowicz, Gallick et al., 1984) and the average 
passage number for each line was 5 (range 5–7) . 
 
3.5.1.1. Neurologically normal control samples: Blood samples were drawn from 
neurologically normal, unrelated, white individuals at many different sites within the 
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USA. Each participant underwent a detailed medical history interview and asked 
specifically regarding the following disorders, which were not present: Alzheimer's, 
amyotrophic lateral sclerosis, ataxia, autism, bipolar disorder, cerebrovascular disease, 
dementia, dystonia, Parkinson's, and schizophrenia. None had any first-degree relative 
with a known primary neurological disorder. The mean age of participants at sample 
collection was 68 years (range 55–88). 
 
3.5.1.2. Parkinson’s disease samples: Blood was obtained from unique and unrelated 
white individuals from the USA with idiopathic Parkinson’s disease including 166 males 
and 110 females. The mean age at onset was 66 years, ranging from 55 to 84 years. 
Disease onset was defined as the time when symptom(s) of the disease were first noted, 
including at least one of the following: resting tremor, rigidity, bradykinesia, gait disorder 
and postural instability.  
In order for subject inclusion, completion of the NINDS Repository Clinical Data 
Elements (http://ccr.coriell.org/Sections/Collections/NINDS/CDE/pd.aspx?PgId=336) 
were required. Furthermore, only subjects who met the UK Brain Bank Criteria 
idiopathic Parkinson's disease were included (Hughes, Daniel et al., 1992). By those 
criteria, all subjects had bradykinesia, and at least one of the following: muscular rigidity, 
4-6 Hz resting tremor and postural instability (not caused by primary visual, vestibular, 
cerebellar, or proprioceptive dysfunction). None had exclusionary features. All had 
documentation of sustained, excellent response to dopamine replacement therapy.  
All subjects were queried regarding family history of parkinsonism, dementia, tremor, 
gait disorders, and other neurological dysfunction. Subjects both with and without a 
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reported family history of Parkinson's disease were included on this panel. None were 
included who had three or more relatives with parkinsonism, nor with apparent 
Mendelian inheritance of PD. 
 
3.5.2. Genotyping. 
3.5.2.1. Platform used: The platform we used for this study was Illumina’s Infinium 
genome-wide genotyping beadarray (Illumina, http://www.illumina.com). This 
technology is based on 3 μm silica beads that self assemble by Van de Waals forces and 
hydrostatic interactions with the walls of micro-wells over a planar silica substrate in a 
slide format. When randomly assembled to this substrate, the beads have a uniform 
spacing of approximately 5.7 μm. Each bead is covered with hundreds of thousands of 
copies of a specific 50 mer nucleotide that act as the capture sequences for the 
fragmented target DNA. These oligos are coupled to the beads through an amine linkage, 
creating a “bead type” for each bead-oligo combination. “Bead types” are pooled together 
to form assay panels up to 1,000,000 targets depending on the chip version. 
The concept of the Infinium whole-genome genotyping assays is based on direct 
hybridization of fragmented whole-genome amplified genomic DNA to these 50 mer 
locus-specific oligos. After hybridization, each SNP is “tagged” by an enzymatic-based 
extension assay, using labeled nucleotides. These “tags” are visualized by staining with 
an immunohistochemistry assay that increases the overall sensitivity of the assay (figure 
8). 
All samples in this study were assayed using Illumina’s Infinium Human-1 (Infinium I) 
and Infinium HumanHap300 SNP chips (Infinium II).  
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Infinium Human-1 genotyping beadchip assays 109,365 gene-centric SNPs. Of those, 
48% (49,183) are within 10Kb of an exon, 23% (24,292) within trancripts, 15% (16,086) 
in highly conserved regions and 14% (19,804) to achieve uniform spacing across 
genome. This product is suited for both whole-genome association studies and LOH/copy 
number analysis. 
Infinium II HumanHap300 assays 317,511 haplotype tagging SNPs (tagSNPs) derived 
from Phase I HapMap Project. tagSNPs are loci that can serve as proxies for many other 
SNPs. The use of tagSNPs greatly improves the power of association studies, as the same 
information and power from a larger number of SNPs can be gathered by genotyping 
only a subset of loci, thus making possible to achieve more statistical power and genomic 
coverage using fewer SNPs and statistical tests, compared to other strategies using larger 
numbers of randomly chosen SNPs. This beadchip version contains a higher density of 
tag SNPs in regions of the genome that are within 10 kb of a gene or in evolutionary 
conserved regions. In addition, it contains about 7,300 nsSNPs (non-synonymous amino-
acid changing SNPs), and a higher SNP density across the Major Histocompatibility 
Complex (MHC). 
This product is ideally suited for both whole-genome association studies and LOH/copy 
number studies, and provides higher genomic coverage with fewer SNPs, compared to 
whole-genome genotyping strategies using randomly selected SNPs. 
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There are 18,073 SNPs in common between the Human-1 and HumanHap300 arrays; 
thus the assays combined provide data for 408,803 unique SNPs. 
 
3.5.2.2. Infinium Workflow: The Infinium assay protocols, feature single-tube sample 
preparation without PCR or ligation steps, significantly reducing labor and potential 
sample handling errors. An enzymatic discrimination step provides high call rates and 
accuracy with unconstrained locus selection. The Infinium workflow can be divided on 
five main stages: 1) Sample preparation, 2) sample fragmentation and hybridization, 3) 
extension and staining, 4) scanning, and 5) data analysis (figure 9). 
 
Figure 8: Illumina’s Infinium genome-wide genotyping beadarray. Each bead is covered with 
thousands of copies of a specific 50 mer capture sequence that hybridize fragmented DNA, making a 
beadtype. Bead types are pooled together to form assay panels up to 1,000,000 targets depending on the 
chip version. 
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• Sample preparation: In stage 1, 750-1,000 ng of DNA is used as 
template for amplification over 20-24 hours at 37ºC with WG# -AMM solution. This 
generates a sufficient quantity of each individual DNA sample to be assayed in further 
steps. Prior to 37ºC incubation, DNA is denatured with NaOH 0.1N for ten minutes and 
neutralized by adding WG# -MP1 reagent. To facilitate plate-based amplification and 
isopropanol precipitation, each DNA sample is amplified in four separate wells within the 
same plate. After fragmentation, precipitation and resuspension in hybridization buffer, 
the four wells are recombined. 
 
Figure 9: Infinium II assay workflow. 
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• Sample fragmentation and hybridization: After whole-genome 
amplification is performed in the first stage, each individual sample is enzymatically 
fragmented to an average size of around 300 bp by using an endpoint enzymatic reaction 
by the addition of WG# -FRG solution, vortexing at 1600 rpm for one minute and 
incubating at 37ºC for one hour. This endpoint fragmentation process eliminates the risk 
of over-digestion. 
Once the digestion is performed, WG# -PA1 reagent and isopropanol are added to 
precipitate each DNA sample. After 30 minutes of incubation at 4ºC, and a 3,000 Xg 
centrifugation also at 4ºC, excess of isopropanol and WG# -PA1 is removed, and pellets 
air-dried for one hour. Once the pellets are dry, the formamide-containing hybridization 
buffer (WG# -RA1) is added to each well, followed by a one-hour-incubation at 48ºC and 
vortexing at 1800 rpm for one minute. After a 20 minute denaturation at 95ºC, DNA is 
ready to be hybridized to the surface of the beadchip. Before performing this step, the 
beadchip has been prepared for hybridization by washing with 100% ethanol for 10 
minutes and detergent WG# -PB1 for 5 minutes, followed by assembly in a Flow Though 
Chamber that allows solutions to be added to the surface of the beadchip. 100% 
formamide is dispensed into the Flow Through Chamber reservoir afterwards, to pre-wet 
the beadchip surfaces. Then WG# -RA1 is dispensed to equilibrate the Chamber and 
beadchip surfaces. 
Now, utilizing Tecan’s GenePaint automated slide processor (Tecan, 
http://www.tecan.com), DNA samples are loaded into the Flow Through Chambers at 
22ºC. These are then removed from the GenePaint processor and placed in a container 
humidified with WG# -PB2 for a minimum of 16 hours (24 hours maximum) at 48ºC. 
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• Extension and staining: For the following steps Tecan’s GenePaint 
automated slide processor is used. The GenePaint system employs a capillary gap flow-
through chamber to enable reagent entrapment and exchange over the beadchip’s active 
surface. Washing, blocking, extension, and signal amplification are all performed by 
simple reagent additions to the Flow Through Chamber. Although these processes can be 
performed manually, automated robotic processing assures maximum consistency from 
slide to slide. 
Two different primer extension assays can be employed: allele-specific primer extension 
(ASPE) for Infinium I assays, and single-base extension (SBE) for Infinium II assays 
(figure 10). 
The ASPE assay, a one color format, is specifically designed to allow the detection of all 
SNP classes by employing two identical bead types differing only at their 3’ base of the 
attached oligo (allele-specific bead type). For a given SNP the capture sequence of the 
allele-specific bead type is the perfect match hybrid for allele A, and the other is the 
perfect match hybrid for allele B of a certain SNP. After hybridization, multiple biotin-
labeled nucleotides are added only to those oligos perfectly matched to a captured DNA 
target. 
In order to perform this series of reactions, the beadchips are first treated with WG# -
RA1 to wash away unhybridized and non-specific hybridize DNA sample. WG# -XB1 
and WG# -XB2 reagents are used for preparing the beadchip for the extension reaction. 
WG# -EMM reagent, containing polymerase and biotin-labeled nucleotides, is dispensed 
to extend oligos correctly matched to DNA on the beadchip, incorporating biotin-labeled 
nucleotides at 37ºC. NaOH-formamide treatment for two minutes removes the hybridized 
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DNA to reduce extraneous signal, leaving the extended oligos. After neutralization with 
WG# -XB3 reagent, the labeled extended oligos are stained in a muli-layer way to 
amplify and detect the incorporated label (WG# -LMM, WG# -ASM and WG# -XB3). 
Now the beadchips are removed from the Tecan’s GenePaint system, the Flow Through 
Chambers, and washed during ten minutes in WG# -PB1 detergent. Once dried by gentle 
centrifuging, they are ready to be imaged. 
The SBE assay format uses a single oligo per SNP with two color read-out. This 
characteristic reduces the required number of oligos needed by half compared to the 
ASPE assay. After target hybridization, those SNP locus-specific oligos perfectly 
matched to a captured DNA target are extended in the presence of labeled 
dideoxynucleotides. These dideoxynucleotides are biotin-labeled ddCTP and ddGTP, and 
2,4-dinitrophenol (DNP)-labeled ddATP and ddUTP. These labeled dideoxynucleotides 
are incorporated by the polymerase and allow detection after a dual-color multi-layer 
immunohitochemical assay. The limitation of this assay is that only 83% of common bi-
allelic polymorphisms can be detected on a single beadchip. A and T nucleotides are 
stained in one color and C and G in another. Thus, AT and GC polymorphisms can not be 
detected. 
To perform this assay the beadchips are first washed with WG# -RA1. WG# -XC1 and 
WG# -XC2 are added later to condition the beadchips surface for the extension reaction. 
This SBE is performed by adding a polymerase and labeled dideoxynucleotide mix (WG# 
-TEM). NaOH-formamide wash is the performed to remove the hybridized DNA. After 
neutralization using WG# -XC3 reagent, the labeled extended primers undergo a multi-
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layer staining process. Next the Flow Through Chambers are disassembled and beadchips 
washed with WG# -PB1 detergent and coated with WG# -XC4. 
 
 
 
 
 
• Scanning: In order to scan the processed bead chips, an Illumina Stand-
Alone BeadArray Reader was used. This reader is a two-color (543nm/643nm) confocal 
fluorescent scanner with 0.84 μm pixel resolution. The scanner excites the fluorescent 
group generated during signal amplification of the allele-specific (one color) or single-
base (two colors) extension products on the beads of the beadchip. Light emissions from 
these fluorescent groups are then recorded in high-resolution images of each beadchip 
section using BeadScan software. 
Figure 10: Infinium I and Infinium II technologies. Infinium I 
and Infinium II technologies use two different primer extension 
assays: allele-specific primer extension (ASPE, upper panel) and 
single-base extension (SBE, lower panel). 
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• Data analysis: In order to extract genotypes from the raw image data, a 
normalization procedure must be undertaken. The BeadStudio software package, 
normalizes raw data from each BeadChip, generates genotype calls, performs clustering 
and analyzes data intensity using data generated from Infinium assays. Any normalization 
procedure applied to Illumina’s genotyping data must be applied on the sub-bead pool 
level. A sub-bead pool is a group of beads that were manufactured together and are 
located in roughly the same beadchip analytical position (a stripe). Thus, for example 
Human-1 beadchips are divided into 12 stripes each of them containing two different 
pools. Therefore, Human-I beadchips contain a total of 24 different sub-bead pools. The 
sub-bead pool information is provided along with each beadchip as a bead pool manifest 
(*.bpm) file. 
Because the performance of external controls can vary from sample to sample, Illumina’s 
standard normalization is performed by means of a self-normalization algorithm which 
draws on information contained in the array itself. The normalization algorithm is 
designed to remove outliers, adjusts for channel-dependent background and global 
intensity differences, and also scales the data. During this process, the X and Y color 
channels (alleles A and B) undergo an affine coordinate transformation to make the data 
appear as accurate as possible with the homozygotes lying along the transformed X or Y 
axes. Five steps are performed: 1) Oultier removal; 2) translation correction in which the 
asymptotes are fitted to candidate AA or BB homozygotes. Two straight lines are fit into 
candidate homozygote A and B alleles. The intersection of these two lines is computed 
and defines the translated origin; 3) rotational correction: the angle between the AA 
homozygote asymptote and the translated X axis is used to define the rotational 
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correction. This angle corresponds to the theta (θ) parameter; 4) shear correction: the 
angle of the BB homozygote asymptote with respect to the translated and rotated Y axis 
is used to define the shear correction. This angle corresponds to the shear parameter; 5) 
scaling correction: statistical centroids are computed for the candidate AA homozygotes 
to define an X-axis scaling parameter, and for candidate BB homozygotes to define a Y-
axis scaling parameter. The translated, rotated, shear-corrected data are normalized to a 
scale of ∼1 using the scaling parameters. 
After normalization, the genotyping data are transformed to a polar coordinate plot of 
normalized intensity R = Xnorm + Ynorm and allelic intensity ratio θsubject = (2/Π) * arctan 
(Ynorm/Xnorm), where Xnorm and Ynorm represent transformed normalized signals from 
alleles A and B for a particular locus. The log R ratio of signal intensities is shown as log2 
*(Rsubject/Rexpected) and is the base 2 logarithm of the ratio of observed intensity versus 
expected intensity. Rexpected is computed from a linera interpolation of the observed allelic 
ratio (θsubject) with respect to the canonical genotype clusters. The three canonical 
genotype clusters were generated at one point in time by training on 120 normal samples, 
and serve as standards for all future experiments. In addition to computing Rexpected,, the 
observed allelic intensity ration (θsubject) is used to estimate a quantitative B allele 
frequency for the particular SNP in the given sample by using interpolation of known B 
allele frequencies of the three canonical clusters (0, 0.5 and 1.0). 
This two transformed parameters (log R ratio and B allele frequency) are then plotted 
along the entire genome for all SNPs in the array using the Illumina Genome viewer tool 
(IGV) within BeadStudio software (Illumina, http://www.illumina.com). This allows 
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identification of chromosomal aberrantions and tracks of contiguous homozygous calls 
(figure 11). 
 
 
 
 
 
 
 
 
3.5.3. Quality-Control procedures. 
3.5.3.1. Low quality genotyping: Any sample with a call rate below 95% was repeated 
on a fresh DNA aliquot and if the call rate persisted below this level the sample was 
excluded from the analysis. Low-quality genotyping led us to repeat 11 individual 
samples, of which seven were ultimately excluded from the analysis. 
 
Figure 11. Normalization and transformation processes applied to the Infinium raw genotype data. A: 
Normalization andThe log2 R ratio compares the observed normalized intensity (Rsubject) of the subject sample 
to the expected intensity (Rexpected; gray dot) based on the observed allelic ratio, θsubject, through a linear 
interpolation (gray lines) of the canonical clusters AA, AB, and BB (shown as circles). The normalized intensity 
value obtained from a single SNP is represented as a purple dot. The R and θ values for the subject are shown 
with thick black dotted lines. B: The canonical clusters (shown as circles) are also used to convert θ values, that 
is, θsubject, to B allele frequency (allelic copy ratio). This is accomplished by a linear interpolation of the known 
allele frequencies assigned to each cluster (0.0, 0.5, and 1.0). The allele frequency for an observed θ value falling 
between two clusters is also calculated by linear interpolation with lines D1 and D2.  
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3.5.3.2. Population substructure: In an attempt to detect the presence of significant 
population substructure or ethnically mismatched individuals we selected 267 random, 
unlinked SNPs from throughout the genome and ran STRUCTURE v2.2 
(http://pritch.bsd.uchicago.edu/structure.html) on these data from all genotyped 
individuals. This software provides allows inferring the presence of distinct populations, 
assigning individuals to populations, studying hybrid zones, identifying migrants and 
admixed individuals, and estimating population allele frequencies in situations where 
many individuals are migrants or admixed. It can be applied to most of the commonly 
used genetic markers including SNPs. 
 
3.5.4. Statistical analysis. 
Power calculations were performed using the program PS v2.1.30 (Dupont and Plummer, 
1990). Based on the average observed minor allele frequency (26%) and assuming that 
either the causal variant is typed or that there is complete and efficient tagging of 
common variation by the genotyped tSNPs, our data provides 80% power to detect an 
allelic association with an odds ratio of more than 2.09 and less than 0.40 at an 
uncorrected significance level of p = 0.000001. 
For each SNP we computed a series of estimates and tests using a program developed at 
Wake Forest University called SNPgwa 
(http://www.phs.wfubmc.edu/public_bios/home.cfm). Each SNP was tested for 
departures from Hardy-Weinberg equilibrium. Five tests of genotypic association were 
computed: two degrees of freedom overall test for 2×3 tables, dominant model, additive 
model (Cochran-Armitage trend test), recessive model, and lack of fit to an additive 
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model. We calculated odds ratios (ORs), 95% CIs, and p values for each of the asociation 
models. We used the program Dandelion, which ran within SNPgwa, to do two-marker 
and three marker moving-window haplotype-association analyses for those SNPs that 
were consistent with Hardy-Weinberg equilibrium in controls. For all p values with an 
uncorrected significance of less than 0.05 we did permutation tests within SNPgwa using 
a variable number of permutations based on the p value of the test. For each permutation, 
SNPgwa permutes the affection status (case or control) of the entire sample represented 
in the input file while preserving the total number of cases and total number of controls in 
each permutation. The permutation is done using a Wichman-Hill random number 
generator (Wichmann, 1982).  
 
3.5.5. Beyond association 
The genotypic data generated the illumine Infinium assays can be used to look at copy 
number variation and to score homomozygosity. This can be done by direct visualization 
with the IGV tool of log R ratio and B allele frequency (see data analysis in section 
3.5.2.2). 
Because there is considerable redundancy at each locus interrogated (each SNP is assayed 
several times within a beadtype), both alleles of each SNP are assayed multiple times; 
accordingly, B allele value for an individual SNP in a single sample gives an estimate of 
the proportion of times an individual allele at each polymorphism was called A or B. This 
metric is simply viewed as B allele frequency, thus an individual homozygous for A 
allele would have a score close to 0, an individual homozygous for B allele a score close 
to 1, and a score approximately 0.5 would indicate a heterozygous A/B genotype. 
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Significant deviation of these values in contiguous SNPs is indicative of an alteration in 
copy number.  
Robserved is a measure of the signal intensity for a locus and thus, when compared with an 
average expected value for that locus (Rexpected), the resulting log R ratio provides an 
indirect measure of copy number. A signal in a sample which is stronger than the 
expected signal is indicated by a log R ratio above 1.00 and indicates a copy number 
increase. On the other hand, a weaker signal than that expected for a certain SNP results 
in a decreased log R ratio and is suggestive of a deletion. 
Considering these two metrics, a profile indicative of genomic duplication is an increase 
in log R ratio in the presence of four allele clusters outside the expected three. These 
clusters correspond to A/A/A, A/A/B, A/B/B and B/B/B genotypes (figure 12). 
A profile indicative of hererozygous duplications would be a decrease in log R ratio in 
the presence of a lack of heterozygous calls (figure 12). 
Resolution of this technique is sensitive to SNP density of the assay at any particular 
genomic locus. For all platforms this varies throughout the genome. However, typically 
we observe copy number variations as small as 200 kb using the Infinium I assays 
(109,365 SNPs) and as small as 50 kb using the Infinium II assays (317,511 SNPs). 
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Visualization of B allele frequency and log R ratio was performed by two individuals 
blinded to each others results. All apparent discrepancies were assessed by a third person. 
For both Human-1 and HumanHap300 BeadChips individually, homozygosity was 
scored based on a simple presence/absence basis; the areas of extended homozygosity 
were first highlighted by a simple script that searched for contiguous tracks of 
homozygous genotypes greater than 5 Mb, this was then followed by visual examination 
to rule out a drop in the log R ratio value across the same region, which would indicate 
Figure 12: Illumina Genome Viewer visualization of Infinium genotypic data. Log R ratio 
(upper panel) and B allele frequency (lower panel) visualization with IGV for sample ND04177. A 
drop in log R ratio along with lack of heterozygous calls in B allele frequency plot shows a 
heterozygous 0.17 Mb heterozygous deletion in chromosome 6q26 (shaded in red). An increase of 
log R ratio coupled with the appearance of four clusters in the B allele frequency plot (corresponding 
with A/A/A, A/A/B, A/B/B and B/B/B genotypes) indicates a 0.24 Mb heterozygous duplication in 
chromosome 6q27 of this same sample (shaded in green). 
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genomic deletion. Once the Human-1 and HumanHap300 data was merged, we also 
defined a homozygous track as a continuous track of homozygous genotypes where the 
track had to be at least 1 Mb in length and contain at least 10 SNPs (figure 13).  
In order to test whether the extended homozygosity and structural genomic alterations 
were a result of, or amplified by, the LCL creation and passage process we repeated the 
genome-wide SNP genotyping in DNA extracted directly from the blood samples initially 
used for LCL creation. We assessed six out of the 26 control samples identified with one 
or more regions of contiguous homozygosity greater than 5 Mb in size, and all 24 control 
samples that harbor putative genomic deletions or multiplications.  
 
 
 
Figure 13: Illumina Genome Viewer visualization of Infinium genotypic data. Log R ratio (upper panel) 
and B allele frequency (lower panel) visualization with IGV for sample 2035-44. Lack of heterozygous calls 
in the B allele frequency ply, along with no copy variation changes, indicates an extended homozygous track 
(shaded in blue) spanning more than 19 Mb in chromosome 1. 
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3.5.6. Confirmation of structural alterations by Real-time PCR 
In order to confirm that the structural alterations found in these samples were not artifacts 
of the methodological or analytical process, quantitative PCR was performed in all 272 
control samples using 14 TaqMan MGB probes targeting a 0.5 Mb duplication at 
chromosome 7q11 a 0.019 Mb deletion in chromosome 11q21, a 33 Mb heterosomic 
deletion in chromosome 13p12-q21 and a 0.11 Mb duplication in chromosome 16q23.2. 
In addition 10 individual probes across the PARK2 locus were used to verify the presence 
and size of copy number variation observed in this region in both control and PD 
individuals. 
Primer and probes (sequence in table 20) were designed with Primer Express v2.0.0 
software (Applied Biosystems, http://www.appliedbiosystems.com). TaqMan MGB 
probe for reference gene encoding β-globin was labeled with 6-FAM whereas probes 
against each target region in chromosomes 7, 11, 13 and 16, as well as those 10 targeting 
the PARK2 locus, on chromosome 6 were labeled with VIC. Real-time PCR was 
performed on a ABI7900Ht Sequence Detector system (Applied Biosystems). 
PCR was carried out with TaqMan Universal PCR Master Mix (Applied Biosystems) 
using 25 ng of genomic DNA, 900 nmol/L primers and 250 nmol/L probes on a total 
volume of 20 ml. PCR cycling conditions were 95°C for 10 min, 95°C for 15 s and 60°C 
for 1 min (40 cycles). The plates contained four replicates of each genomic DNA sample, 
control DNA and a no-template water control. The cycle in the log phase of PCR 
amplification at which a significant fluorescent threshold was reached (Ct) was used to 
quantify each amplimer. The dosage of each amplimer relative to the reference gene (β-
globine) and normalized control DNA was determined using the 2-ΔΔCt method 
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(Corporation, 1997). To be considered valid, the requirements were a standard deviation 
(SD) of 0.16 and threshold values reached before 28 cycles. A value was considered a 
heterozygous deletion between 0.3 and 0.6, normal between 0.8 and 1.2 and heterozygous 
duplication between 1.3 and 1.6. Interestingly, individual ND04946, carrying a 
heterosomic deletion, showed a 2-ΔΔCt value between heterozygous deletion and normal, 
0.62 (+0.08 SD). 
 
 
 
 
 
 
 
 
 
Oligo name Target gene-exon Chromosome Sequence 5’-3’ 5' label 
Gene: β-Globin     
Beta globin-F β-Globin-Exon 2 11p15.4 TGGGCAACCCTAAGGTGAAG  
Beta globin-R β-Globn-Exon 2 11p15.4 GTGAGCCAGGCCATCACTAAA  
Beta globine Probe β-Globn-Exon 2 11p15.4 CTCATGGCAAGAAAGTGCTCGGTGC FAM 
Gene: PΑΡΚ2     
Parkin Exon 1-F PARK2-Exon 1 6q25.2-q27 CCACCTACCCAGTGACCATGA  
Parkin Exon 1-R PARK2-Exon 1 6q25.2-q27 CGGCGCAGAGAGGCTGTA  
Parkin Exon 1 Probe PARK2-Exon 1 6q25.2-q27 TACGTGGGTACCTGCC VIC 
Parkin Exon 2-F PARK2-Exon 2 6q25.2-q27 CCCAGTGGAGGTCGATTCTG  
Parkin Exon 2-R PARK2-Exon 2 6q25.2-q27 CCCCTGTCGCTTAGCAA  
Parkin Exon 2 Probe PARK2-Exon 2 6q25.2-q27 CCAGCATCTTCCAGCTCAAGGAGGTG VIC 
Parkin Exon 4-F PARK2-Exon 4 6q25.2-q27 TTCTTCTCCAGCAGGTAGATCAATC  
Parkin Exon 4-R PARK2-Exon 4 6q25.2-q27 TTTTCCCGGCTGCACTCTT  
Parkin Exon 4 Probe PARK2-Exon 4 6q25.2-q27 TTTTATGTGTATTGCAAAGGCCCCTGTCA VIC 
Parkin Exon 5-F PARK2-Exon 5 6q25.2-q27 CCGGATGAGTGGTG  
Parkin Exon 5-R PARK2-Exon 5 6q25.2-q27 AGAGGAATGAATGTGACCAGGTACT  
Parkin Exon 5 Probe PARK2-Exon 5 6q25.2-q27 CCACACTGCCCTGGGACTAGTGCA VIC 
Parkin Exon 6-F PARK2-Exon 6 6q25.2-q27 GCACACCCCACCTCTGACA  
Parkin Exon 6-R PARK2-Exon 6 6q25.2-q27 TGCAAGTGATGTTCCGACTATTTG  
Parkin Exon 6 Probe PARK2-Exon 6 6q25.2-q27 AAACATCAGTAGCTTTGCACCTGATCGCA VIC 
Table 20: Primers and probes sequences utilized to perform Real-time to verify the presence and size of copy number variation 
observed in these regions in both control and PD individuals
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Oligo name Target gene-exon Chromosome Sequence 5’-3’ 5' label 
Gene: PARK2     
Parkin Exon 7-F PARK2-Exon 7 6q25.2-q27 CCGCCACGTGATTTGCTTA  
Parkin Exon 7-R PARK2-Exon 7 6q25.2-q27 CTGCCGATCATTGAGTCTTGTC  
Parkin Exon 7 Probe PARK2-Exon 7 6q25.2-q27 CTGTTTCCACTTATACTGTG VIC 
Parkin Exon 8-F PARK2-Exon 8 6q25.2-q27 GCAGCCTTTGAGATGCTCACT  
Parkin Exon 8-R PARK2-Exon 8 6q25.2-q27 AGAGCTCCATCACTTCAGGATTCT  
Parkin Exon 8 Probe PARK2-Exon 8 6q25.2-q27 ACCTGCTCTTCTCC VIC 
Parkin Exon 9-F PARK2-Exon 9 6q25.2-q27 GGACACACTCCTCTGCACCAT  
Parkin Exon 9-R PARK2-Exon 9 6q25.2-q27 CAATCTGCTTTTTGGGTTTTGC  
Parkin Exon 9 Probe PARK2-Exon 9 6q25.2-q27 CTGCTGGTACCGGTTG VIC 
Parkin Exon 11-F PARK2-Exon 11 6q25.2-q27 GCTCGGCGGCTCTTTCA  
Parkin Exon 11-R PARK2-Exon 11 6q25.2-q27 ACGCCTTTCCTCTTTGTTTCC  
Parkin Exon 11 Probe PARK2-Exon 11 6q25.2-q27 CGACTCTGTAGGCCTG VIC 
Parkin Exon 12-F PARK2-Exon 12 6q25.2-q27 CGAACCCACCACACCTTTGT  
Parkin Exon 12-R PARK2-Exon 12 6q25.2-q27 TGCGGACACTTCATGTGCAT  
Parkin Exon 12 Probe PARK2-Exon 12 6q25.2-q27 TTCTGCCCCCAACAGGAGGCTG VIC 
Gene: MAML2     
ND01496-F MAML2- Intron 1-2 11q21 CCTTTCCCTACCCAGCAAGTT  
ND01496-R MAML2- Intron 1-2 11q21 GGGCACATGCTTTCAGATCTG  
ND01496-Probe MAML2- Intron 1-2 11q21 TCTCTGCTTAGCTATCATG VIC 
Gene: ZNF273     
ND02214-F ZNF273-Intron 3-4 7q11.21 GCACCCGACCTGCAATAGAC  
ND02214-R ZNF273-Intron 3-4 7q11.21 GTGCCCCAGGTAAGCACAAT  
ND02214-Probe ZNF273-Intron 3-4 7q11.21 TTTCCTTCTATATGGCTCTTT VIC 
Gene: BCMO1     
ND03628-F BCMO1-Intron 2-3 16q21-23 GTTGGGATCATTGGAAGTATTGG  
ND03628-R BCMO1-Intron 2-3 16q21-23 TCTCTTAAGCATCTACCAGGTGTCA  
ND03628-Probe BCMO1-Intron 2-3 16q21-23 CGTTCTAGCAAGGGC VIC 
Gene: ZC3H13     
ND04946-F ZC3H13-Intron 1-2 13q14.12 TGTCCTCTGTTGCCTGATTCG  
ND04946-R ZC3H13-Intron 1-2 13q14.12 AGCTCTCAGACCAGCAAAGCA  
ND04946-Probe ZC3H13-Intron 1-2 13q14.12 ACTACTCTCCTCCCTTGAC VIC 
Table 20 (continued)
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3.6. WHOLE-GENOME SNP GENOTYPING IN PARKINSON’S DISEASE 
AND NEUROLOGICALLY NORMAL CONTROLS. STAGE 2. 
 
3.6.1. Subject collection. 
The sample size used for Stage 1 of this project was increased to a total of 4134 (3581 
more than in stage 1, see section 3.5.1), by adding 604 late-onset PD, 108 YOPD and 552 
neurologically normal control samples from the NINDS-funded Neurogenetics repository 
hosted by the Coriell Institute for Medical research (http://ccr.coriell.org); 2,243 control 
samples from the Cancer Genetic Markers of Susceptibility initiative (CGEMS); and 75 
YOPD samples collected from different parts of North America by one of ours 
specialists. 
 
3.6.1.1. Late-onset PD samples: Besides NDPT001, NDPT005 and NDPT007, panels 
NDPT017, NDPT018 and 250 non-paneled samples from the Coriell institute were 
included in these experiments, making a total of 880. 
All patients were Caucasian individuals with idiopathic Parkinson's disease from the 
United States. The mean age at onset of parkinsonian syndrome was 62 years, ranging 
from 41 to 98 years. Age at onset was defined as when symptom(s) of PD were first 
noted (including at least one: resting tremor, rigidity, bradykinesis, gait disorder, postural 
instability. 
In order for subject inclusion, complete NINDS Repository Clinical Data Elements were 
required. Furthermore, only subjects who met the UK Brain Bank Criteria idiopathic 
Parkinson's disease were included (Hughes, Daniel et al., 1992). By those criteria, all 
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subjects had bradykinesia, and at least one of the following: muscular rigidity, 4-6 Hz 
resting tremor, postural instability (not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction). None had exclusionary features. All had documentation of 
sustained, excellent response to anti-parkinsonian therapy. All samples and data were 
collected with informed consent under local approved protocols.  
All subjects were queried regarding family history of parkinsonism, dementia, tremor, 
gait disorders, and other neurological dysfunction. Subjects both with and without a 
reported family history of Parkinson's disease were included on this panel. None were 
included who had three or more relatives with parkinsonism, nor with apparent 
Mendelian inheritance of PD.  
 
3.6.1.2. YOPD samples: Here we define YOPD as when parkinsonian symptom(s) 
appear before or at age of 40. Folowing this criterion, only samples included in Coriell 
panel NDPT014, fourteen from panel NDPT015, those two erroneously included in 
NDPT007 (see structural variation in PD-related loci in section 4.5.2.3) and those 75 
collected from North America by one of our specialists, were considered as YOPD. The 
mean age at onset for these samples was 32.7 years, ranging from 7 to 40 years. For those 
samples from the Coriell institute. In order for subject inclusion, complete NINDS 
Repository Clinical Data Elements (CDEs) were required. Furthermore, only subjects 
who met the UK Brain Bank Criteria idiopathic Parkinson's disease were included 
(Hughes, Daniel et al., 1992). By those criteria, all subjects had bradykinesia, and at least 
one of the following: muscular rigidity, 4-6 Hz rest tremor, or postural instability (not 
caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction). None had 
Javier Simón Sánchez  Methods 
 125
exclusionary features. All had documentation of sustained, excellent response to 
dopamine replacement therapy. 
 
3.6.1.3. Coriell Institute neurologically normal control samples: Besides those 
samples included in NDPT002, NDPT006 and NDPT009, those samples from Coriell the 
Institute panels NDPT019, NDPT020, NDPT021, NDPT022, NDPT023 and NDPT024, 
were used for these set of experiments. 
Each of these panels contains DNA of 92 unique and unrelated Caucasian individuals free 
from neurological disorders. All were asked specifically regarding the following 
disorders, which were not present: Alzheimer's, amyotrophic lateral sclerosis, ataxia, 
autism, bipolar disorder, cerebrovascular disease, dementia, dystonia, Parkinson's, and 
schizophrenia. None had any first-degree relative with a known primary neurological 
disorder and the mean age of participants was 58 years, ranging from 15 to 98 years. 
3.6.1.4. CGEMS initiative control samples: The National Cancer Institute-funded 
Cancer Genetic Markers of Susceptibility (CGEMS, http://cgems.cancer.gov) is a three-
year, $14 million initiative aiming to identify genetic alterations that make people 
susceptible to prostate and breast cancer. For this purpose they have collected a total of 
1,177 males with prostate cancer and 1,200 females with breast cancer, as well as 1,101 
male and 1,142 female controls. Genotyping data from all these 2,243 control samples 
was generously shared by the National Cancer Institute and included in our study. 
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3.6.2. Genotyping 
Samples within DNA panels NDPT014, NDPT015, NDPT016, NDPT017, NDPT018, 
NDPT019, NDPT020, NDPT021, NDPT022, NDPT023, NDPT024 and those 252 not-
paneled samples; as well as those 75 collected from one the specialists at our laboratory, 
were assayed with Infinium II HumanHap550 genotyping beadchips version 3 and 
version 1 respectively. These two different versions of this product enable whole-genome 
genotyping of 555,363 and 561,467 SNPs respectively derived from the recently 
completed Phase I and Phase II International HapMap Project (http://www.hapmap.org). 
The Phase I + II HapMap data set contains over 2 million common SNPs (those with a 
minor allele frequency (MAF) ≥ 0.05 in each population studied (Caucasian [CEU], Han 
Chinese/Japanese [CHB+JPT], and Yoruba [YRI])). To capture this variation, Illumina 
scientists used an algorithm for the linkage disequilibrium (LD) statistic, “r2”, to select 
tagSNPs in all HapMap populations (Carlson, Eberle et al., 2004). This was 
supplemented with additional SNPs to achieve even spacing across genome. On average 
there is one common SNP (minor allele frequency > 0.05) every 5.5, 6.5 and 6.3 kb on 
the autosomes of the CEU, CHB + JPT and YRI respectively. In addition there are 4,300 
SNPs from recently reports on copy number polymorphism regions of the genome, 7,800 
non- synonymous SNPs, 1,800 tagSNPs of the Major Histocompatibility Complex, 177 
mitochondrial SNPs and 11 Y-chromosome SNPs. Coverage using HumanHap550 is 
equivalent to that of over one million randomly selected SNP markers. 
Those samples previously assayed with Infinium Human-1 and Infinium HumanHap300 
SNP chips for Stage 1 of this project (samples within DNA panels NDPT001, NDPT002, 
assayed with NDPT005, NDPT006, NDPT007 and NDPT009) were assayed with 
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Infinium II HumanHap 240S genotyping beadchips. This array utilizes the Infinium II 
assay to interrogate an additional 241,846 tagSNPs loci derived from the Phase I and 
Phase II of the International HapMap project and provides tag SNP coverage in regions 
of lower linkage disequilibrium (LD) in the genome. Combination of this array with the 
HumanHap300 genotyping bead chip provides the same genotyping information as 
Infinium II HumanHap550 v.1 beadchips. 
Using these genotyping platforms, more than 545,066 unique SNPs were genotyped for 
each sample of our cohort. Given that most of these were tagSNPs selected from all 
HapMap populations, it is equivalent to over one million randomly-selected SNPs. 
For more details about these genotyping platforms and infinium workflow, see section 
3.5.2. 
 
3.6.3. Quality-control procedures. 
Besides providing the opportunity to scan the whole genome in a relative short period of 
time, this approach also has a major problem: the high rate of false positive results. Thus, 
eliminating any systematic bias like population stratification (existing when the case and 
control groups are not well-matched genetically or where there are several distinct, but 
unrecognized, sub-populations in a cohort) or not documented relatedness is required to 
minimize the rate of false positives. 
 
3.6.3.1. Low quality genotyping: Any sample with a call rate below 95% was repeated 
on a fresh DNA aliquot and if the call rate persisted below this level, the sample was 
excluded from the analysis. Low-quality genotyping led us to repeat 57 individual 
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samples, of which 40 were ultimately excluded from the analysis, including 11 late-onset 
PD, 5 YOPD, 13 neurologically normal control samples from the Coriell Institute and 12 
controls from CGEMS initiative. 
 
3.6.3.2. Gender problems: PLINK v1.01 (http://pngu.mgh.harvard.edu/~purcell/plink/) 
(Purcell, Neale et al., 2007) was utilized to flag individuals whose reported sex did not 
match with the estimated sex based on heterozygosity on chromosome X genotypes 
(inbreeding coefficient [F] in this chromosome). A male call is made if F is more than 0.8 
and a female call if F is less than 0.2. A problem arouse if two sexes did not match or if 
the SNP data and pedigree data are ambiguous with regard to the sex. All problematic 
samples were analyzed by visual examination of log R ratio and B allele frequency 
metrics with the IGV tool within BeadStudio v3.1.12 (Illumina, 
http://www.illumina.com) to rule out whether this discrepancy was caused because of 
copy number variation or extended homozygosity in chromosome X. These analyses led 
to the exclusion of 15 samples, including 9 late-onset PD, 2 YOPD and 4 neurologically 
normal control samples from the Coriell Institute. 
 
3.6.3.3. Population substructure: In an attempt to detect the presence of significant 
population substructure or ethnically mismatched individuals, 10,000 random SNPs in 
linkage equilibrium with each other were selected. These SNPs were selected from a list 
of ∼50,000 obtained after LD-pruning with PLINK v1.01 
(http://pngu.mgh.harvard.edu/~purcell/plink/).  
Javier Simón Sánchez  Methods 
 129
Subsequent analysis of these 10,000 SNPs in all genotyped individuals along with 30 
trios from Yoruba (Nigeria), 45 unrelated individual from the Tokyo area in Japan, 45 
unrelated individuals from Beijing (China) and US-resident trios with Northern and 
Western European ancestry from the Centre d’Etude du Polymorphisme Humain (CEPH, 
Paris, France); all downloaded from the HapMap website (http://www.hapmap.org), 
allowed inference of the presence of individuals belonging to a distinct population. This 
approach was carried out using STRUCTURE v2.2 software 
(http://pritch.bsd.uchicago.edu/structure.html). 
These results were confirmed by plotting a matrix of pairwise Identity By State (IBS) 
distances created with PLINK v1.01 (http://pngu.mgh.harvard.edu/~purcell/plink/) 
(Purcell, Neale et al., 2007). Thus, IBS distance to its “nearest neighbor” was calculated 
for each individual. This distribution was standardized (by the sample mean and variance 
of nearest neighbor) and inspected for outliers. For this last purpose Multidimensional 
scaling (MDS) was performed. This scaling is a set of techniques often used for data 
visualization for exploring similarities or dissimilarities in data. 
 
3.6.3.4. Non-reported relatedness: The pairwise clustering based on IBS distances (see 
previous section) is useful for making estimations of pairwise Identity by Descent (IBD) 
to find pairs of individuals who look more similar than expected by chance in a random 
sample. By estimating the probability of sharing 0, 1, or 2 alleles IBD for any two 
individuals, a proportion of IBD can be calculated (PI-HAT = P [IBD = 2] + 0.5 x P [IBD 
= 1]).  
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Using 0.2 as a threshold for PI-HAT, 17 sample pairs were considered too similar to each 
other. Thus, one member of each pair was removed from further SNP association tests. 
These were 6 late-onset PD, 5 YOPD and 6 neurologically normal control samples from 
the Coriell Institute. 
Besides, PI-HAT data revealed 50 replicates within our dataset including 9 late-onset PD, 
40 YOPD and 1 neurologically normal control sample from the Coriell Institute. These 
were removed from further analyses. 
 
3.6.4. Statistical analysis. 
Power calculations were performed using the program PS v2.1.30 (Dupont and Plummer, 
1990). Based on the average observed minor allele frequency (26%) and assuming that 
either the causal variant is typed or that there is complete and efficient tagging of 
common variation by the genotypes tagSNPs, our data provides 80% power to detect an 
allelic association with an odds ratio of more than 1.38 and less than 0.69 at an 
uncorrected significance level of p = 0.000001. 
All estimates and tests were performed with the PLINK v1.01 toolset, developed by 
Shaun Purcell and co-workers at the Center for Human Genetic Research, Massachusetts 
General Hospital, and the Broad Institute of Harvard and Massachusetts Institute of 
Technology (http://pngu.mgh.harvard.edu/~purcell/plink/) (Purcell, Neale et al., 2007). 
Only those SNPs genotyped in at least 95% of our control cohort as well as those with a 
minimum allele frequency (MAF) above 5% and with no extreme departure from Hardy-
Weinberg equilibrium (HWE) in controls (p > 0.01) were included in further statistical 
analysis. 
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For each SNPs that successfully passed these three filters (474,995 SNPs), five tests were 
applied including the basic allele test, Cochran-Armitage trend test, genotypic test (two 
degrees of freedom), dominant gene action test (one degree of freedom) and recessive 
gene action test (one degree of freedom). We calculated odds ratios (ORs), 95% CIs, and 
p values for each of the association models. All calculation were performed with plink 
v1.01 software. 
For multiple test correction, 1000 max T permutations were performed. For each 
permutation, PLINK v.1.01 permutes the affection status (case or control) of the entire 
sample represented in the input file while preserving the total number of cases and total 
number of controls in each permutation. The difference between an adaptive permutation 
analyses, is that max T doesn’t drop early clearly nonsignificant SNPs. Thus, if 1000 
permutations are specified, then all 1000 will be performed for all SNPs. The benefit of 
doing this is that two sets of empirical significance values can then be calculated and also 
a value that controls for that fact that thousands of other SNPs were tested. This is 
achieved by comparing each observed test statistic against the maximum of all permuted 
statistics (i.e. over all SNPs) for each single replicate.  
Multiple test correction based on Bonferroni and FDR-BH methods (based on 
Bonferroni) were also performed. 
 
3.6.5.  Combined analysis. 
In order to add power to our genome-wide association study and further confirm the 
results we obtained, we performed a collaborative analysis with Drs. Thomas Gasser 
(Hartie-Institute for Clinical Brain Research, Tuebingen, Germany) and Tatsushi Toda 
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(Osaka University Graduate School of Medicine, Suita, Japan) who have performed 
similar approaches in a German and a Japanese cohort respectively. 
 
3.6.5.1. German cohort: This cohort consisted of a total of 1,686 samples including 
742 PD cases and 944 controls from Germany. All samples with a genotyping success 
below 95%, gender mismatch and with a standard deviation of ± 4 from the mean 
heterozygosity value were excluded. After IBS distance clustering, samples with a non-
European ancestry were also removed. 
Since only genotypic counts for each SNP were shared with us, population stratification 
analysis could not be assessed between our and the German cohort. For further analysis, 
genotypic counts for all the SNPs that successfully passed the HWE and MAF filters in 
the German cohort (498,560) were merged with that of our successful SNPs 474,995 
giving a total of 465,684 successful SNPs common to both cohorts. For this purpose it 
was assumed that the minor allele in both populations are the same. Besides, since gender 
can not be accounted if using genotype counts only, results for non-autosomal SNPs were 
removed. 
All tests and corrections used for our cohort (see section 3.6.4) were applied for each of 
these SNPs.  
 
3.6.5.2. Japanese cohort: This cohort consisted on 1,000 PD cases and 2,500 
neurologically normal controls from Japan. All samples with a genotyping success below 
95%, gender mismatch and with a standard deviation of ± 4 from the mean 
heterozygosity value were excluded. After IBS distance clustering, samples with a non-
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Japanese ancestry were also removed. After HWE and MAF filtering, 398,416 successful 
SNPs were left for analysis. Given the existing differences in the genetic background of 
Asian and Caucasian populations genetic counts were not merged for analysis. Thus, this 
population was used for side by side comparison of results. 
 
 
3.7. AUTOZYGOSITY MAPPING IN BRAZILIAN FAMILIES 
 
3.7.1. Subject collection. 
All subjects gave informed consent and the study was approved by a local ethics board. 
Families DYT16-1 and DYT16-2 (figure 14) were identified by Drs. Sarah Camargos and 
Francisco Cardoso at the Movement Disorder Clinic at the Federal University of Minas 
Gerais, Brazil. These families shared singular dystonic features (table 21) and both stated 
parental consanguinity. The family members were questioned regarding the presence of 
additional affected members outside of the nuclear family; however no additional 
affected family members were reported and building of a family tree failed to link these 
two families genealogically. The inheritance pattern observed in these families was 
consistent with an autosomal recessive mode of inheritance. Thus, there is a high 
possibility that affected individuals had inherited both copies (paternal and maternal) of 
the mutated gene from a common ancestor. As a consequence of this principle (Lander 
and Botstein, 1987) the chromosomal region surrounding the mutated gene may be 
expected to be homozygous and identical by descent (IBD) among affected individuals 
(autozygous). In order to identify the disease-causing gene, these individuals were 
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selected for autozygosity mapping, in which identical by state (IBS) homozygous 
segments between affected individuals are searched.  
In addition, Sarah Camargos and Francisco Cardoso, collected DNA samples from 45 
young-onset PD patients (age at onset ranging from 18 to 40 years), 12 apparently 
unrelated young-onset dystonia patients, including individual 2035-61 (age at onset 
ranging from 8 to 42 years), and 83 neurologically normal controls (age at sampling 
ranging from 25 to 50 years). All these additional samples belonged to Brazilian 
individuals collected at the Movement Disorder Clinic at the Federal University of Minas 
Gerais, Brazil. 
 
 
  
 
 
Figure 14: Schematic representation of DYT16-1 and DYT16-2 pedigrees. A black 
symbol indicates an affected family member, an open symbol indicates an unaffected 
family member, and a grey symbol indicates a family member reported as affected by 
history but unexamined. Squares are males, circles are females. Multiple siblings are 
denoted by a diamond; the number of individuals is indicated in the diamond. Individual 
2035-61 does not belong to either of these families (see results section 4.7.3). 
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A detailed description of patients in which mutations in PRKRA were described (see 
results section 4.7) can be found below. Brain CT scans of all affected family members of 
DYT16-1 and DYT16-2 and brain MRI scans on family members 2035-1 and 2035-11 of 
DYT16-1 and DYT16-2, respectively, showed no specific abnormalities are shown in 
figure 15. No abnormalities were seen. 
 
3.7.1.1. Family DYT16-1: 
• Individual 2035-1: This patient is currently 32 years-old. Until 11 
years of age he was described as neurologically normal, when he developed a gait 
disturbance and pain in the lower limbs. After two years, the symptoms spread causing a 
swallowing disturbance. He was placed on medication (biperiden up to 24 mg a day and 
levodopa/carbidopa 125/12.5 mg three times a day) without significant improvement. 
Physical exam showed mildly high blood pressure. Neurological exam showed a marked 
generalized dystonia with severe retrocollis and opisthotonic posture. Currently the 
patient scores 96 on the Burk-Fahn-Marsden Scale with a disability score of 26 (Burke, 
Fahn et al., 1985). Botulinum toxin injection of the muscles of the neck (splenii capitis) 
Patient Age at onset First symptom 
Generalized 
dystonia 
Fahn Marsden 
Scale Parkinsonism 
UPDRS 
motor score 
Pyramidal 
signs 
2035-1 11 Lower limbs dystonia Severe 96 Absent 0 No 
2035-2 12 Lower limbs dystonia moderate 58 Present 21 Yes 
2035-3 2 Lower limbs dystonia moderate 36 Absent 0 Yes 
2035-11 11 Upper limbs dystonia Severe 64 Present 21 No 
2035-12 2 Spasmodic dystonia Slight 14 Present 30 No 
2035-119 18 Lower limbs dystonia Moderate 44 Present 18 No 
2035-61 7 Upper limbs dystonia Severe 103 Absent 19 Yes 
Table 21: Summary of clinical features of affected members of families DYT16-1 and DYT16-2 as well as individual 2035-61. 
UPDRS: Unified Parkinson’s disease rating scale. 
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was attempted with no response. There were no cortico-spinal tracts signs or 
parkinsonism. 
 
• Individual 2035-2: Currently aged 35 years, this patient had an 
uneventful early childhood although he did not start to speak until the age of 2 years. A 
movement disorder began at the age of 12 with pain in the lower limbs and involuntary 
leg adduction when walking. Shortly thereafter the voice became spasmodic and he 
developed oromandibular dystonia, laterocollis and upper limb dystonia. Reflexes were 
brisk with ankle clonus. Bradykynesia was marked with a UPDRS part III score of 21 
(Fahn, Elton et al., 1987). The patient scored 58 on the Burke-Fahn-Marsden Scale with a 
disability score of 23. His generalized dystonia was mainly characterized by involvement 
of legs, hands and voice. The outcome with anticholinergic drugs (biperiden, 24mg per 
day) and levodopa/carbidopa (375/37.5 mg per day) treatment was poor although the 
bradykynesia had mild improvement with levodopa. 
 
• Individual 2035-3: This patient is currently 19 years old. Despite 
normal pregnancy and normal delivery, this patient exhibited delay of developmental 
motor and cognitive milestones. He started to walk at age 2 years when relatives noted 
feet inversion and knee flexion, suggestive of spasticity. He has never had intelligible 
language and speech is apparently affected by a spasmodic dysphonia. Lower limb 
dystonia spread to superior limbs and orofacial muscles and trunk. At age 14 he had an 
appropriate behavior when seen at the UFMG Movement Disorders Clinic despite the 
mention of occasional outbursts of aggressiveness by his relatives. The neurological 
Javier Simón Sánchez  Methods 
 137
examination showed generalized dystonia characterized by involvement of legs, hands, 
trunk and voice with a Burk-Fahn-Marsden scale score of 36 on the objective section and 
16 on the disability part. There was severe bradykinesia but no tremor. His deep reflexes 
were brisk. Use of levodopa/carbidopa (375/37.5 mg per day, six months) and biperiden 
(24 mg per day) did not benefit the dystonia but there was moderate improvement of the 
bradykinesia without significant UPDRS change. 
 
3.7.1.2. Family DYT16-2: 
• Individual 2035-119: This patient is 64 years old and has only been 
followed up at the UFMG Movement Disorders Clinic for the past year. He has no 
recollection of any neurological symptom until the age of 18, when he noticed an 
involuntary contraction of the left leg during walking. The symptoms progressed slowly, 
involving the right leg and the left arm. Ten years later, the patient developed a right 
laterocollis and a dysarthric speech. The trunk at this time also developed contractions in 
the same direction of the neck. Neurological examination showed right laterocollis, right 
laterotrunk, spasmodic dysphonia, extension of the left leg when walking, slight 
bradikynesia but normal tendon reflexes. He has been treated with anticholinergic drugs 
(biperiden 12mg per day) and baclofen (30 mg per day) with modest, if any, 
improvement. 
 
• Individual 2035-11: This patient is 34 years old and has been followed 
for the past 14 years. The mother reported no problems during pregnancy or delivery. 
There was, however, a slight delay in the developmental milestones (he started to walk at 
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age 18 months and did not speak before 5 years of age). At the age of 11 he noticed an 
involuntarily closing of the left hand and he needed to use his right hand to open the left. 
In the same year the movement disorder deteriorated, with involuntary pushing of the left 
shoulder backwards and downwards. At age of 13 years, the right shoulder was also 
involved and there was hoarseness of the voice. Three years later, the patient reported 
that his neck moved backwards involuntarily. The symptoms ameliorated when he 
touched his head. At this time, aged 20 years, he began to display impaired walking with 
right foot inversion and academic problems; at this point he sought medical assistance. 
Neurological exam at that time showed no Kayser-Fleischer ring, a brisk mentonian 
reflex and facial grimacing. The voice was dysarthric, with tongue dystonia. There was 
retrocollis and a laterocollis with contraction of both splenius capitis and scapular 
elevator. There was protrusion of left shoulder, hyperextension of left elbow, 
hyperflexion of the left wrist and fingers and hyperextension of the right wrist. The gait 
was dystonic with inversion of the right foot. Deep tendon reflexes, cerebellar tests and 
sensitivity were normal. There was no response to levodopa/carbidopa (375/37.5 mg per 
day, 6 months). Baclofen (60mg per day, 4 months) and anticholinergic drugs (biperiden, 
24 mg per day until the date) also failed to provide meaningful benefit. In 1993 the 
patient underwent botulinum toxin injection with excellent improvement of laterocollis 
and retrocollis. Despite this, the dystonia of inferior limbs and voice worsened. One year 
later the patient developed opisthotonic posturing and writer´s cramp. At age 29 there 
was deterioration of the movement disorders rendering the patient unable to walk, dress 
and feed without assistance. At this time, the patient lost weight and there was worsening 
of the arm and trunk dystonia. When the patient was 31-years-old speech was 
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unintelligible most of the time and there was moderate neck pain caused by the dystonia. 
He continued to receive periodic injections of botulinum toxin but increasing dosages 
(maximum of 600U units of Botox per session) were necessary to alleviate the retrocollis. 
Even during the peak of the effect, although the neck contractions improved at rest, there 
was intense overflow with return of the dystonic posturing of he neck during the gait. The 
only side effect was worsening of the dysphagia. The Burke-Fahn-Marsden scale rating 
during botulinum toxin effect score was 64 on the objective part and 21 on the disability 
section. 
 
• Individual 2035-12: This patient is currently 48 years old and has been 
followed for 3 years. She was born by natural delivery, following an uneventful 
pregnancy. Motor development was normal but her mother mentioned that she started to 
speak just at age 2 years and that her speech has always been difficult to understand. At 
the age 10 years, her mother noticed slowness of the hands although the patient became 
aware of this symptom as well as of tremor in the hands only when she turned 20. One 
year later she noticed involvement of the right leg. Since then there has been a slow 
worsening of the movement disorder. Currently the patient mentions freezing of her gait 
and writing as well as dysphagia. Neurological examination at age 45 years showed facial 
grimacing, severe hypomimia, and a slight oromandibular dystonia. The voice was 
characterized by a combination of lower volume and strangled character suggestive of a 
mixed form of spasmodic dysphonia. The patient also had dystonic posturing in the hands 
at rest (flexion of the fingers) and when writing (flexion of the wrist) as well as left foot 
eversion when walking. There was bradikynesia, slight postural tremor of the arms and 
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rigidity in the upper and lower limbs. There was no abnormality of deep tend reflexes, 
cerebellar or sensory functions. 5 mg per day, six months) and biperiden (24 mg per day) 
did not benefit the dystonia but there was moderate improvement of the bradykinesia 
without significant UPDRS change. 
 
3.7.1.3.  Individual 2035-61: This 42 year-old woman has been followed up for 12 years 
at the UFMG Movement Disorders Clinic. The symptoms began at the age of 7 years 
with difficulty in writing. Five years later she developed gait disturbance (extension of 
the left leg) followed by rapid spread to upper limbs, trunk, face and voice. There is a 
report of one of her brothers having had had similar symptoms with onset at age 8. 
Unfortunately he died at the age of 34 years from pneumonia before we could examine 
him. At the time of his death he was severely disabled and wheelchair-bound. The parents 
were cousins and died from cardiac problems. Neurological examination of our patient at 
age 30 years showed generalized dystonia, with facial grimacing, protrusion of tongue 
and lips, anarthria, left scoliosis, extension of both wrists with flexion of fingers, flexion 
of knees with feet inversion. The deep tendon reflexes were brisk but there were no 
parkinsonian features. The Burke-Fahn-Marsden scale score was 103 with disability of 
19. Levodopa (375/37.5mg per day), baclofen (30mg per day) and trihexyphenidyl (20mg 
daily) resulted in no improvement. Botulinum toxin injection in the submental area has 
consistently improved the dysphagia (brief summary in table 21). 
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3.7.2. Exclusion of known genes 
Affected family members from both families (DYT16-1 and DYT16-2) were screened for 
missense mutations in PRKN (linked to young-onset Parkinson’s disease; PARK2), 
ATP1A3 (linked to rapid-onset dystonia parkinsonism; DYT12) and GCH1 (linked to 
dopa responsive dystonia; DYT5) by direct sequencing of exons and flanking intronic 
sequence (Ichinose, Ohye et al., 1994; Kitada, Asakawa et al., 1998; De Carvalho 
Figure 15: Brain MRI and CT scans for affected individuals of families DYT16-1 and 
DYT16-2. (A, B) Coronal T1-weighted MRI after gadolinium contrast injection in patient 2035-
11. (C) Coronal T2-weighted MRI in patient 2035-11. (D) CT scan of patient 2035-12. No 
specific abnormalities can be appreciated. 
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Aguiar, Sweadner et al., 2004). The TOR1A ΔGAG mutation (linked to primary torsion 
dystonia; DYT1) was screened in both families by sequencing of the affected exon 
(Ozelius, Hewett et al., 1997).  
In each PCR reaction, 20 ng of genomic DNA was amplified with 5 pmol of each primer 
(primers sequence in table 22) and 2U of FastStart TaqDNA polimerase (Roche 
Diagnostics Corporation, http://www.roche.com). The final volume was of 15 μl. The 
thermal cycling program used was a 60td50 program (table 4). 
The PCR products were verified in a 2% ethidium-bromide-containing agarose-TBE gel 
and visualized via ultraviolet transillumination. Prior to loading each PCR product on a 
gel, it was mixed with 6X Orange G Loading Dye Solution. 
After verification, PCR products were purified with MultiScreen 96-Well Filter Plates 
(Millipore, http://www.millipore.com) as explained in section 3.1.2. 
Each purified product was sequenced using forward or reverse primers with Applied 
Biosystems BigDye terminator v3.1 sequencing chemistry (for more details see section 
3.1.2). Sequencing products were then purified with MultiScreen 96-Well Filter Plates 
(section 3.1.2) and electrophoresed in an ABI3730 XL genetic analyzer (Applied 
Biosystems, http://www.appliedbiosystems.com). Sequencher v4.1.4 software (Gene 
Codes, http://www.genecodes.com) was used to analyze results. All changes that derived 
from the wild type sequence were verified by PCR amplification of a fresh DNA aliquot 
and sequencing in both forward and reverse directions. 
 
Copy number mutations in PRKN were screened by means of real-time PCR as described 
in section 3.5.5. 
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An affected family member of DYT16-2 had previously been screened for missense 
mutations in LRRK2, PINK1 and SNCA in addition to whole gene multiplication mutation 
of SNCA as previously described (Johnson, Hague et al., 2004). 
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Exon Forward primer (5’-3’) Reverse primer (5’-3’) 
Gene: ATP1A3   
Exon 1 TATTGCGGAGGTCTCTGGG GACCACATGGATTGGCTGG 
Exon 2 GCATGGAGGGCCGGTGTC GACATCTTGTGCTCTGTCTG 
Exon 3 GAGGTGGCTATGGTAAGCC CCTTCACCAGACCCCCAG 
Exon 4 TTCTGGGGGTCTGGTGAAG CTCTTGCTGGGTGATTGTGA 
Exon 5 TCAGACACACCAACCCTCAT CGTTCACCTGCATCTTCTCA 
Exon 6 AGGAGGCCAAGAGCTCCAAG GGGGGCCTGGACTCCTG 
Exon 7 TTCTAGCTGTGATCTCCAGG GATGCCAGGGTGGCGATAC 
Exon 8 CCACCAACTGTGTGGAAGG TCCAGGCCTCTAGCCCCT 
Exon 9 CTCATTCTTTTCCAGGCCCT GCCACCCAGGTGTGCGAA 
Exon 10 AGAACCGCATGACAGTCGC GGGTTGTCAGAACAGGGAC 
Exon 11 CGCTGGGCTCTGCAATCG ATTATCATTCCCATTTTACAGAC 
Exon 12 AGGTCTCTGTGAGAGAGTGT AAGACGGCCAGTCAGCATTC 
Exon 13 GAATGCTGACTGGCCGTCTT CGTTGCCCTCAGAGATGATG 
Exon 14 ACTTCACCACGGACAACCTC TCCCAGAAAGAATGGGACAG 
Exon 15 GTCCTCTGGCTCTCCTGG TCAGACCCAGGGGTCCAG 
Exon 16 GTCTGAGGGAGGAAGGTCT CAGGGGAGGAAGACAGAAAA 
Exon 17 AAAAAAAAAAGGACGTTGGATGA CTGTCTCTTCATGATGTCGC 
Exon 18 CTCTGCATCGATCTGGGC GTGCAGACCCCCCCCAC 
Exon 19 AGGGCCAGGAGGGCATAC GGGCCATCGTAGGAAGTGG 
Exon 20 AGGCCCTGAGGACCCCAT GAGCTATGATTACACCACTGA 
Exon 21 GGGTGTCTGCACTGTGCC ATGGGGACTGCAGTGGGG 
Exon 22 CACCTGTGAGCACGAAGGA ACCCGTGAGAAGACAGAGTG 
Gene: TOR1A   
Exon5 AATGTGTATCCGAGTGGAAATG TGCCAATCATGACTGTCAATC 
Gene: GCH1   
Exon1 GTTTAGCCGCAGACCTCGAAGCG GAGGCAACTCCGGAAACTTCCTG 
Exon 2 GTAACGCTCGCTTATGTTGACTGTC ACCTGAGATATCAGCAATTGGCAGC 
Exon 3 AGATGTTTTCAAGGTAATACATTGTCG CTCGCAAGTTTGCTGAGGC 
Exon 4 GTCCTTTTTGTTTTATGAGGAAGGC GGTGTGCACTCTTATAATCTCAGC 
Exon 5 GTGTCAGACTCTCAAACTGAGCTC TCACTTCTAGTGCACCATTATGACG 
Exon 6 ACCAAACCAGCAGCTGTCACTCC AATGCTACTGGCAGTACGATCGG 
Gene: PRKN   
Exon 1 
Exon 2 
Exon 3 
Exon 4 
Exon 5 
Exon 6 
Exon 7 
Exon 8 
Exon 9 
Exon 10 
Exon 11 
Exon 12  
GCGCGGCTGGCGCCGCTGCGCGCA 
ATGTTGCTATCACCATTTAAGGG 
ACATGTCACTTTTGCTTCCCT 
ACAAGCTTTTAAAGAGTTTCTTGT 
ACATGTCTTAAGGAGTACATTT 
AGAGATTGTTTACTGTGGAAACA 
TGCCTTTCCACACTGACAGGTACT 
TGATAGTCATAACTGTGTGTAAG 
GGGTGAAATTTGCAGTCAGT 
ATTGCCAAATGCAACCTMTGTC 
ACAGGGAACATAAACTCTGATCC 
GTTTGGGAATGCGTGTTTT  
GCGGCGCAGAGAGGCTGTAC 
AGATTGGCAGCGCAGGCGGCATG 
AGGCCATGCTCCATGCAGACTGC 
AGGCAATGTGTTAGTACACA 
TCTCTAATTTCCTGGCAAACAGTG 
GAGTGATGCTATTTTTAGATCCT 
TCTGTTCTTCATTAGCATTAGAGA 
ACTGTCTCATTAGCGTCTATCTT 
AATATAATCCCAGCCCATGTGCA 
TTGGAGGAATGAGTAGGGCATT 
CAACACACCAGGCACCTTCAGA 
AGAATTAGAAAATGAAGGTAGACA 
Table 22: Forward and reverse primers sequences utilized for exclusion of ATP1A3, TOR1A, GCH1 and PRKN as 
candidates to cause disease in families DYT16-1 and DYT16-2.
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3.7.3. Genome-wide SNP genotyping. 
Based on number of affected family members and DNA availability, families DYT16-1 
and DYT16-2 were selected from a collection of 58 Brazilian young-onset PD and 
generalized dystonia cases for autozygosity mapping. Thus, DNA from all affected 
available members of these families was genotyped with Illumina’s HumanHap 550 
genotyping chips (version 1) as previously described in this work (sections 3.5.2 and 
3.6.2). Data was analyzed using BeadStudio v3 (Illumina, http://www.illumina.com).  
 
3.7.4. Autozygosity mapping. 
As previously explained (section 3.5.5), genotypic data generated by Infinium technology 
has numerous applications. The profile indicative of the existence of a homozygous track 
is lack of heterozygosity in the B allele frequency plot with no change at that same region 
of the log R ratio plot. In kindreds with an apparently recessive disorder, particulary in 
those where consanguinity is suspected, this approach can be used to score and compare 
extended regions of homozygosity across family members. Whether this approach will 
lead to the identification of single or multiple regions of interest and the size of these, 
relies on several factors: the degree of parental consanguinity, the number of informative 
family members and the relative stochastic nature of recombination.  
Homozygous tracks for each sample were scored using an in-house tool developed to 
help visualization of contiguous tracks of homozygosity (tracker v0.99, available at 
http://www.neurogenetics.org/XXXX). 
Following the identification of all homozygous tracks within affected individuals, 
genotypes were exported from BeadStudio v3.1 and compared for identity by state across 
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all six affected family members (i.e. stretches of identical genotype calls across all 
affected persons from both apparently unrelated families). 
All regions in the genome that were homozygous at greater than 50 contiguous SNPs and 
identical by state between family members both within and between families were 
considered as candidate disease gene regions. 
 
3.7.5. Sequencing of genes within critical intervals. 
All genes and transcripts included in candidate regions flanked by markers rs1434087 to 
rs10497541, rs13405069 to rs7581560 and rs1518709 to rs10930936, were identified 
using the Map Viewer tool (Build 36.2) within the National Center for Biotechnology 
Information (NCBI) website (http://ncbi/mapview/) and the ENSEMBL (based on the 
NCBI 36 assembly) data set (http://www.ensembl.org/Homo_sapiens/index.html). 
Primers were designed to allow amplification and sequencing of all coding exons and at 
least 30bp of flanking intronic sequence with the online tool ExonPrimer 
(http://ihg.gsf.de/ihg/ExonPrimer.html). Thus, the coding exons of OSBPL6, PRKRA, 
DFNB59, FKBP7, PLEKHA3, TTN, FLJ39502, SESTD1, LOC728984, LOC644776, 
ZNF533 and LOC72900 were sequenced (Supplementary material table S1).  
 
3.7.6. Assay for the c.665C>T (P222L) mutation. 
We analyzed this mutation by direct sequencing of exon 7 of PRKRA. This exon was 
amplified and sequenced with primer pair x7F-PRKRA 
(5’-AATGTTGTCTTGTTTAAATTG-3’) and x7R-PRKRA 
(5’-TACTATCCACAAGAATGGG-3’). The PCR amplification was carried out in a final 
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volume of 15μl containing 10ng of genomic DNA, 10pmol of forward and reverse 
primers and 10μl of FastStart PCR Master mix (Roche Diagnostics Corporation, 
http://www.roche.com). The thermal cycling program used was a 57td50 program (table 
5). 
The PCR poducts were verified in a 2% ethidium-bromide-containing agarose-TBE gel 
and visualized via ultraviolet transillumination. Prior to loading each PCR product on a 
gel, it was mixed with 6X Orange G Loading Dye Solution. 
After verification, PCR products were purified with MultiScreen 96-Well Filter Plates 
(Millipore, http://www.millipore.com) following the protocol displayed in section 3.1.2. 
Each purified product was sequenced using forward or reverse primers with BigDye 
terminator v3.1 chemistry and purified with MultiScreen 96-Well Filter Plates (see 
section 3.1.2 for details). 
Purified sequencing reactions were then electrophoresed on an ABI3730 XL genetic 
analyzer (Applied Biosystems, http://www.appliedbiosystems.com) and analyzed with 
Sequencher software v4.1.4 (Gene Codes, http://www.genecodes.com). All changes that 
deviated from the wild type sequence were verified by PCR amplification of a fresh DNA 
aliquot and sequencing in both forward and reverse directions. 
This exon was thus sequenced in all samples collected by Drs. Sarah Camargos and 
Francisco Cardoso (all available DYT16-1 and DYT16-2 family members as well as those 
45 young-onset PD patients, 12 apparently unrelated young-onset dystonia patients, and 
83 Brazilian neurologically normal controls), 439 North American Caucasian 
neurologically normal controls from panels NDPT002, NDPT006, NDPT009, NDPT022, 
NDPT023 and NDPT024 as well as 249 North American Caucasian patients with young-
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onset PD from panels NDPT014, NDPT015 and NDPT016 from the Coriell Institute 
repository (see sections 3.51 and 3.6.1 for details), 426 neurologically normal controls 
from Portugal collected by Jose Braas and Rita Guerreiro, and 738 samples from the 
Human Genome Diversity Project DNA panels that includes samples representing diverse 
populations worldwide, including 44 Brazilian subjects (http://www.cephb.fr/HGDP-
CEPH-Panel). In addition all coding exons of PRKRA were sequenced in all young-onset 
dystonia patients as described above (section 3.7.5). 
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4. RESULTS 
 
4.1. GENETIC ANALYSIS OF PARK8-LINKED PARKINSON’S DISEASE 
PATIENTS. 
 
4.1.1. Minimal haplotype shared by UGM03, UGM04, UGM05 and UGM06.  
A rare variant segregating with the disease in UGM03, UGM04 and UGM06 (Basque 
allele frequency of 0.01) indicated that these four kindreds might be ancestrally related 
(Paisan-Ruiz, Jain et al., 2004). In an effort to examine the existence of a minimal 
interkindred disease haplotype, 23 SNPs contained in the region with strongest linkage to 
disease (D12S331 to D12S1668) were sequenced in all affected members from the four 
families. This analysis showed a shared haplotype and that rs10876410 delimited the 
critical interval on the p arm in families UGM03, UGM05 and UGM06. Interestingly, 
UGM04 also shared a haplotype limiting the minimal interkindred disease haplotype at 
rs4548690 in the p arm, narrowing down the critical region to a 2.6 Mb region flanked by 
this SNP and D12S1653 (figure 16). This region contained only 11 genes and predicted 
transcripts. Systematic sequence analysis of these 11 genes (experiments performed by 
Dr. Coro Paisan-Ruiz) showed segregating mutations within a putative kinase domain 
containing transcript, DKFZp434H2111, which contains a 7,449 open reading frame 
encoding a 2,482 amino acid protein that includes a leucine-rich repeat, a kinase domain, 
a RAS domain and a WD40 domain. The change identified was a p.R1441G, not 
identified in 1300 chromosomes from North American controls and 160 chromosome 
from the Basque country. 
Javier Simón Sánchez  Results 
 150
This gene was later given the name of LRRK2 and the encoding protein dardarin. 
Dardarin comes from the Basque word dardara, meaning tremor. 
 
 
Figure 26 
 
 
 
4.1.2. A founder effect of p.R1441G in Basque population. 
With our allele-specific PCR assay (figure 17), we were able to identify 17 patients with 
this mutation, 10 of which were considered as sporadic (∼7% of the 238 analyzed). The 
Figure 16: Markers used to fine-map the candidate interval and determine 
interfamily shared haplotype and the boundaries of this haplotype. The 
black outline indicates the extent of the haplotype common between each Basque 
family. a Phase not determined. b Within KIF21A. c Within LRRK2. 
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relatively high frequency of this mutation in the Basque population, can be interpreted in 
two different ways, either this position is susceptible to several mutational events, as 
supported by the fact that p.R1441C and p.R1441H have been found in families with 
different ethnicities (Zimprich, Biskup et al., 2004; Mata, Kachergus et al., 2005), or all 
Basque carriers of the p.R1441G mutation could have inherited this alteration from a 
single founder. To differentiate between these two possibilities, we analyzed the 
chromosomal region surrounding LRRK2 in carriers of the mutation using the same 11 
SNPs that defined the critical haplotype in the four original Basque families (figure 17). 
We found that all carriers showed genotypes consistent with the haplotypes found in 
those families (table 23), thus supporting the idea that p.R1441G is a founder mutation.  
The minimal shared haplotype (656 Kb) is derived from a single individual, 01-407, who 
appeared to have a high degree of homozygosity for the rarer alleles at several of the 
SNPs assayed. Without this individual, the minimal shared haplotype would span 1.08 
Mb from rs10876886 to rs10784616. Thus, to rule out the presence of a microdeletion in 
this patient leading to this high degree of homozygosity, we performed a semi 
quantitative analysis of SNPs rs1047736 and rs937110, using a non-related genomic area 
on 11p11.2 as an endogenous control. With this approach, we determined that there was 
no deletion in this area. 
One alternative explanation to the fact that all carriers of the p.R1441G mutation shared 
the same haplotype, was that the haplotype where the mutation lies may be extremely 
frequent in the general Basque population. In order to rule out this possibility, we 
determined the frequency of this haplotype (that composed of 11 SNPs) in the general 
population, 80 control individuals from the Basque Country and 82 non-Basque Spanish 
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controls were genotyped. We failed to find this haplotype in the Basque population, 
indicating that it is less frequent than the haplotype with the lowest frequency found 
(0.625%). Curiously enough, we found more than 70 different haplotypes in the general 
Basque population, indicating that there is weak linkage disequilibrium in this region. 
Proof of this can be seen in figure 18, showing r2 and D’ values (two linkage 
disequilibrium measures) between those 11 SNPs that defined the critical disease interval. 
In the non-Basque Spanish individuals analyzed, the frequency of this same haplotype 
was up to 3% (frequency of the less represented haplotype in this population). 
 
 
 
 
Interestingly, typing rs4768224, rs12423567, rs1820544 and rs10784616 in five 
p.R1441G carriers from Asturias (PE008, PE155, PE040, PE066 and PE139) derived 
from a study performed by Mata and collaborators (Mata, Ross et al., 2006), showed that 
they share the same ancestral haplotype as the Basque carriers (table 23). 
Figure 17: Chromosomal region surrounding LRRK2. A: Schematic representation of the area covered with 
the single nucleotide polymorphisms (SNPs) assayed in this work. Below the chromosome 12 ideogram, the 
different genes are represented by gray arrows with the names of the genes shown. Distances are in Mb. The 
position of each SNP is indicated at the bottom. LRRK2 is indicated by a darker arrow. The vertical arrow 
points to the position of the R1441G mutation within LRRK2. B: Sample of the genotyping of one of the SNPs 
in panel B using ARMS and showing several homozygous for the T allele (samples 01, 03, 04, and 07) and 
several heterozygous genotypes. No homozygous for the C allele were observed in the population. 
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Finally, table 24 shows a summary of clinical features characterizing the disease in the 
mutation carriers. As shown, there are no differences in any of the clinical parameters 
analyzed between mutation carriers and PD patients without this mutation. Thus, it can be 
considered that PD due to the p.R1441G mutation in Dardarin is clinically 
indistinguishable from idiopathic PD. When considering the age at onset of those carriers 
among the Basque mutation in LRRK2, all but one of the carriers had a late-onset disease; 
the only case with an young-onset disease showed initiation of the disease at 44 years of 
age. 
 
 
 
 
 
 
Figure 18: Linkage disequilibrium across the chromosomal region surrounding 
LRRK2. Graphical Overview of Linkage Disequilibrium (GOLD) plots showing 
linkage disequilibrium of those 11 SNPs that defined the critical disease interval in 4 
Basque families, in Basque population. Pairwise LD analysis was performed using 
EMLD; D’ is shown in the upper left, r2 in the lower right.
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 rs1523118 rs10876410 rs10747736 rs10876886 rs11172282 rs937110 rs4768224 p.R1441G rs12423567 rs1820544 rs10784616 rs10879192 
01-102 T/T A/A T/T C/C G/G C/G A/T C/G G/T C/C C/C C/C 
01-113 C/T T/T C/T C/C G/G C/C T/T C/G G/T C/T C/G C/T 
01-142 T/T T/T C/T C/C G/G C/G T/T C/G G/T C/C C/C C/C 
01-407 T/T A/A C/C C/C G/G G/G T/T C/G G/T C/T C/G T/T 
01-492 T/T A/T T/T A/C C/G C/G T/T C/G G/G C/T G/C C/C 
01-517 T/T A/A T/T C/C G/G C/C T/T C/G G/G C/T C/G C/C 
01-371 C/T A/A C/T A/C C/G C/G T/T C/G G/G C/C C/C C/T 
01-226 C/T A/T T/T C/C G/G C/C T/T C/G G/G C/C C/C C/C 
02-143 T/T A/T T/T C/C G/G C/G T/T C/G G/G C/C G/C C/C 
02-209 C/T A/A C/T A/C C/G C/G T/T C/G G/T C/T C/C C/C 
02-254 T/T A/T T/T A/C C/G C/C A/T C/G G/T C/C C/G C/T 
04-259 C/T T/T T/T C/C G/G C/C T/T C/G G/T C/C C/C C/T 
04-400 C/T T/T T/T C/C G/G C/C T/T C/G G/T C/T C/G C/T 
04-409 C/T A/A C/C A/C C/G C/C T/T C/G G/T C/T C/G C/T 
04-410 C/T A/A C/T A/C C/G C/C T/T C/G G/T C/T C/G C/C 
04-419 C/T A/A  A/C C/G C/G A/T C/G G/T C/C C/C C/C 
04-466 C/T T/T C/T C/C G/G C/C T/T C/G G/G C/T C/G C/T 
PE008       T/A C/G G/T C/C C/G  
PE155       T/A C/G G/G C/C C/G  
PE040       T/T C/G G/T C/T C/C  
PE066       T/A C/G G/T C/C C/G  
PE139       T/T C/G G/T C/C C/G  
Families T T T C G C T G G C C C 
 Whole sample Basque origin Not Basque Familial  Sporadic 
    Basque Not Basque  Basque Not Basque 
N of R1441G carriers 17 16 1 6 1  10 - 
AAO*-carriers 63.5±8.5 63.8±8.7 59 65.0±11.0 59  65.7±10.2 - 
AAO*-non carriers 64.7±10.4 65.6±10.4 63.1±10.3 65.8±12.2 62.4±9.6  62.6±6.3 - 
Sex ratio (M:F) 0.643 0.583 1 0.5 1  0.75 - 
Years of evolution 10.2±6.7 9.6±6.3 21 7.3±6.4 21  10.9±6.1 - 
Response to L-Dopa Good Good Good Good Good  Good - 
Presenting symptom in carriers UT UT UT UT UT  Cl - 
 0.538 0.5  0.625   0.5  
Presenting symptom in non-carriers UT UT UT UT UT  UT - 
(% of cases) 0.602 0.559 0.667 0.556 0.723  0.563  
Genotypes for all 11 SNPs analyzed in all individuals carrying the R1441G mutation (bold) are shown. Those alleles consistent with 
Table 24: Summary of clinical features of Basque p.R1441G mutation carriers. 
Table 23: Genotypes of SNPs surrounding the LRRK2 locus in carriers of the p.R1441G mutation 
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4.2. IN SITU HYBRIDIZATION OF LRRK2 mRNA IN ADULT MOUSE 
BRAIN  
 
We studied LRRK2 mRNA expression in adult mouse brains through in situ hybridization 
analysis using digoxigenin-labelled RNA probes. We first confirmed the specificity of the 
probe by comparing the staining pattern of the antisense probe with that of the sense 
probe. The antisense probe showed specific signal patterns, whereas no signal was 
observed with the sense probe. This difference between both probes indicates that the 
antisense probe can specifically hybridize with its corresponding transcript (figure 19). 
As a result we found that LRRK2 mRNA was expressed throughout the mouse brain. As 
summarized in table 25, signal intensities varied from undetected (–), faint (+), moderate 
(++) and strong (+++). A detailed description of the most relevant findings organized into 
brain areas is as follows. 
 
 
 
 
Figure 19: LRRK2 mRNA expression in the mouse brain. Note that the antisense probe (A) shows a 
specific hybridization pattern and that the sense probe (C) show no hybridization signal. The hybridization 
pattern observed after 2 h of developing time is shown in A. In (A) and (B) note the strong reaction in the 
substantia nigra pars compacta and in some midbrain nuclei, including the interpeduncular and red nuclei as 
well as the periaqueductal gray and superior colliculus. Calibration bars, 200 μm. 
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4.2.1. Telencephalon. 
Varying LRRK2 mRNA expression patterns were observed in different cortical areas. In 
some areas, LRRK2 was expressed throughout the six cortical areas and the signal 
intensity depended on the cell density in each layer. This was the case of cingular-frontal 
(figure 20A), temporal (figure 20D) or occipital and the medial prefrontal cortex. In other 
areas, LRRK2 was absent or in disperse neurons in specific cortical layers. In the 
hindlimb area of the cortex (figure 20B) and in the parietal cortex (figure 20C), labelling 
was specifically scattered into the layers II ⁄ III and in layer V. Within the septal area, 
LRRK2 mRNA was not expressed in the nucleus triangularis septalis and was weakly 
expressed in the dorsal, ventral and intermediate parts of the lateral septal nucleus. 
However, a strong signal was observed in the horizontal limb of the medial septal 
nucleus, and a less but consistent labelling appeared in its vertical division dorsal tenia 
tecta. Furthermore, this gene was also highly expressed in the adjacent septohippocampal 
nuclei (figure 21A). Within the hippocampus, LRRK2 mRNA was abundantly expressed 
in the pyramidal cell layer of Ammon’s horn (CA1, CA2 and CA3) as well as in the 
granular cell layer of the dentate gyrus (figure 21B). A strong expression was also 
observed in disperse neurons either located in the molecular or in the radiatum-oriens 
layers. Strong labelling was also observed in the hilar region of the dentate gyrus. LRRK2 
mRNA was strongly expressed in almost every part of the amygdala except for the 
cortical-superficial area (figure 21C). Thus, it was strongly expressed in the amygdaloid 
intercalary grey area, the amygdalostriatal transition area, and it was moderately 
expressed in the amygdalopiriform transition area. With regard to the basal amygdaloid 
nucleus, very strong LRRK2 expression was observed in the lateral, basomedial, 
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basolateral and posterior basal divisions (figure 21D). Strong LRRK2 expression was 
noted in the medial amygdaloid nucleus in both the posterodorsal and posteroventral 
parts. LRRK2 expression was also detected in the intra-amygdaloid division of the bed 
nucleus of the stria terminalis close to the posterodorsal area of the medial amygdaloid 
nucleus and also in the central amygdala. The cortical nucleus, located proximally to the 
medial amygdaloid nucleus, also expresses LRRK2 mRNA in both the posterolateral and 
posteromedial parts. No signal was seen in the nucleus of the lateral olfactory tract or in 
the cortical amygdala (figure 21C). LRRK2 mRNA expression was high in the most 
superficial layers of the piriform cortex (figure 21E). The olfactory tubercule and the 
islands of Calleja are located close to the piriform cortex, which also showed strong 
LRRK2 expression (figure 21F). Within the basal ganglia, LRRK2 mRNA was detected 
throughout the striatum, where no patchy differences were observed that can indicate a 
possible differential reaction between striosome and matrix. Interestingly, the globus 
pallidus was nearly devoid of any LRRK2 expression (figure 22A). 
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Figure 20: LRRK2 mRNA expression in different cortical areas. (A) cingular ⁄ frontal cortical areas 
(B) hindlimb cortical area (C) parietal cortex, and (D) temporal cortex. Note that in both the hindlimb and 
parietal cortices, layers II ⁄ III and V showed scattered labeling. A long (12 h) chromogenic reaction was 
performed in all these cases. Calibration bars, 200 μm.
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Figure 21: LRRK2 mRNA distribution in telencephalic areas. (A) Rostral telencephalic areas tenia 
tecta and infralimbic medial prefrontal cortex. (B) Hippocampus, note that the nonpyramidal neurons of 
the Ammons horn (arrows) as well as the hilar neurons also express LRRK2. (C and D) Amygdala, note 
the scattered labeling in cortical amygdala and the nucleus of the lateral olfactory tract the square in C as 
magnified in D. (E) Piriform cortex, note the strong reaction of the superficial layer. (F) Rostral ventral 
telencephalon showing the islands of Calleja and the ventral striatum. A long (12 h) chromogenic reaction 
was performed in all these cases. Calibration bars, 200 μm. 
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4.2.2. Diencephalon. 
With the exception of the paraventricular thalamic nucleus (figure 22B) and the reticular 
nucleus (figure 22C), which strongly expresses LRRK2 mRNA, all the nuclei within the 
thalamus moderately expressed this gene (figure 22C). Some labelled cells were observed 
in both the medial and lateral geniculate nuclei. A strong LRRK2 mRNA expression was 
also observed in the medial habenular nucleus. However, only a very faint expression 
could be seen in the lateral nucleus (figure 22B). The zona incerta also contained strongly 
labeled neurons (figure 22C). On regard to the hypothalamus, a LRRK2 mRNA 
expression was observed in the posterior and dorsal areas, although its expression was 
very weak in the ventrolateral nucleus. The ventromedial hypothalamic nucleus showed a 
moderate-to-high expression in the dorsomedial and central parts but not in the 
ventrolateral one (figure 22D). The dorsomedial hypothalamic nucleus showed a high 
LRRK2 mRNA expression in compact, ventral and dorsal parts (figure 22D). A scattered 
reaction was observed in the lateral hypothalamic area. 
In addition to these above-mentioned diencephalic areas, the geniculate, zona incerta and 
subthalamic nucleus also expressed LRRK2 moderately. 
 
4.2.3. Brainstem. 
Strong LRRK2 mRNA expression was observed in both the dorsal and ventral tiers of the 
substantia nigra pars compacta. In contrast, weak LRRK2 mRNA expression was 
detected throughout the substantia nigra pars reticulata (figure 19B). The ventral 
tegmental area and the nucleus of Darkschewitsch moderately expressed LRRK2 mRNA. 
A strong reaction was observed in the intermediate grey layer of the superior colliculus 
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(figure 19B) and the red nucleus. Moreover, dispersely labeled neurons also occurred in 
the inferior colliculus and the nuclei of the lateral lemniscus (figure 22E). The 
periaqueductal grey also showed disperse staining (figure 19B). Moderate labeling was 
detected in the dorsal and in the median raphe nucleus. In contrast, the dorsal tegmental 
nuclei were almost devoid of expression. 
Faint LRRK2 mRNA expression was seen in the anterior, posterior and medial pretectal 
nuclei. Disperse labeling was observed along the reticular formation, whereas some cells 
of the pontine nuclei also expressed LRRK2 (figure 22E). 
 
4.2.4. Cerebellum. 
As seen in figure 22F the granular cell layer of the cerebellum exhibited a moderate 
LRRK2 mRNA expression. On the other hand, neither the Purkinje cell layer nor the basal 
nuclei showed LRRK2 mRNA expression. 
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Figure 22: LRRK2 mRNA distribution in subcortical areas. (A) Striatum, note the strong labelling in the putamen 
and contrastingly, the specific scattered reaction in the globus pallidus. (B) Habenula and paraventricular thalamic 
nucleus, contrasting the high signal in the medial habenula, the lateral habenula only showed disperse cells. (C) 
Reticular thalamic nucleus in the case of a short (2 h) chromogenic reaction. (D) Ventral tuberal region of the 
hypothalamus, note the scattered labelling in the ventrolateral division of the ventromedial hypothalamic nucleus 
contrasting with the rest of the hypothalamic region and areas. (E) Ventral pons, note the strong reaction in the pontine 
nuclei and the ventral division of the lateral lemniscus. (F) Cerebellum, note the strong reaction in the granular layer. 
A long (12 h) chromogenic reaction was performed in all the cases except C. Calibration bars, 200 μm. 
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Brain area LRRK2 mRNA  Brain area LRRK2 mRNA 
Telencephalon   Diencephalon  
Cerebral cortex  ++  Centrolateral nucleus  + 
Olfactory tubercle  ++  Paraventricular nucleus  +++ 
Piriform cortex  +++  Geniculate  ++ 
Claustrum  +  Habenular complex  
Hippocampal formation   Medial nucleus  +++ 
Ammon’s horn  +++  Lateral nucleus – 
Dentate gyrus  +++  Subthalamus  ++ 
Septal area   Zona incerta  ++ 
Tenia tecta  ++  Hypothalamus  
Vertical medial septal nucleus  +  Preoptic nuclei – 
Horizontal medial septal nucleus  ++  Posterior area  + 
Lateral septal nucleus  +  Dorsal area  + 
Septohippocampal nucleus  ++  Ventrolateral nucleus  + 
Nucleus Triangularis septalis –  Ventromedial nucleus  ++ 
Amygdala and extended amygdala   Dorsomedial nucleus  ++ 
Amygdaloid intramedullary grey  +++  Brainstem  
Amygdalopiriform transition area  ++  Pretectum  + 
Amygdalostriatal transition area  +++  Ventral tegmental area  + 
Basolateral amygdaloid nucleus  +++  Red nucleus  ++ 
Basomedial amygdaloid nucleus  +++  Nucleus of Darkschewitsch  ++ 
Central amygdaloid nucleus  +  Ventral tegmental area  + 
Medial amygdaloid nucleus  +++  Periaqueductal gray  ++ 
Lateral amygdaloid nucleus  ++  Median raphe  ++ 
Nucleus of the lateral olfactory tract –  Dorsal raphe  ++ 
Cortical amygdala  –  Dorsal tegmental nuclei  – 
Bed nucleus of the stria terminalis  ++  Pontine nuclei  ++ 
Basal ganglia   Superior colliculus  ++ 
Globus pallidus  –  Inferior colliculus  + 
Caudate putamen  +++  Substantia nigra  
Nucleus accumbens  –  Pars compacta  +++ 
Diencephalon   Pars reticulata  – 
Thalamus   Cerebellum  
Anterodorsal nucleus  ++  Cerebellar nuclei  – 
Reticular nucleus  ++  Cortex  
Parafascicular nucleus  +  Purkinge cell layer  – 
Mediodorsal nucleus  ++  Granule cell layer  ++ 
Table 25: Relative levels of expression of LRRK2 in adult mouse brain. 
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4.3. SEQUENCING ANALYSIS OF OMI/HTRA 
 
After analyzing the entire protein coding region of OMI/HTRA2 (RefSeq NM_013247) in 
a total of 644 PD patients and 828 neurologically normal controls we identified the c. 
1195G>A substitution in exon 7 (leading to p.G399S), previously identified as a mutation 
associated with PD by Strauss and collaborators (Strauss, Martins et al., 2005) , in a total 
of 5 PD patients (0.77%) and 6 neurologically normal control individuals (0.72%) (figure 
23). The PD patients carrying this substitution were ND00428, ND00154, ND01247, 
ND09816 and ND00148. 
ND00428 and ND00154 were both diagnosed with YOPD with ages at onset of 38 and 30 
years respectively. ND01247, ND09816 and ND00148 were diagnosed with late-onset PD 
with ages at onset of 56, 65 and 77 years respectively. 
The control samples carrying p.G399S were ND01699, ND05065, ND10345, ND03376, 
ND10860 and ND08025. These samples were derived from panels NDPT002, NDPT006 , 
NDPT019, NDPT020, NDPT0 21 and NDPT023 with ages at sampling of 85, 70, 25, 42, 
46 and 62 years respectively. Fisher’s exact association test showed no association 
between p.G399S and PD (table 26). 
Fisher’s exact association tests considering either YOPD or late-onset PD samples along 
with their corresponding age-matched controls were performed. No association was seen 
after these analyses (table 26). 
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Table 26 also shows the frequency of genotypes of the variant c.421G>T in exon 1 of 
OMI/HTRA2 (leading to p.A141S). The T allele of this variant has previously been 
associated with PD (Strauss, Martins et al., 2005); however, we failed to find such an 
association in our dataset performing Fisher’s exact association tests considering all 
samples and only YOPD and late-onset PD cases independently, along with their 
corresponding age-matched neurologically normal controls (table 26). Only ND4314 and 
ND04275 (two neurologically normal control individuals of 49 and 55 years respectively) 
were homozygous for this change (figure 22). 
We failed to find the synonymous p.F149F variant, previously identified by Strauss and 
colleagues, in our population. 
In addition to these variants, we identified 8 novel heterozygous coding variants, both 
synonymous (p.V109V, p.L118L, p.R209R and p.L367L) and non-synonymous 
Minor Allele MAF 
Variant Samples included in analysis 
(Cases-Controls) Cases - Controls 
Fisher's p value OR C.I 95% 
PD: all, n = 644 
p.G399S 
Controls: all, n = 828 
A (5-6) 0.388%-0.363% 1 1.069 0.3256-3.511 
PD: age at onset ≤ 40, n = 106 
p.G399S Controls: age at sampling ≤ 40, n = 
141 
A (2-1) 0.944% - 0.354% 0.5794 2.676 0.2411 - 29.71 
PD: age at onset > 40, n = 538 
p.G399S Controls: age at sampling > 40, n = 
687 
A (3-5) 0.278% - 0.365% 1 0.7633 0.182 - 3.201 
PD: all, n = 644 
p.A141S 
Controls: all, n = 828 
T (28-46) 2.215% - 2.991% 0.2365 0.7348 0.4566 - 1.182 
PD: age at onset ≤ 40, n = 106 
p.A141S Controls: age at sampling ≤ 40, n = 
141 
T (7-9) 3.398% - 3.214% 1 1.059 0.3879 - 2.892 
PD: age at onset > 40, n = 538 
p.A141S Controls: age at sampling > 40, n = 
687 
T (21-37) 1.985% - 2.941% 0.1815 0.6683 0.3887 - 1.149 
Table 26: Minor allele frequencies (MAF), Fisher’s exact test p values, odds ratios (OR), and 95% confidence intervals (C.I 95%), for 
variants p.G399S and p.A141S. 
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(p.W12C, p.P128L, p.F172V and p.A227S), in both cases and control samples. None of 
these seem to be causative of disease in our population (table 27). 
In addition to these variants, 8 SNPs have been described within the OMI/HTRA2 coding 
region, two being exonic and six residing within introns. Of these only rs2231249, 
rs2231248, rs11538692, rs2241027 and rs2241028 were within our sequencing 
boundaries and thus, were genotyped. Variants rs2231248 (exon 1), rs2241027 (intron 4) 
and rs2241028 (intron 5) had at least one sample with a variant allele; however, none of 
these SNPs showed association with PD after Fisher’s exact association tests (table 27). 
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Figure 23: Chromatogram showing p.G399S and p.A141S variants 
in OMI/HTRA2. Green arrows indicate wild-type sequence, blue arrows 
heterozygous changes, and the red arrow in the bottom panel shows a 
homozygous change for p.A141S. 
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Minor Allele MAF Variant Samples included in analysis 
(Cases-Controls) Cases-Controls 
Fisher's p value OR C.I 95% 
p.V109V PD: all, n = 644 Controls: all, n = 828 A (2-0) 0158% - 0% - - - 
PD: age at onset ≤ 40, n = 106 
p.V109V Controls: age at sampling ≤ 40, n = 
141 
A (1-0) 0. 4854% - 0% - - - 
PD: age at onset > 40, n = 538 
p.V109V Controls: age at sampling > 40, n = 
687 
A (1-0) 0.0945% - 0% - - - 
p.L118L PD: all, n = 644 Controls: all, n = 828 G (0-2) 0% - 0.130% - - - 
PD: age at onset ≤ 40, n = 106 
p.L118L Controls: age at sampling ≤ 40, n = 
141 
G (0-2) 0 - 0.714% - - - 
PD: age at onset > 40, n = 538 
p.L118L Controls: age at sampling > 40, n = 
687 
G (0-0) 0% - 0% - - - 
p.R209R PD: all, n = 644 Controls: all, n = 828 G(2-0) 0.156% - 0% - - - 
PD: age at onset ≤ 40, n = 106 
p.R209R Controls: age at sampling ≤ 40, n = 
141 
G (0-0) 0% - 0% - - - 
PD: age at onset > 40, n = 538 
p.R209R Controls: age at sampling > 40, n = 
687 
G (2-0) 0.187% - 0% - - - 
p.L367L PD: all, n = 644 Controls: all, n = 828 C (0-1) 0% - 0.063% - - - 
PD: age at onset ≤ 40, n = 106 
p.L367L Controls: age at sampling ≤ 40, n = 
141 
C (0-0) 0% - 0% - - - 
PD: age at onset > 40, n = 538 
p.L367L Controls: age at sampling > 40, n = 
687 
C (0-1) 0% - 0.077% - - - 
p.W12C PD: all, n = 644 Controls: all, n = 828 G (0-1) 0% - 0.064% - - - 
PD: age at onset ≤ 40, n = 106 
p.W12C Controls: age at sampling ≤ 40, n = 
141 
G (0-0) 0% - 0% - - - 
PD: age at onset > 40, n = 538 
p.W12C Controls: age at sampling > 40, n = 
687 
G (0-1) 0% - 0.078% - - - 
p.P128L PD: all, n = 644 Controls: all, n = 828 C (0-1) 0% - 0.065% - - - 
PD: age at onset ≤ 40, n = 106 
p.P128L Controls: age at sampling ≤ 40, n = 
141 
C (0-1) 0% - 0.357% - - - 
PD: age at onset > 40, n = 538 
p.P128L Controls: age at sampling > 40, n = 
687 
C (0-0) 0% - 0% - - - 
Table 27: Minor allele frequencies (MAF), Fisher’s exact test p values, odd ratios (OR) and 95% confidence intervals (C.I 95%) for all new variants 
found in our data set as well as 3 SNPs within OMI/HTRA2.  
MAFs, p values, ORs and C.I 95% were calculated in both the entire group (644 PD cases and 828 neurologically normal controls) and only testing 
YOPD and Late-onset PD cases independently with corresponding age-matched control groups. 
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Minor Allele MAF Variant Samples included in analysis 
(Cases-Controls) Cases-Controls 
Fisher's p value OR C.I 95% 
p.F172V PD: all, n = 644 Controls: all, n = 828 G (1-0) 0.0782% - 0% - - - 
PD: age at onset ≤ 40, n = 106 
p.F172V Controls: age at sampling ≤ 40, n = 
141 
G (1-0) 0.4762% - 0% - - - 
PD: age at onset > 40, n = 538 
p.F172V Controls: age at sampling > 40, n = 
687 
G (0-0) 0 - 0 - - - 
p.A227S PD: all, n = 644 Controls: all, n = 828 T (1-0) 0.078% - 0% - - - 
PD: age at onset ≤ 40, n = 106 
p.A227S Controls: age at sampling ≤ 40, n = 
141 
T (0-0) 0% - 0% - - - 
PD: age at onset > 40, n = 538 
p.A227S Controls: age at sampling > 40, n = 
687 
T (1-0) 0.093% - 0% - - - 
rs2231248 PD: all, n = 644 Controls: all, n = 828 G (1-0) 0.079% - 0% - - - 
PD: age at onset ≤ 40, n = 106 
rs2231248 Controls: age at sampling ≤ 40, n = 
141 
G (0-0) 0% - 0% - - - 
PD: age at onset > 40, n = 538 
rs2231248 Controls: age at sampling > 40, n = 
687 
G (1-0) 0.094% - 0% - - - 
rs2241027 PD: all, n = 644 Controls: all, n = 828 G (6-8) 0.465% - 0.493% 1 0.9442 0.3268-2.728 
PD: age at onset ≤ 40, n = 106 
rs2241027 Controls: age at sampling ≤ 40, n = 
141 
G (3-1) 1.415% - 0.354% 0.3187 4.033 0.4166-39.05 
PD: age at onset > 40, n = 538 0.5269 
rs2241027 Controls: age at sampling > 40, n = 
687 
G(3-7) 0.278% - 0.522% 
 
0.5324 0.1374-20.64 
rs2241028 PD: all, n = 644 Controls: all, n = 828 G (60-85) 4.73% - 5.400% 0.4412 0.8701 0.6199-1.221 
PD: age at onset ≤ 40, n = 106 
rs2241028 Controls: age at sampling ≤ 40, n = 
141 
G (13-20) 6.311% - 7.140% 0.8556 0.8756 0.4251-1.804 
PD: age at onset > 40, n = 538 
rs2241028 Controls: age at sampling > 40, n = 
687 
G (47-65) 4.420% - 5.020% 0.5596 08755 0.5961-1.286 
Table 27 (continued) 
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4.4. ANALYSIS OF SCA-2 AND SCA-3 REPEATS IN PARKINSONISM 
 
Analysis of ATXN-2 and ATXN-3 xpansions in 280 probands with PD (both with and 
without positive family history) with differen ethnical backgroud (see methods section 
3.4), showed no evidence of ATXN-3 expansion in any of the patients analyzed (repeat 
sizes ranged from 11 to 44). However, one Caucasian proband (patient 374-1) had an 
expanded ATXN-2 allele with 37 repeats. The remaining individuals had ATXN-2 
trinucleotide repeats lengths within the normal range (17–29). Assessing the ATXN-2 
locus in available family members of patient 347-1 demonstrated that the expanded allele 
was also found in the other family member with parkinsonism (individual 374-5, with 
repeat sizes of 22 and 37) but not in subject 374-9, who had essential tremor (figure 24). 
These results show that this expansion mutation within ATXN-2 is the cause of disease in 
this family (figure 24). 
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4.5. WHOLE-GENOME SNP GENOTYPING IN PARKINSON’S DISEASE 
AND NEUROLOGICALLY NORMAL CONTROLS. STAGE 1 
 
4.5.1. Whole-genome association 
We genotyped 276 samples from patients with idiopathic PD and 276 from unrelated 
neurologically normal controls with Illumina’s Infinium I and Infinium II HumanHap 300 
genotyping beadchips.  
Genotyping of the control and the three PD replicate samples with the Infinium I assay 
gave genotype concordance rates greater than 99.99%. Besides, analysis of the 18,073 
Figure 24: Pedigree of family 374. Number pairs 
underneath each sampled individual represent SCA-2 
repeat sizes. A black section represents that parkinsonism 
is present. Gray section on individual 374-9 indicates 
essential tremor. 
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SNPs that overlap between Infinium I and Infinium II platforms revealed genotype 
concordance rates of 99.94% between the assays across samples. 
All samples with a call rate below 95% were re-assayed using a new aliquot of DNA 
extracted directly from blood. Those samples that did not reach the 95% threshold after 
repeated assay were dropped from further analysis. Thus, four control samples and three 
PD samples were dropped from our study. Since two YOPD samples had erroneously 
been included in panel NDPT007 (see structural variation in PD-related loci in section 
4.5.2.3) the final number of fully genotyped samples was 271 controls and 267 PD 
patients. For those 408,803 SNPs assayed, the genotype call rate was greater than 99% 
for 395,275 SNPs (96.6%) and greater than 95% for 406,312 (99.4%). The Hardy-
Weinberg equilibrium p value was higher than 0.01 for 395,493 SNPs and higher than 
0.05 for 375,527 SNPs (figure 25). The average minor allele frequency for autosomes 
was 26.47%. A total of 219,577,497 unique genotype calls were made and the average 
call rate across all samples was 99.6%. 
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Analysis with STRUCTURE v2.2 (http://pritch.bsd.uchicago.edu/structure.html) showed 
that there is no discernible difference in the population substructure between cases and 
controls (figure 26). Furthermore, comparison of the cases and controls pooled together 
versus genotypes from a cohort of 173 non-white participants showed clear separation of 
the Parkinson’s disease and control group from the non-white group, with the exception 
of a single patient from the former cohort, who, based on these analyses, had significant 
non-white genetic background. This individual was removed from the association 
analysis. 
 
Figure 25: Hardy-Weinberg p value distribution in our final set of samples. 
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Statistical analysis of association was done for all genotypes regardless of Hardy-
Weinberg disequilibrium or minor allele frequency (figure 27). Analysis of our data 
showed 26 SNPs with a two-degree of freedom p value below 0.0001 (table 28), with 
ORs ranging from 0.2 (95% CI 0.04-0.5) to 0.6 (0.5-0.8) and from 1.7 (1.3-2.2) to 2.2 
(1.6-3.2). However, a stringent Bonferroni correction based on 408,803 independent tests 
means that a precorrection p value of less than 1.2 x 10-7 would be needed to provide a 
Figure 26: Bar and Triangle Plots from Structure using 267 random Autosomal SNPs. A) Bar plot for K = 
2 sorted by putative population where Population 1 consists of 271 Caucasian controls and population 2 consists 
of 267 sporadic PD patients. B) Bar plot for K = 2, sorted by putative population using the same set of 267 SNPs 
where population 1 consists of 538 Caucasians (sporadic PD case/control series) and Population 2 consists of 
173 non-Caucasian subjects. C) Triangle plot with same putative populations as bar plot A but with K = 4 where 
blue dots are population 1 (Controls) and red dots are population 2 (PD cases). D) Triangle plot with same 
putative populations as bar plot B) but with K = 4 where blue dots are Population 1 (Caucasian sporadic PD 
cases and controls) and red dots are population 2 (non-Caucasian subjects). Arrows indicate non-white individual 
dropped from further analyses. 
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corrected significant p value of less than 0.05. Thus, none of the values listed were 
significant after correction. 
A secondary objective of this project was the release of genome-wide data from a well-
characterized publicly available cohort of both controls and PD patients. Thus, 
genotyping data obtained in our experiments can be downloaded from 
(http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gap). 
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Figure 27: Example of the plots obtained after statistical analysis with SNPgwa software. Log p values are plotted across 
chromosome 4 (upper panel) and across a significant region (lower panel). A high degree of linkage disequilibrium can be seen 
across the significant region, which explains the significant association of many neighboring SNPs. LPV=log p value. PV=p 
value. 2DF=two degree of freedom genotype test. Add=additive model. Rec=recessive model. Dom=dominant model. 
Allelic=allelic association. LRS 2 marker=two marker haplotype association (two contiguous markers). LRS 3 marker=three 
marker haplotype association (three contiguous markers). HWE=p value indicating deviation from Hardy Weinberg equilibrium. 
HW Comb=for cases and controls. HW cases=for cases. HW controls=controls. D’and R2 squared are both measures of linkage 
disequilibrium. 
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Chr. Location SNP ID Location bp  No. Geno Gene HWE p-value 
2DF p-
value  
2DF 
Empirical 
p-value  
Dom/Add/Rec  
p-value  OR (95% CI) 
Dom/Add/Rec 
Empirical   p-
value  
11q14 rs10501570 84095494 536 DLG2 0.396 7.3x10-06 2.0x10-06 5.3x10-04R 0.2 (0.0-0.5) 4.9x10-04R 
17p11.2 rs281357 19683106 537 ULK2 0.852 9.8x10-06 4.0x10-06 0.0002R 0.4 (0.2-0.6) 1.5x10-05R 
4q13.2 rs2242330+ 68129844 537 BRDG1 0.708 1.7x10-05 1.2x10-05 2.9x10-06A 0.5 (0.4-0.7) <1x10-06A 
10q11.21 rs1480597* 44481115 525 Intergenic 1.000 1.9x10-05 7.0x10-06 3.2x10-06D 0.4 (0.3-0.6) 2.0x10-06D 
4q13.2 rs6826751+ 68116450 536 BRDG1 0.024 2.0x10-05 1.8x10-05 3.5x10-06A 0.6 (0.4-0.7) 5.0x10-06A 
16q23.1 rs4888984 78066835 537 Intergenic 1.000 2.7x10-05 1.1x10-05 4.6x10-06A 0.5 (0.3-0.7) 3.0x10-06A 
4q35.2 rs4862792 188438344 511 Intergenic 0.358 3.5x10-05 8.0x10-06 6.8x10-06D 2.9 (1.8-4.6) 7.0x10-06D 
4q13.2 rs3775866+ 68126775 537 BRDG1 0.911 4.6x10-05 3.3x10-05 7.8x10-06A 0.5 (0.4-0.7) 8.0x10-06A 
20q13.13 rs2235617‡ 47988384 530 ZNF313 0.034 4.7x10-05 4.7x10-05 8.8x10-06D 0.4 (0.3-0.6) 1.2x10-05D 
1p31 rs988421 72322424 536 NEGR1 0.667 4.9x10-05 4.3x10-05 7.0x10-04R 2.0 (1.3-3.0) 8.2x10-04R 
10q11.21 rs7097094* 44530696 537 Intergenic 0.294 5.0x10-05 2.7x10-05 8.9x10-06D 0.5 (0.3-0.7) 8.0x10-06D 
10q11.21 rs999473* 44502322 537 Intergenic 0.294 5.0x10-05 3.8x10-05 8.9x10-06D 2.2 (1.5-3.1) 8.0x10-06D 
11q11 rs1912373 56240441 537 Intergenic 0.375 5.6x10-05 6.1x10-05 9.7x10-06D 2.2 (1.6-3.2) 1.2x10-05D 
1q25 rs1887279# 182176783 537 GLT25D2 0.424 5.7x10-05 3.5x10-05 1.2x10-05A 0.5 (0.4-0.7) 6.0x10-06A 
1q25 rs2986574# 182173237 536 GLT25D2 0.350 6.3x10-05 2.4x10-05 1.3x10-05A 2.0 (1.4-2.7) 6.0x10-06A 
22q13 rs11090762 46133989 536 Intergenic 0.730 6.3x10-05 4.2x10-05 1.2x10-05D 0.4 (0.3-0.6) 8.0x10-06D 
20q13.13 rs6125829‡ 48002336 509 ZNF313 0.004 6.6x10-05 7.2x10-05 1.4x10-05D 2.2 (1.6-3.2) 1.8x10-05D 
7p12 rs7796855 49627992 537 Intergenic 0.931 6.6x10-05 7.2x10-05 1.3x10-05D 0.4 (0.3-0.6) 1.2x10-05D 
4q13.2 rs355477+ 68079120 533 BRDG1 0.207 7.9x10-05 7.4x10-05 1.5x10-05A 0.6 (0.5-0.8) 1.7x10-05A 
1q25 rs3010040# 182174845 537 GLT25D2 0.421 8.0x10-05 6.2x10-05 1.6x10-05A 0.5 (0.4-0.7) 1.2x10-05A 
1q25 rs2296713# 182176340 537 GLT25D2 0.421 8.0x10-05 6.2x10-05 1.6x10-05A 2.0 (1.4-2.7) 1.2x10-05A 
4q13.2 rs355461+ 68063319 537 BRDG1 0.150 8.3x10-05 6.0x10-05 1.6x10-05A 1.7 (1.3-2.2) 1.9x10-05A 
4q13.2 rs355506+ 68068677 537 BRDG1 0.150 8.3x10-05 6.0x10-05 1.6x10-05A 1.7 (1.3-2.2) 1.9x10-05A 
4q13.2 rs355464+ 68061719 531 BRDG1 0.086 8.9x10-05 9.3x10-05 1.7x10-05A 1.7 (1.3-2.2) 2.1x10-05A 
4q13.2 rs1497430+ 68040409 535 BRDG1 0.150 9.7x10-05 8.0x10-05 1.8x10-05A 1.7 (1.3-2.2) 1.9x10-05A 
4q13.2 rs11946612+ 68018566 535 BRDG1 0.150 9.7x10-05 8.5x10-05 1.8x10-05A 0.6 (0.5-0.8) 2.1x10-05A 
Table 28: p values with uncorrected significance greater than 1x10-5. 
Only data from SNPs that gave successful genotypes in >95% of samples (406,312 of 408,803 SNPs) is included in this table. While the SNPs outlined here 
remain candidates, an appropriate replication or joint-analysis follow up is required and would include genotyping of loci that are significant down to a less 
stringent p value.*,#,‡,+ each of these indicate closely associated SNPs 
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4.5.2. Beyond association 
We embarked on a whole genome SNP genotyping project, primarily to generate publicly 
available genotyping data for PD patients and neurologically normal controls derived 
from the NINDS-funded open-access Neurogenetics repository at Coriell Cell 
Repositories so that these data could be mined and augmented by other researchers, and 
also to undertake a preliminary analysis in an attempt to localize common genetic 
variation exerting a large effect on risk of PD in a cohort of white North Americans. 
However, analysis of B allele frequency and log R ratio metrics can be used to visualize 
copy number variation and tracks of homozygosity in the analyzed samples. As explained 
in section 3.6.5, the log R ratio gives an indirect measure of copy number of each SNP by 
plotting the ratio of observed to expected hybridization intensity. B allele frequency plots 
the proportion of times an allele is called A or B at each genotype: thus the expected 
ratios are 1.0 (B/B), 0.5 (A/B) and 0.0 (A/A). Using these two metrics, we scored copy 
number variation and tracks of contiguous homozygosity both in the PD cohort and in the 
neurologically normal controls. 
 
4.5.2.1. Extended homozygosity in control population: Using a cut-off of 5Mb, 26 
neurologically normal control samples were found to harbor at least one track of 
consecutive homozygous SNPs (9.5% of the neurologically normal control cohort). Out 
of these 26 samples, 11 (42.3%) showed more than one region of homozygosity greater 
than 5 Mb in size. If this co-occurrence was due to chance alone, we would expect a total 
of ∼ 2.44 control samples (0.095 x 0.095 x 271 control samples) with more than one 
homozygous track bigger than 5Mb. Thus, the co-occurrence detected here is 4.5-fold 
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greater than expected by chance alone. This supports the idea that parental consanguinity 
is the cause (table 29, figure 28). 
Genotyping six of these samples using DNA extracted directly from blood, revealed 
identical patterns of homozygosity in the replicate DNA samples, discarding the 
possibility that lymphoblast cell line (LCL) creation and cell culture is the cause (figure 
29). 
 
 
 
Member Chromosome Size (Mb)  Member Chromosome Size (Mb) 
ND01217 3p12.2-12.1 5.45  5p15.2-p15.3 9.66 
ND01317 3p12.2-12.1 5.23  8q12-q22 39.68 
ND01565 3q25.1-25.32 5.37  9q21 6.21 
3q25-q26.3 17.47  9q21-q22 8.38 
5q35.2-35.3 5.93  9q33-q34 15.85 
11p13-p15 14.10  
ND04275*+ 
11q11-q13 11.05 
11q22-q23 5.58  7q31 5.29 
12q23.2-23.3 6.05  15q11.2-q14 14.32 
18q21-q22 23.66  
ND04276 
20p11.2-q12 15.28 
ND01567 
21q21-q22 5.99  9p13-p21 9.24 
ND02422 11p11.2-q11 5.83  
ND04305*+ 
9q22-q31 5.15 
1p35.1-p36.11 9.74  6q22-q23 5.53 
3q26.31-26.33 6.83  
ND04312 
11p11.1-p14 28.15 ND03549 
6p11.1-p12 21.72  ND04404 9q32-33.1 6.59 
4q12-q13 13.08  ND05283 3p21.31-21.2 5.24 
17p11.1-p11.2 7.64  ND05296 1p31 14.91 ND03713 
22q12-q13 9.83  ND05369 2q36-q37 6.47 
ND03715 3q25-q26.1 6.10  ND05372* 1p35 6.26 
15q24-q25 4.96  8p21-q12 36.74 ND04016*+ 
16q12.1-q13 7.06  15q14-q15 5.83 
ND04104*+ 15q21 5.37  
ND00674*+ 
18q21-q22 14.58 
1p22-p31 19.70  ND00677 11p11.1-p11.2 8.31 
8p11.1-p21 17.96  ND00689 3p21.31-21.2 5.11 ND04178 
21q21 12.54  10q26 8.57 
ND04214 14q21 6.62  
ND00707 
17q24-q25 5.82 
ND04240 8q24.2-q24.3 5.24     
Table 29: Regions of contiguous extended homozygosity >5 Mb identified in 26 of 272 individuals analyzed (9.5%). 
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Figure 28: Data from Human-1 BeadChips revealing extended homozygosity. 
Extended homozygosity detected on chromosome 3 (top panel), chromosome 8 (middle 
panel) and chromosome 11 (bottom panel) in samples ND00674 (chromosome 8) and 
ND01567 (chromosomes 3 and 11). Each panel includes two plots. The upper plot is the 
log R ratio, which is a measure of copy number for each SNP. The mean of the log R ratio 
(over a 50 kb sliding window) is denoted by a red line. The lower plot shows B allele 
frequency, and shows genotypes for BB (B allele frequency = 1), AB (B allele frequency 
= 0.5) and AA (B allele frequency = 0). A lack of AB genotypes across a large contiguous 
area, in the absence of an alteration in copy number is indicative of a large area of 
homozygosity. The homozygous regions are indicated by gray shading 
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Figure 29: Composite heat map of Loss Of Homozygosity (LOH) statistics calculated using 
BeadStudio. LOH statistics were calculated for a moving window of >1Mb. Lanes 1-5 each 
contain duplicate samples designated with homozygous regions >5Mb, each lane shows results 
from a pair of samples, one from DNA extracted from EBV immortalized cell lines (E) and one 
from DNA extracted directly from blood (B). Lane 1 ND04305; lane 2 ND04016; lane 3 
ND00674; lane 4 ND04275; lane 5 ND04104. Lanes 6-9 are 4 representative samples without 
extended homozygosity. 
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4.5.2.2. Copy number variation in control population:  
• Genomic deletions: Analysis of log R ratio and B allele frequency in each 
of the 271 samples assayed with the Human-1 BeadChips revealed data consistent with 
genomic deletion in nine samples, six sub-chromosomal (ranging in size from 0.6 to 32.9 
Mb) and three affecting the whole chromosome X (table 30).  
Of those sub-chromosomal deletions, only one (2.6M), on chromosome 3 of ND01493 
was consistent with simple heterozygous deletion. This was indicated by a decrease in the 
log R ratio and a lack of heterozygous SNP calls (figure 30). For the remaining five, we 
observed contiguous drops in log R ratio, consistent with a decrease in copy number. 
However, the observed drop in log R ratio was not coupled with an absence of 
heterozygous calls in these regions, thus excluding simple, heterozygous genomic 
deletion (table 30). Analysis at the sites of interests of B allele frequency revealed four 
clusters of contiguous genotypes, rather than the expected three. These were at 1 (100% 
B allele), 0 (100% A allele) and at two other locations, one situated between 0.5 and 1 
(cluster c) and one between 0 and 0.5 (cluster d). Within each sample, the average 
position for cluster c was the same as 1 minus the average position for cluster d, and these 
cluster positions ranged approximately from B allele frequency 0.15 and 0.85 to 0.45 and 
0.55. The observed alterations are consistent with heterosomic deletions, where a 
heterozygous genomic deletion is present in only a proportion of the cells contained 
within a sample (figure 31). 
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Individual Chr. Approximate Size (Mb) 
Alteration in EBV 
DNA 
Alteration confirmed in 
DNA from blood 
ND04019 11p12 0.2 Duplication Confirmed 
ND03628 16q23 0.2 Duplication Confirmed 
ND05067 9q32 0.3 Duplication Confirmed 
ND01525 14q21 0.3 Duplication Confirmed 
ND05016 1q44 0.4 Duplication Confirmed 
ND02214 7q11 0.5 Duplication Confirmed 
ND05052 2p22 0.7 Duplication Confirmed 
ND04274 17q25 0.8 Duplication Confirmed 
ND01678 12p11-q12 0.9 Duplication Confirmed 
ND01702 15q13 1.0 Duplication Confirmed 
ND01934 13q12 1.3 Duplication Confirmed 
ND01493 3p12 2.6 Deletion Confirmed 
ND04946 13q12-q21 32.9 Partial Deletion Confirmed 
ND01577 22q11.2 0.5 Partial Deletion Not confirmed 
ND03792 22q11.2 0.5 Partial Deletion Not confirmed 
ND01354 8q21.3 1.1 Duplication Not confirmed 
ND01684 16p13.3 2.8 Duplication Not confirmed 
ND02760 5p14-p15.1 6.6 Partial Deletion Not confirmed 
ND01569 15q26 10.1 Partial Deletion Not confirmed 
ND00412 6p22-25 26.6 Duplication Not confirmed 
ND00674 12 Entire Chr. Duplication Not confirmed 
ND01552 X Entire Chr. Partial Deletion Not confirmed 
ND02212 X Entire Chr. Partial Deletion Not confirmed 
ND01424 X Entire Chr. Partial Deletion Not confirmed 
Table 30: Location, size and replication of detected structural alterations. 
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Analysis of the scan data obtained from each of the 271 samples using the HumanHap300 
beadchips confirmed all nine deletions and revealed the existence of 119 more, giving a 
total of 128, of which 28 were heterosomic (supplementary material, table S2). 
Comparison of observed deletion events with those published in the database for genomic 
variants (http://projects.tcag.ca/variation/) revealed that 34 of the 100 identified genomic 
deletions overlapped with previously reported structural variants. 
In an attempt to examine whether the LCL creation and culture process lead to the 
appearance of the genomic deletions noted, we re-assayed DNA extracted directly from 
blood for all samples in which this type of mutation was noted in the Human-1 BeadChip 
Figure 30: Data from Human-1 BeadChips revealing genomic deletion in LCL 
ND01493. This deletion consisted of a 2.6 Mb region at chromosome 3p12. A high 
resolution view of the deleted region is shown in the upper panel, a lower resolution 
whole chromosome view is shown in the low panel. The deletion is identified by a drop 
in the log R ratio (indicating a decrease in copy number) and a lack of heterozygous 
genotype calls in the area, as seen in the B allele frequency plot. This deletion was also 
identified in the source blood used for LCL creation. 
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data (table 30). The blood sample corresponding to ND01493 confirmed the presence of 
the simple heterozygous deletion in the source tissue.  
Only one of the eight heterosomic deletions, detected in ND04946, was detected in these 
replicate experiments (figure 30). Notably the mean cluster positions for clusters c and d 
described above differed between the DNA extracted from blood and the DNA extracted 
from the cell line for this subject. These data indicate that this heterosomic deletion was 
present in the blood of this patient, and that the EBV immortalization process and 
subsequent culture have altered the ratio of cells with and without the deletion. In this 
specific instance there is decreased heterosomy in the DNA extracted from the cell line, 
indicating preferential immortalization and/or culture of cells with a full diploid genome. 
This region of chromosome 13 covers 32.9 Mb, contains ∼189 genes, and encompasses 
the minimal common deleted region described for multiple myeloma and chronic 
lymphocytic leukemia (Migliazza, Bosch et al., 2001; Elnenaei, Hamoudi et al., 2003). 
Also of note, two of the heterosomic deletions identified in LCLs but not in blood, were 
apparently identical in size and position. These were identified in ND01577 and 
ND03792 at 22q11.2 and span a 0.5 Mb region containing the immunoglobulin lambda 
gene cluster, a region previously described to be duplicated (Sebat, Lakshmi et al., 2004). 
These events probably represent V(D)J-type recombination either in the LCLs or as a rare 
event in blood, amplified by the process of LCLs moving toward a clonal state. The five 
remaining deletions, all apparently heterosomic, were not identified in the original blood 
samples, suggesting that they were either an artifact of the EBV immortalization process, 
or a biased representation of the donor tissues state at immortalization, caused by LCL 
creation and culture.  
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Figure 31: Log R ratio and B allele frequency plots for observed heterosomic deletions using 
Human-1 BeadChips. Each panel consists of a log R ratio plot (top) and a B allele frequency plot 
(bottom) across a single chromosome for DNA extracted from LCLs and directly from blood. The 
regions containing apparent deletions are shaded gray. A: An apparent heterosomic deletion of 32.9 
Mb in chromosome 13 in ND04946, present both in DNA extracted from EBV immortalized 
lymphocytes and from blood. B: An apparent heterosomic deletion of 10. 1Mb in chromosome 15 
in ND01569, present in DNA extracted from EBV immortalized lymphocytes but not visible in 
DNA extracted from the blood sample used for the creation of this LCL. 
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• Genomic multiplications: Results indicative of genomic multiplication 
were identified in 15 LCL-derived samples after analysis with the Human-1 BeadChip, 
ranging in size from 0.2 Mb to the entire chromosome. The profile indicative of a 
genomic multiplication is an increase in log R ratio in the presence of allele clusters 
outside the expected homozygous or heterozygous range for the value of B allele 
frequency (figure 32A). As positive controls for the utility of this approach to detect 
genomic copy number changes, we assayed DNA samples derived from a subject who 
carries the SNCA locus triplication, ∼1.6 Mb in length (Singleton, Farrer et al., 2003) and 
a subject with trisomy 21. Data from these samples clearly showed the triplication 
mutation and the presence of an additional copy of chromosome 21 (figures 32B and C).  
 
 
 
 
 
 
Figure 32: Analysis of subjects with genomic multiplication mutations using Human-1 BeadChips. Each panel 
contains log R ratio and B allele frequency plots across a single chromosome. A: Increased log R ratio and 
divergence of B allele frequency away from normal clusters for A/A (0), A/B (0.5) and B/B (1) genotypes reveals a 
0.5 Mb duplication in chromosome 7 in LCL ND02214 (gray shading). The duplication is clearly present in DNA 
extracted from both the cell line and the blood sample used to create the line. B: Analysis of a positive control DNA 
known to harbor a 1.6 Mb triplication mutation across the SNCA locus on chromosome 4 (gray shading) indicated 
by an increase in log R ratio and divergence of B allele frequency away from normal clusters for A/A (0), A/B (0.5) 
and B/B (1). C: Analysis of a positive control DNA extracted from the blood of a person with trisomy 21. The 
chromosomal-wide increase in log R ratio and the presence of 4 genotype clusters (A/A/A, A/A/B, A/B/B and 
B/B/B) is consistent with trisomy. 
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Again, analysis of the scan data of the HumanHap300 BeadChip, confirmed all 15 
alterations and revealed 197 more (supplementary material, table S3).  
Comparison of observed deletion and duplication events with those published in the 
database for genomic variants (http://projects.tcag.ca/variation/) revealed 77 of 212 
observed sub-chromosomal multiplications overlapped with previously reported 
structural mutations. 
Analysis of DNA extracted directly from the blood used for the creation of the LCLs in 
which genomic duplication was noted revealed 11 of the 15 alterations were also present 
in the source tissue. The genomic multiplications with discordant results between LCLs 
and blood comprised four of the five largest multiplications identified (table 30). 
Interestingly, four duplications affecting the PARK2 locus were found in four different 
control samples, affecting exon 2 in ND04788 and ND01583, exon 7 of ND05536, and 
exons 2, 3 and 4 of individual ND05093 (table 31). 
 
• Confirmation of structural changes by real-time PCR: In order to 
confirm that the structural alterations found in these samples were not artifacts of the 
methodological or analytical processes, quantitative PCR was performed in all 271 
samples using 14 TaqMan probes. This was performed using probes for a 0.5 Mb 
duplication at chromosome 7q11 (not previously described), a 0.019 Mb deletion in 
chromosome 11q21 (not previously described), a 33 Mb heterosomic deletion in 
chromosome 13p12-q21 (overlapping with TCAG’s variant number 0313) and a 0.11 Mb 
duplication in chromosome 16q23.2 (not previously described). In all instances, structural 
changes predicted by Infinium analyses were confirmed according to the 2-ΔΔCt value 
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obtained (Corporation, 1997) (figure 33). No additional carriers of any of these structural 
changes were found, supporting the sensitivity of this approach.  
 
 
 
 
 
 
 
 
 
In addition, 10 individual probes across PARK2 were used to verify the presence and size 
of the four unique duplications observed in this region in individuals ND01583, 
ND05536, ND04788 and ND05093. Structural changes were confirmed in all instances. 
No additional carriers were found, supporting the sensitivity of this approach (figure 34).  
Figure 33: Data from quantitative real-time PCR experiments demonstrating genomic 
structural changes in control subjects. 2-∆∆Ct value obtained after performing real-time PCR for 
target regions in chromosomes 7q11, 11q21, 13p12-q21 and 16q23.2. Grey shading indicates the 2-∆∆Ct 
value expected from a normal diploid genome; a value below this range indicates loss of copy number 
and a value above this range an increase in copy number. Data shown is assay for these four loci in 
four samples, each of which contained a copy number change in one of these loci as indicated by 
initial GW-SNP assay. ND01496 shows deletion at 11q21; ND02214 shows duplication at 7q11; 
ND03628 shows duplication at 16q23.2; ND04946 shows a value indicative of heterosomic deletion at 
13p12-q21. In all instances the duplication or deletion events predicted by Infinium data were 
confirmed by real-Time PCR. 
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Figure 34: Data from Infinium II and quantitative real-time PCR experiments demonstrating 
genomic duplication events in control subjects. An increase in log R ratio (upper panels) indicates an 
increase in the gene dosage of the highlighted area (grey shading). The B allele frequency plots show 
the appearance of unexpected allele clusters indicative of genotypes A/A/A, A/A/B, A/B/B and B/B/B, 
indicative of duplication. The lower panel plots the 2-∆∆Ct value obtained after performing real-time 
PCR for exons of PARK2 in these samples. In all instances the duplication events predicted by the log 
R ratio and B allele frequency metrics produced from analysis of Infinium II data were confirmed by 
real time PCR (indicated by grey shading of 2-∆∆Ct values in each plot). 
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4.5.2.3. Copy number variation in PD population:  
• Overall structural variation: Analysis of the B allele frequency and log 
R ratio metrics from both arrays, revealed both subchromosomal deletion and 
multiplications, and whole chromosome duplications. Thus, sample ND01532 showed 
heterosomic deletion of the entire chromosome 9, samples ND00200 and ND02978 
heterosomic deletion of chromosome 12, and samples ND00171, ND00740 and ND00410 
heterosomic deletion of chromosome X. 
As for the subchromosomal changes, different number and size of CNVs was detected 
depending on the beadchip utilized. Thus, Infinium Human-I analysis revealed data 
consistent with subgenomic multiplications in 35 different PD samples, ranging in size 
from a 0.074 Mb duplication in chromosome 6q27 of individual ND04177 to a 88.4 Mb 
one in chromosome 5q15-35.3 of individual ND01216. Results indicative of subgenomic 
deletion were identified in 14 North American PD samples, 10 heterosomic deletions and 
4 simple heterozygous deletions ranging in size from 1.23 Mb on chromosome 18q22.1 
of individual ND00216 to 3.36 Mb on chromosome 18q22.2-q22.3 of individual 
ND02854. 
Analysis of the B allele frequency and log R ratio metrics corresponding to the Illumina 
Infinium HumanMap300 data, confirmed all the subgenomic structural changes found 
using the Illumina Infinium Human-I platform, in addition to 147 new multiplication 
events (182 in total in 130 different samples) and 157 new heterozygous deletions (161 in 
total in 114 different samples) (supplementary material, tables S4 and S5). 
The smallest events found were a 0.03 Mb duplication on chromosome 22q13.33 of 
individual ND02575 and a 0.016 Mb deletion on chromosome 20p11.21 of ND02918. 
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Thirty seven new heterosomic deletions were identified. As we demonstrated in the 
results we obtained in our control population (previous section) this is likely to result 
from the Epstein-Barr virus (EBV) transformation and cell culture process, being absent 
in the source DNA. Of these 47 heterosomic deletions, 23 were located on chromosome 
22q11.22 and span a region containing the immunoglobulin lambda gene cluster, a region 
previously described to be duplicated (Sebat, Lakshmi et al., 2004). These events 
probably represent V(D)J-type recombination either in the LCLs or as a rare event in 
blood, amplified by the process of LCLs moving toward a clonal state. Likewise the 
additional heterosomic deletions, as well as the largest structural variants, are likely to be 
artifacts of the LCL creation and culture process. 
Comparison of observed heterozygous deletion and duplication events with the changes 
previously identified in our control population and those published in the Database for 
Genomic Variants (http://projects.tcag.ca/variation) revealed that 144 out of 182 (79.1%) 
identified duplications overlapped with previously reported structural variants and 117 
out of 161 (72.6%) observed multiplications overlapped with previously reported 
structural mutations. Since the Database of Genomic Variants publishes only variation 
data identified in control populations, it is unlikely, although not impossible, that these 
changes are directly related to the pathogenesis of PD in this population. While we can 
not rule out that the remaining alterations (38 duplications and 44 deletions) harbor genes 
related to the etiology of PD in this population only one region in chromosome 22q12.1, 
had structural changes affecting more than one single sample and absent from controls. 
These changes were three different heterozygous deletions in chromosome 22q12.1 in 
individuals ND01683, ND04397, and ND02631. These deletions spanned 0.05, 0.06, and 
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0.26 Mb, respectively, and involved exons 2, 3, and 4 of TCC28 (Tetratricopeptide 
RepeatDomain 28) predicted transcript (figure 35). To check whether these deletions 
were actually heterozygous deletions and not artifact, we performed real-time PCR at 
exons 2 and 4 of TTC28 in new stock DNA from individuals ND01683, ND04397, and 
ND02631. The 2-ΔΔCt values obtained did not confirm the results expected, ranging in all 
three samples from 0.8 to 1.2 (Corporation, 1997). Analysis of new DNA stocks for 
samples ND01683, ND04397, and ND02631 using Infinium HumanHap240S arrays, 
confirmed that no heterozygous deletion events were present at this locus in any of these 
three new sample aliquots; however, the genotype concordance between overlapping 
SNPs on the HumanHap240S and Human-I arrays reassured us that these samples were 
derived from the same individuals. Thus the observed TTC28 deletions were likely an 
artifact resulting from the LCL creation and culture process (figure 35). 
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• Structural variation in PD-related loci: No structural changes were 
found in SNCA, PARK7, PINK1, or LRRK2. However, structural variation was found in 
PARK2 (table 31). A single PD sample (ND02298) showed a duplication within PARK2, 
involving exon 4. Besides, data consistent with genomic heterozygous deletion was found 
in PD samples ND02146 and ND04177 (figure 36, table 31). The former indicated a 
0.125 Mb deletion involving exons 3 and 4, the latter a 0.218 Mb deletion involving only 
exon 2. To note, no deletions were found in DNA samples from the 271 control samples 
analyzed (see previous section). 
Interestingly, we also identified a homozygous deletion affecting PARK2 in sample 
ND05841 (figure 35, table 31). Because this mutation would typically cause YOPD, we 
Figure 35: Data from HumanHap300 beadchips revealing heterozygous deletions affecting TCC28 in 
ND01683. The upper plot show B allele frequency, and shows genotypes for BB (B allele frequency = 1), 
AB (B allele frequency = 0.5) and AA (B allele frequency = 0) in three different PD samples. The lower 
plot is the log R ratio, which is a measure of copy number for each SNP. The mean of the log R ratio is 
denoted by a grey line. The deletion is identified by a drop in the log R ratio and a lack of heterozygous 
genotype calls. 
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reexamined the subject details for the samples included within this cohort, this revealed 
that two young-onset patients, including ND05841 (age at onset 13 years), had 
erroneously been included within NDPT007. 
All copy number variation events affecting PARK2 were confirmed by means of 
quantitative PCR assay according to the 2-ΔΔCt value obtained (Corporation, 1997). 
 
 
 
 
 
 
Figure 36: Data from HumanHap300 and quantitative real-time PCR experiments 
demonstrating genomic duplication and deletion events in PD patients. In all instances the 
duplication and deletion events predicted by the log R ratio and B allele frequency metrics 
produced from analysis of HumanHap300 data were confirmed by real time PCR (see figure 33). 
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4.6. WHOLE-GENOME SNP GENOTYPING IN PARKINSON’S DISEASE 
AND NEUROLOGICALLY NORMAL CONTROLS. STAGE 2 
 
By means of combining genotyping results from different Infinium platforms (see section 
3.7.2) we obtained a total of 545,066 unique SNPs genotyped in a total of 880 patients 
with late-onset PD, 183 with YOPD and 828 neurologically normal controls from the 
NINDS-funded Coriell institute for research. This dataset was increased with genotypes 
from 2,243 control individuals generously shared by the Cancer Genetic Markers of 
Susceptibility initiative, hosted by the National Cancer Institute (CGEMS, 
http://cgems.cancer.gov/), giving us a total of 3071 control samples. 
 
4.6.1. Quality-control approaches. 
Low call rate genotyping led us to remove 41 individual samples, including 11 late-onset 
PD, 5 YOPD, 13 neurologically normal controls from the Coriell Institute and 12 controls 
from the CGEMS initiative. 
Sample ID Status Change SNP 3' Position 3' SNP 5' Position 5' Size (Mb) Exons involved 
ND05841 Affected Deletion rs1790024 162283949 rs10945791 162336195 0.052 6  
ND02146 Affected Deletion rs2023075 162534963 rs9356000 162659755 0.125 3 and 4 (F) 
ND04177 Affected Deletion rs9364646 162629938 rs2023001 162847793 0.218 2  
ND02298 Affected Duplication rs1954926 162436616 rs9458486 162547280 0.111 4  
ND01583 Not affected Duplication rs7739802 162623409 rs9456785 162863945 0.241 2  
ND05536 Not affected Duplication rs11968578 162122933 rs6455783 162243987 0.09 7 
ND04788 Not affected Duplication rs7752854 162714014 rs2803108 162985009 0.271 2  
ND05093 Not affected Duplication rs4605857 162485708 rs2023001 162847793 0.362 2, 3 and 4 
Table 31: Structural Genomic Copy Number Variants Identified in PARK2 in both control and PD samples. Only deletion affecting ND02146 was in 
frame (F). 
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Analysis of 10,000 SNPs in linkage equilibrium using STRUCTURE v2.2 
(http://pritch.bsd.uchicago.edu/structure.html) showed that except for three individuals 
with genetic background indicative of African ancestry, the rest of our sample clearly 
shared Caucasian ancestry. Since population stratification and population admixture are 
one of the most common confounds in genome-wide studies, those three samples were 
dropped from further analysis (figure 37). These results were confirmed by plotting IBS 
distances of each sample to its “nearest neighbor” along with that same value for each of 
the samples included in the HapMap project. In this case, control samples from the 
CGEMS initiative were also included (figure 38). 
 
 
 
 
 
Figure 37: Bar and triangle plots from Structure v2.2 using 10,000 pruned autosomal SNPs. A) Bar plot for K = 3 sorted by 
putative population where population 1 consists of all Coriell PD cases and controls plus those 30 Caucasian trios from the 
HapMap project; population 2 consists of 45 Chinese and 45 Japanese individuals from the HapMap project, and population 3 in 
30 Yoruban trios also from the HapMap project. This plot shows how our cohort (except for the three outliers) genetically 
resembles those Caucasian individuals from HapMap and differs from both the Asian ant the African samples. B) Triangle plot 
with same putative populations as bar plot A where red dots are controls, blue dots are PD cases and green, pink, light blue and 
yellow are Caucasian, Japanese, Chinese and Yoruban samples from the HapMap project. This plot clearly shows how two cases 
and one control sample from our cohort, is closer genetically to African than Caucasian population. 
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Another common confound in genome-wide association studies is the existence of non-
reported relatedness in the studied population. Thus, an estimation of the proportion of 
IBD values (PI-HAT, see section 3.6.3.1) allowed us to remove 17 samples (6 late-onset 
PD, 5 YOPD and 6 neurologically normal controls from the Coriell Institute) from further 
analysis. These data also allowed the identification of 50 replicates in our cohort. This 
high number of repeated samples was driven by the way the samples were collected from 
Figure 38: Identity By State (IBS) distances between every sample and its “nearest neighbor”. After 
distribution standardization, the matrix was plotted by means of Multidimensional Scaling. Clusters harboring 
individuals with African (right upper corner), Asian (right lower corner) and Caucasian ancestry were clearly 
separated. This technique allowed the identification of ND01228, ND02819 and ND09964 as belonging to a 
different population as that of the rest of our cohort (clustered I the same sport as the Caucasian individuals from 
the HapMap project).  
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worldwide laboratories (including ours) by the Coriell Institute. All these samples were 
also dropped from further analysis.  
Last, 15 samples including 9 late-onset PD, 2 YOPD and 4 neurologically normal 
controls from the Coriell Institute, were removed because of a mismatch between 
reported and genotype gender. 
After this extensive quality-control phase, the final number of fully genotyped samples 
was 4,005 including 840 late-onset PD, 131 YOPD, 803 neurologically normal controls 
from the Coriell institute and 2,231 CGEMS controls. 
For those 545,066 SNPs assayed in these samples the genotyping call rate was 98.7%. 
Those SNPs with a Hardy-Weinberg equilibrium p value smaller than 0.01, MAF smaller 
than 5% or missing in more than 5% in our control cohort, were excluded from further 
analysis, giving a total of 474,995 SNPs with a total genotyping rate of 99.82 %. 
 
4.6.2. Statistical analysis 
We assessed evidence for association in several ways including 1 degree of freedom and 
2 degrees of freedom test (for more details see section 3.7.4). Corrections, including 1000 
max T permutation, Bonferroni and FDR-BH methods were applied for multiple test 
correction. Quantile-quantile plots for the allelic association test and Cochran-Armitage 
trend test show a minor deviation from the null distribution, except in the extreme tails 
which correspond to the association reported below (figure 39). These plots, along with 
association in loci previously linked with PD (reported below) give confidence in the 
quality of our data and the robustness of our analysis. 
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The highest association detected was for rs4889730, rs2627426 and rs3784847 with trend 
p values of 1.6 x 10-37, 7.45 x 10-15 and 2.75 x 10-12. However, reexamination of B allele 
frequency and log R ratio clusters with Beadstudio v3.1 (see data analysis in section 
3.6.2.2) showed that bad genotyping of these three SNPs had occurred. Thus, association 
results in these SNPs will be disregarded. The next 30 “hits” we obtained are displayed in 
table 32. This table shows p values obtained after basic allelic, Cochran-Armitage trend, 
genotypic and dominant/recessive tests. Interestingly 5 of these hits are in SNPs within 
SNCA locus, described as the gene most strongly associated with PD pathology. 
The totality of Cochran-Armitage Trend p values for each of the 474,995 SNPs analyzed 
(excluding those with poor clustering after visual inspection), are plotted in figure 40. 
 
 
 
Figure 39: Quantile-quantile plots for the allelic and the trend p values distribution obtained. 
Results of these two statistical approaches are shown in black for all 474,995, showing a minor 
deviation from the null distribution (in red) except for those SNPs at the extreme tail. 
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HWE p value Chr. 
Location SNP ID 
Location 
bp Gene Controls Cases 
Trend  p 
value 
Allelic  p 
value 
Genotypic 
p value 
Dom/Rec  p 
value OR (95%CI) 
1 rs4949254 30,567,547 MATN1 0.01116 3.13 x 10-12 1.06x 10-07 3.50x 10-07 3.68 x 10-11 5.86 x 10-12 R 0.740 (0.660 - 0.8317) 
4 rs2736990 90,897,564 SNCA 0.6878 0.4391 1.45x 10-07 1.38x 10-07 5.12x 10-07 8.68 x 10-07 R 1.317 (1.189 - 1.459) 
7 rs859522 38,936,691 LOC400750 1 0.3151 3.34x 10-07 2.83x 10-07 1.29x 10-06 1.94 x 10-06 D 1.573 (1.322 - 1.872) 
4 rs11931074 90,858,538 BARHL2 0.5741 0.04077 3.83x 10-07 3.13x 10-07 1.21x 10-07 9.77 x 10-06 R 1.575 (1.322 - 1.877) 
10 rs11591754 35,247,159 ZMYM6 0.3753 0.8941 4.18x 10-07 4.90x 10-07 2.52x 10-06 7.61 x 10-07 D 0.692 (0.600 - 0.799) 
4 rs3857059 90,894,261 SNCA 0.5736 0.03905 4.81x 10-07 3.91x 10-07 1.44x 10-07 1.22 x 10-05 D 1.57 (1.318 - 1.872) 
3 rs1605527 21,351,855 ECE1 0.1022 0.8599 6.26x 10-07 4.53x 10-07 2.73x 10-06 4.27 x 10-07 D 1.582 (1.322 - 1.892) 
10 rs2492448 35,235,412 ZMYM6 0.9306 0.3808 1.91 x 10-06 1.76x 10-06 7.22x 10-06 1.97 x 10-06 D 0.750 (0.667 - 0.844) 
4 rs3775439 90,928,764 SNCA 1 0.09297 2.04 x 10-06 1.63x 10-06 3.01x 10-06 4.05 x 10-05 D 1.422 (1.23 - 1.642) 
14 rs12431733 53,360,580 SLC1A7 0.1843 0.07237 2.81 x 10-06 2.86x 10-06 8.60x 10-07 1.98 x 10-07 R 1.277 (1.153 - 1.415) 
14 rs1950712 68,550,317 LOC149224 0.9064 1 3.23x 10-06 3.16x 10-06 NaN NaN 0.596 (0.478 - 0.742) 
7 rs10487302 110,478,664 IMMP2L 1 0.1516 3.29x 10-06 3.81x 10-06 9.23x 10-06 4.89 x 10-07 D 1.458 (1.242 - 1.713) 
6 rs7756430 228,03,604 NOTCH2 0.6077 0.1044 3.30x 10-06 2.58x 10-06 7.58x 10-06 1.52 x 10-06 D 0.756 (0.673 - 0.850) 
4 rs6830403 22,803,604 EPHA8 0.5468 0.2279 4.13x 10-06 3.30x 10-06 1.53x 10-05 7.01 x 10-06 D 0.776 (0.698 - 0.864) 
8 rs2616510 89,087,241 GTF2B 0.09716 0.005525 4.47x 10-06 4.23x 10-06 3.13x 10-08 1.35 x 10-08 R 1.329 (1.177 - 1.500) 
3 rs7622285 146,367,022 FLJ39739 0.06545 0.8832 5.10x 10-06 6.40x 10-06 1.15x 10-05 4.66 x 10-05 R 1.292 (1.156 - 1.444) 
13 rs9525776 42,928,966 LOC647049 0.1421 0.791 5.62x 10-06 4.31x 10-06 3.17x 10-05 3.33 x 10-05 D 1.278 (1.151 - 1.418) 
12 rs12425761 114,119,258 RSBN1 0.755 0.7824 5.81x 10-06 5.30x 10-06 3.43x 10-05 1.25 x 10-05 D 1.435 (1.227 - 1.677) 
4 rs7655536 77,395,792 PIGK 0.8206 0.6678 5.81x 10-06 5.75x 10-06 3.21x 10-05 1.15 x 10-05 R 1.321 (1.171 - 1.491) 
7 rs1371608 12,373,351 FLJ14712 0.6851 0.1398 5.84x 10-06 6.89x 10-06 2.32x 10-05 1.82 x 10-05 D 1.265 (1.142 - 1.401) 
12 rs7485262 37,088,013 GRIK3 0.5481 0.7556 5.89x 10-06 5.16x 10-06 3.50x 10-05 1.03 x 10-05 D 1.469 (1.244 - 1.735) 
12 rs12366742 64,313,976 ROR1 0.3037 0.7978 6.23x 10-06 5.31x 10-06 3.22x 10-05 9.95 x 10-05 D 0.763 (0.679 - 0.857) 
12 rs797770 6,173,418 RPL22 0.6059 0.678 6.23x 10-06 5.44x 10-06 3.65x 10-05 1.07 x 10-05 D 1.561 (1.287 - 1.894) 
12 rs6582668 37,052,871 GRIK3 0.675 0.4822 7.22x 10-06 6.19x 10-06 3.76x 10-05 2.97 x 10-05 D 1.387 (1.203 - 1.6) 
12 rs4508240 37,186,069 GRIK3 0.6143 0.4803 7.47x 10-06 6.34x 10-06 3.88x 10-05 3.08 x 10-05 D 1.387 (1.203 - 1.6) 
9 rs11244079 135174347 LOC653163 0.08245 0.1166 5.89 x 10-06 5.16 x 10-06 3.50 x 10-05 NA 1.469(1.244-1.735) 
12 rs2170504 128432246 TMEM132D 0.3047 0.2508 6.23 x 10-06 5.31 x 10-06 3.22 x 10-05 6.14 x 10-05R 0.763 (0.679-08579 
10 rs11191064 103357814 intergenic 0.0562 0.08505 6.23 x 10-06 5.44 x 10-06 3.65 x 10-05 2.18 x 10-05D 1.561 (1.287-1.894) 
4 rs356220 90860363 intergenic 0.1237 0.1637 7.22 x 10-06 6.19 x 10-06 3.76 x 10-05 2.20 x 10-04D 1.387 (1.203-1.600) 
4 rs13130144 120092696 SYNPO2 0.1233 0.1632 7.47 x 10-06 6.34 x 10-06 3.88 x 10-05 2.98 x 10-05 D 1.387 (1.203-1.600) 
Table 32: 30 lowest uncorrected p values obtained in our analysis. 
P values corresponding to basic allelic, Cochran-Armitage trend, genotypic and dominant/recessive tests are displayed. For the dominant/recessive tests, D or 
R indicates that the displayed p value was obtained after dominant or recessive test respectively. Besides, Hardy-Weinberg equilibrium p values obtained in 
both cases and controls, as well as odds ratios (OR) and CI 95% are shown. Bolded are thpse SNPs in SNCA locus.  
 
Javier Simón Sánchez  Results 
 202
 
 
 
 
4.6.3. Combined association analysis. 
In order to add power to our genome-wide association study and further confirm the 
results we obtained, we undertook a collaborative analysis with Drs. Thomas Gasser 
(Hartie-Institute for Clinical Brain Research, Tuebingen, Germany) and Tatsushi Toda 
(Osaka University Graduate School of Medicine, Suita, Japan).  
 
4.6.3.1. German cohort: After removing samples that did not reach a success rate of 
95%, gender mismatches and population outliers, 1,686 samples remained (including 742 
Figure 40: - log p values of the Cochran-Armitage for all SNPs except for those excluded because of 
poor clustering after visual inspection. These values are plotted against position on each chromosome. 
Chromosomes are shown in alterning colours. Red line at –log = 7 indicates the significant p value threshold 
of 10-7. This plot was generated with Haploview 4.ORC2 software. 
SNCA 
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cases and 944 controls). Those SNPs with a Hardy-Weinberg equilibrium p value smaller 
than 0.01 in controls and a MAF smaller than 5% in controls were excluded from further 
analysis. Genotypic counts for all those SNPs that successfully passed these filters 
(498,560) were merged with those of our successful 474,995 SNPs, giving a total of 
463,185 SNPs common to both cohorts (see section 3.7.5.1).  
All tests and corrections used for our cohort (see section 3.6.4) were applied for each of 
these SNPs. 
Association of SNCA and disease found in our previous analysis was confirmed after this 
joint analysis. Moreover, association of SNPs within MAPT (highly associated with PD, 
see section 1.6.3.9) was obtained. These results can be used as positive controls for our 
study and add strength to the association reported in other genes not previously related to 
PD. These, along with the comparison of a null distribution of p with that obtained in our 
experiments (figure 41) supports the robustness of our analysis. 
Table 33 shows results obtained for the basic allelic and Cochran-Armitage trend, 
genotypic and dominant/recessive tests for those 30 SNPs with higher association in our 
analysis. The whole distribution of trend p values for this joint analysis is plotted in 
figure 42. 
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Figure 41: Quantile-quantile plots for the allelic and the trend p values distribution in our 
combined analysis. Results of these two statistical approaches are shown in black for all 465,684 SNPs 
common to both the U.S and the German population, showing a minor deviation from the null 
distribution (in red) except for those SNPs at the extreme tail. 
Figure 42: - log p values of the Cochran-Armitage trend test for the US-German those combined 
analysis. Chromosomes are shown in alterning colors. Red line at –log = 7 indicates the significant p value 
threshold of 10-7. This plot was generated with Haploview 4.ORC2 software. 
SNCA 
MAPT
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4.6.3.2. Japanese cohort: Because of population differences between the Japanese and 
the Caucasian cohorts (US population and German population), genotyping counts from 
Dr. Toda’s experiments can not be merged with ours. Thus, side by side comparison of 
the results obtained was performed in this case. Table 34 shows the p values for the 
Cochran-Armitage test obtained in the Japanese cohort. The integrity of trend p values 
HWE p value (USA) HWE p value (GER) 
SNP Chr. Location Position bp Gene Controls Cases Controls Cases 
Trend   p 
value 
Allelic  p 
value 
Genotypic 
p value 
rs2736990 4 90,897,564 SNCA 0.6878 0.4391 0.1474 0.05616 5.69 X 10-09 3.99 X 10-09 1.25 X 10-08 
rs3857059 4 90,894,261 SNCA 0.5736 0.03905 0.7916 0.04442 3.60 X 10-08 2.61 X 10-08 2.97 X 10-09 
rs415430 17 42,214,305 WNT3 0.2133 0.7377 0.4536 0.8841 4.50 X 10-08 5.40 X 10-08 1.50 X 10-07 
rs11931074 4 90,858,538 SNCA (3’ UTR) 0.5741 0.04077 0.7922 0.04195 4.78 X 10-08 3.50 X 10-08 3.62 X 10-09 
rs199533 17 42,184,098 NSF 0.1861 0.8201 0.341 0.8841 5.05 X 10-08 6.36 X 10-08 1.67 X 10-07 
rs356220 4 90,860,363 SNCA (3’ UTR) 0.8774 0.9478 0.5228 0.1994 6.99 X 10-08 5.86 X 10-08 3.45 X 10-07 
rs169201 17 42,145,386 NSF 0.2694 0.5747 0.3405 1 1.25 X 10-07 1.49 X 10-07 4.00 X 10-07 
rs393152 17 41,074,926 C17orf69 0.3263 0.6815 0.3657 0.8906 1.42 X 10-07 1.75 X 10-07 8.12 X 10-07 
rs12185268 17 41,279,463 IMP5 0.1923 0.9171 0.3612 0.781 1.90 X 10-07 2.38 X 10-07 8.35 X 10-07 
rs1981997 17 41,412,603 MAPT 0.1581 0.917 0.3611 0.783 2.02 X 10-07 2.57 X 10-07 8.41 X 10-07 
rs2532274 17 41,602,941 KIAA1267 0.5999 1 0.3553 0.7854 2.21 X 10-07 2.47 X 10-07 1.17 X 10-06 
rs2532269 17 41,605,885 KIAA1267 0.5585 0.8304 0.3076 0.7799 2.70 X 10-07 2.97 X 10-07 1.13 X 10-06 
rs8070723 17 41,436,901 MAPT 0.1747 0.8357 0.3611 0.89 3.36 X 10-07 4.23 X 10-07 1.52 X 10-06 
rs17563986 17 41,347,100 MAPT 0.1925 0.7544 0.361 1 3.44 X 10-07 4.38 X 10-07 1.79 X 10-06 
rs2668692 17 41,648,797 LOC644246 0.3154 0.9157 0.5998 0.7788 3.94 X 10-07 4.44 X 10-07 1.64 X 10-06 
rs11648673 16 317,795 AXIN1 0.3955 1 1 0.9133 4.77 X 10-07 5.16 X 10-07 2.54 X 10-06 
rs12373139 17 41,279,910 IMP5 0.1912 0.917 0.3128 1 4.91 X 10-07 6.19 X 10-07 2.27 X 10-06 
rs239748 23 18,793,279 LOC239748 0.755 0.44 0.569 0.745 1.17 X 10-06 1.35 X 10-06 7.06 X 10-06 
rs12431733 14 53,360,580 BMP4 0.1843 0.07237 1 0.2112 1.52 X 10-06 1.42 X 10-06 2.98 X 10-07 
rs11591754 10 35,247,159 LOC646213 0.3753 0.8941 0.06475 0.9015 1.68 X 10-06 2.08 X 10-06 6.21 X 10-06 
rs7013027 8 2,911,376 CSMD1 0.2426 0.3683 0.5553 0.5569 1.85 X 10-06 2.37 X 10-06 1.15 X 10-05 
rs11012 17 40,869,224 LOC201175 0.06664 0.6256 0.7245 0.5354 2.85 X 10-06 3.59 X 10-06 1.16 X 10-05 
rs7004938 8 140,328,407 COL22A1 0.8821 0.3085 0.09952 0.3536 2.97 X 10-06 2.69 X 10-06 1.70 X 10-05 
rs10857899 1 111,929,241 LOC643329 0.1877 0.3208 0.514 0.3258 3.06 X 10-06 2.71 X 10-06 1.72 X 10-05 
rs6542651 2 3,737,705 LOC728597 0.2543 1 0.8108 0.3916 3.34 X 10-06 2.85 X 10-06 2.02 X 10-05 
rs2285459 16 30,402,913 ITGAL 0.186 0.8931 0.3903 0.8791 3.38 X 10-06 3.64 X 10-06 1.78 X 10-05 
rs13027881 2 6,473,384 LOC391349 0.9429 0.2869 0.3471 0.5692 3.76 X 10-06 3.59 X 10-06 1.99 X 10-05 
rs2492448 10 35,235,412 LOC646213 0.9306 0.3808 0.6477 0.5215 3.84 X 10-06 3.39 X 10-06 1.35 X 10-05 
rs4957473 5 39,378,920 C9 0.7893 0.8312 0.1133 0.683 4.23 X 10-06 4.42 X 10-06 2.30 X 10-05 
rs3775439 4 90,928,764 SNCA 1 0.09297 1 0.1991 4.42 X 10-06 3.58 X 10-06 3.94 X 10-06 
Table 33: 30 lowest uncorrected p values obtained in the USA-German combined analysis. 
P values corresponding to basic allelic, Cochran-Armitage trend and genotypic tests are displayed. Hardy-Weinberg equilibrium p 
values obtained in both the US (USA) and the German (GER) cohort both cases and controls are shown 
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obtained in the Japanese series is shown in figure 43. Note the strong association detected 
across SNCA locus. 
 
 
 
 
SNP ID Chr. location Position bp Gene Trend p value USA min      p value 
GER min      
p value 
Combined min      
p value 
rs11931074 4 90,858,538 SNCA 1.25 X 10-12 1.21 X 10-07 8.95 X 10-03 3.62 X 10-09 
rs3857059 4 90,894,261 SNCA 2.31 X 10-12 1.44 X 10-07 6.07 X 10-03 2.97 X 10-09 
rs3775439 4 90,928,764 SNCA 6.20 X 10-12 1.63 X 10-06 - 3.58 X 10-06 
rs3796661 4 90,906,530 SNCA 6.74 X 10-12 - - - 
rs356220 4 90,860,363 SNCA 1.03 X 10-11 8.40 X 10-06 2.86 X 10-04 5.86 X 10-08 
rs7655606 4 175,548,801 KIAA1712 2.54 X 10-11 - - 2.58 X 10-02 
rs6532194 4 90,999,925 SNCA 2.21 X 10-10 4.69 X 10-04 - 2.77 X 10-03 
rs2736990 4 90,897,564 SNCA 3.17 X 10-10 1.38 X 10-07 1.11 X 10-03 3.99 X 10-09 
rs12644119 4 90,822,442 SNCA 3.23 X 10-10 1.11 X 10-04 1.99 X 10-02 2.00 X 10-05 
rs3822095 4 90,955,540 SNCA 1.65 X 10-09 2.66 X 10-03 - 6.06 X 10-03 
rs12502363 4 90,932,087 SNCA 1.83 X 10-09 5.03 X 10-03 - 8.10 X 10-03 
rs9350203 6 10,335,181 OFCC1 3.77 X 10-09 - - - 
rs10516848 4 90,994,235 SNCA 5.84 X 10-09 2.94 X 10-02 1.83 X 10-02 2.69 X 10-02 
rs13125108 4 90,764,236 SNCA 1.75 X 10-08 1.35 X 10-03 2.56 X 10-02 5.90 X 10-04 
rs9985612 4 90,810,912 SNCA 3.13 X 10-08 2.52 X 10-04 - 2.66 X 10-04 
rs12129824 1 228,973,714 CAPN9 3.26 X 10-08 - - - 
rs3733449 4 90,791,345 SNCA 4.18 X 10-08 4.51 X 10-04 - 2.06 X 10-03 
rs1390280 4 90,738,475 SNCA 1.78 X 10-07 6.85 X 10-04 - 6.68 X 10-03 
rs6850389 4 90,746,367 SNCA 1.96 X 10-07 4.11 X 10-02 - - 
rs7930275 11 134,117,017 B3GAT1 2.46 X 10-07 - - - 
rs7929317 11 134,113,081 B3GAT1 3.24 X 10-07 - - - 
rs12591171 15 90,920,803 LOC400451 4.47 X 10-07 - - - 
rs2364857 11 113,382,767 HTR3A 6.86 X 10-07 - - - 
rs12233759 4 91,099,426 MMRN1 7.12 X 10-07 - - - 
rs1318557 4 91,098,636 MMRN1 7.26 X 10-07 - - - 
rs7943044 11 134,113,328 B3GAT1 7.81 X 10-07 - - - 
rs6854896 4 91,090,584 MMRN1 1.11 X 10-06 - - - 
rs4468458 13 101,546,407 FGF14 1.42 X 10-06 - - - 
rs285705 15 90,919,508 LOC400451 1.74 X 10-06 - - - 
rs2158250 7 20391971 ITGB8 2.07 X 10-06 - - - 
Table 34: 30 lowest uncorrected p values in the Japanese population. 
P values corresponding Cochran-Armitage in the Japanese population are displayed. These are compared with the minimum p 
value at that same locus obtained in the North American (USA) and German (GER) population. P values for those SNPs 
genotyped in the Japanes but not in the North American or German population are represented as -. 
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4.7. AUTOZYGOSITY MAPPING IN BRAZILIAN FAMILIES 
 
4.7.1. Exclusion of known genes. 
Screening for mutations in PRKN, LRRK2, SNCA, GCH1, TOR1A, ATP1A3 and PINK1 
were negative in all patients. Serum and urine copper and ceruloplasmin tests ruled out 
Wilson’s disease (OMIM #277900).  
 
Figure 43: - log p values of the Cochran-Armitage trend test for those SNPs assayed by Toda and 
collaborators. Chromosomes are shown in alterning colors. The peak in chromosome 4 corresponds to 
association in SNCA locus. 
SNCA 
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4.7.2. Autozygosity mapping. 
Analysis of Infinium genotyping data in samples 2035-2 and 2035-3 (DYT16-1), along 
with 2035-11 and 2035-12 (DYT16-2), revealed four regions in the genome that were 
homozygous at greater than 50 consecutive SNPs and identical by state between these 
four samples. Analysis of samples 2035-1 (affected brother of DYT16-1) and 2035-119 
(affected uncle of DYT16-2) showed that one of these regions (containing 81 SNPs 
between markers rs2528907 and rs1695515 in chromosome 7) was not identical by state 
in these samples, therefore discarding it as a candidate locus. 
The remaining three regions were all located on chromosome 2q31.2 and encompassed 
1.2 Mb from rs1434087 to rs10497541 (containing 278 SNPs), 0.13 Mb from rs13405069 
to rs7581560 (containing 67 SNPs), and 0.4 Mb from rs1518709 t rs10930936 
(containing 78 SNPs). Interestingly, 277 of those 278 SNPs in the first region were 
homozygous and identical by state within all affected family members. However, a single 
SNP (rs4897088), 0.23 Mb away from the telomeric edge of this critical region, although 
homozygous in al affected members had genotype AA in affected members from family 
DYT16-1 and genotype GG in affected members of family DYT16-2. Resequencing of the 
region of this SNP from a PCR-amplified fragment using primers designed to amplify the 
region embeded between the two most closely flanking SNPs, showed that the genotypes 
were indeed correct and suggested that the localization of this SNP was correct (primer 
sequences in supplementary data table S1). Although we felt this result was perplexing, 
because it is not consistent with an ancestrally identical genomic segment, and perhaps 
only explained by a gene conversion event or complex structural rearrangement, we felt 
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that this large track of homozygous SNPs that are identical across families still implicated 
this region as a good candidate to contain the disease-causing mutation. 
The primary candidate region (rs1434087- rs10497541) contains the following genes and 
predicted transcripts: OSBPL6, PRKRA, DFNB59, FKBP7, PLEKHA3, TTN, FLJ39502, 
SESTD1, LOC728984, LOC644776 and the first four exons of fragment of ZNF533. The 
second candidate region contains the remaining portion of ZNF533, and the third region 
contains a single transcript, LOC729001 (figures 44 and 45). 
 
 
 
Figure 44: Tracks of contiguous homozygous SNPs were calculated with tracker v0.99. All homozygous 
regions in chromosome 2 are shown herein in red (2035-2), blue (2035-3), green (2035-11) and yellow 
(2035-12). All three candidate regions are located within the gray-shaded area. Bounded in red is the 
primary candidate interval identical by state between all members of families DYT16-1 and DYT16-2 
(rs1434087 to rs10497541, 1.2 Mb in size). 
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 Although we felt that the causal mutation would reside in the first candidate region, 
given that it was five times larger than the next largest region of contiguous 
homozygosity, we sequenced all 12 genes and transcript in these three largest candidate 
intervals. Sequence analysis of all coding exons and immediate flanking intronic 
sequence of all 12 genes (458 exons) revealed a single segregating homozygous variant 
(c.665C>T) in exon 7 of PRKRA (p.P222L) in all affected family members of DYT16-1 
Figure 45: Illumina Genome Viewer plot showing the disease-segregating homozygous region 
identified in the six affected members of families DYT16-1 and DYT16-2. Upper panels show the 
B allele frequency metrics across chromosome 2 for two affected individuals from DYT16-1 (2035-1 
and 2035-2) and DYT16-2 (2035-11 and 2035-12). Stretches of homozygosity are denoted by a 
contiguous stretch of genotypes there is a lack of AB genotype calls (ie, B allele frequency of 0.5). 
The lower panel shows an ideogram of chromosome 2, the primary candidate interval that is 
identical by state between families DYT16-1 and DYT16-2 (rs1434087 to rs10497541; 1,2 Mb in 
size), and the genes in this primary critical interval.
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and DYT16-2 (figure 46). Sequencing of this exon in all 1,992 samples described in the 
methods section 3.8.1 revealed a homozygous c.665C<T mutation in a single sample 
from a Brazilian Patient with generalized dystonia (patient 2035-61). Genotyping DNA 
from this patient with Illumina Infinium HumanHap550 revealed a region identical by 
state with all other affected members positive of c.665C>T between markers rs6738749 
and rs10497541, limiting the disease segregating interval on the centromeric side by 12 
SNPs (0.04 Mb). 
The entire coding region of PRKRA was sequenced in 12 Brazilian patients with dystonia. 
No additional mutations were found after this analysis. 
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Figure 46: Pedigrees of families DYT16-1, DYT16-2, and patient 2035-61. A black 
symbol indicates an affected family member, an open symbol indicates an unaffected 
family member, and a grey symbol indicates a family member reported as affected by 
history but unexamined. Squares are males, circles are females. Multiple siblings are 
denoted by a diamond; the number of individuals is indicated in the diamond. Genotype 
at position c.665 (p.222) is shown below each family member being w = wild type 
(c.665C); m = mutant (c.665T); -/- = genotyping not possible, or attempted but failed. In 
the panel below, chromatograms show the mutation in PRKRA; the blue arrow in top 
panel indicates mutant homozygote, the red arrow in middle panel indicates wild type 
sequence, and the green arrow in bottom panel indicates heterozygous mutation.  
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5. DISCUSSION 
 
5.1. GENETIC ANALYSIS OF PARK8-LINKED PARKINSON’S DISEASE 
PATIENTS. 
 
In the course of sequencing KIF21A as candidate PARK8 gene in a set of four families 
from the Basque region in Spain (UGM03, UGM04, UGM05 and UGM06), Paisan-Ruiz 
and collaborators (Paisan-Ruiz, Jain et al., 2004) identified a rare variant segregating with 
the disease in three of the four families. Given the rarity of this variant in the general 
population from the Basque country, this suggested that these families may be ancestrally 
related and could share a minimal interkindred disease haplotype. In order to confirm the 
existence of this haplotype and confirm its limits, we chose to genotype informative 
SNPs in the region showing strongest linkage to disease in these families. This effort led 
us to reduce the critical disease interval to 2.6 Mb, a region containing 11 genes and 
predicted transcripts. Systematic sequence analysis developed by Dr. Paisan-Ruiz, 
showed segregating mutations within a putative kinase domain containing transcript, 
DKFZp434H2111. This gene was later given the name of LRRK2 and the encoded 
protein was named dardarin, coming from the Basque word for tremor. 
In order to asses the prevalence of this mutation (p.R1441G) in the Basque PD 
population, we genotyped a total of 238 PD patients presenting symptoms of typical late-
onset PD. This analysis led us to find 17 patients (~ 7%), with and without positive 
family history of PD, carrying the p.R1441G mutation (clinical features on table 24).  
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Due to its orographical characteristics, the Basque Country has remained isolated from 
the different populations that invaded the Iberian Peninsula. Because of this, and because 
of an absence of immigration until the late seventies, the Basques are somewhat 
assimilated to a genetic isolate (Calafell and Bertranpetit, 1994; De Pancorbo, Lopez-
Martinez et al., 2001; Jakobsson, Scholz et al., 2008). Thus, it is possible, as in the case 
for other diseases (Urtasun, Saenz et al., 1998; Zivelin, Bauduer et al., 2002; Cobo, Saenz 
et al., 2004), that the most likely situation is that a founder effect in this population 
explains the high prevalence of the mutation. In order to investigate the possibility that all 
these patients have inherited p.R1441G from a common founder, we genotyped all SNPs 
used to narrow down the candidate region in the four Basque families, in these 17 
carriers. This approach revealed genotypes consistent with the haplotypes found in the 
four families, supporting the idea that they all have inherited the mutation as part of an 
ancestral chromosome. 
According to the data presented herein, the p.R1441G mutation in LRRK2 accounts for 
16.4% of familial and 4.0% of sporadic PD in the Basque population, excluding the 
members of the four original families reported by Paisan-Ruiz and collaborators (Paisan-
Ruiz, Saenz et al., 2005). Even though our sample was not collected as part of a 
population-based analysis, it could be considered as representative of the general 
population as it was collected through the combined effort of all Public Hospitals in the 
area of influence of San Sebastian. In this respect, the population served by those 
hospitals comprises 420,000 individuals. On the basis of epidemiological estimates, 
approximately 1,260 PD cases might exist (Bergareche, De La Puente et al., 2004) of 
whom 238 (~ 18.8%) have been included in this study. 
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As for those p.R1441G non-Basques carriers found in our population, there is limited 
information about their ethnicity, as we were able to collect information only from the 
probands and their parents. Thus, the presence of the low-frequency of the disease 
haplotype seen in this population suggests that they have distant ancestors of Basque 
descent. 
Different groups have looked for this mutation in populations across Spain. Thus, Mata 
and coworkers found this mutation in 2.7% of a PD population from Asturias (Mata, 
Taylor et al., 2005), where 4 out of the 5 mutation carriers were considered as sporadic. 
Similar results were obtained by Gaig and collaborators in Catalonia, who found that 
0.7% of the patients they analyzed carried the p.R1441G mutation (Gaig, Ezquerra et al., 
2006).  
Gonzalez-Fernandez and collaborators did not find this change in any of the sporadic PD 
cases they analyzed. However, they found it in one family from Navarra and another 
from La Rioja (Gonzalez-Fernandez, Lezcano et al., 2007). This mutation was not 
identified in 105 PD patients from Cantabria analyzed by Infante and colleagues (Infante, 
Rodriguez et al., 2006). 
These findings suggest the existence of a geographical gradient for this mutation, which 
goes from 4.0% of PD patients in the Basque Country to 2.7% in Asturias and 0.7% in 
Catalonia. If we collectively considered all this information, along with the fact that 
different aminoacid changes (p.R1441C and p.R1441H) have been described in this same 
codon elsewhere (Zimprich, Biskup et al., 2004; Mata, Kachergus et al., 2005) it would 
appear that a R>G change appeared in the hot-spot mutation site 1441 on a Basque 
chromosome, possibly in the valleys where the four original families were identified. 
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This mutation would later have spread through, at least, Northern Spain. In this respect, it 
is interesting to note that the group of p.R1441G carriers analyzed by Mata and 
coworkers share the same ancestral haplotype as the Basque patients we present in this 
study. 
This geographical gradient of p.R1441G, is likely to be related to the global Basque 
diaspora. This diaspora refers to different migratory fluxes the Basque population has 
suffered along history for different reasons. This migration did not only proceed to other 
communities within Spain, but other countries of Europe, Central and South America 
(specially Argentina and Chile) and North America (Western United States and Canada) 
as well. Although several groups have tried to find p.R1441G in Portugal (Bras, 
Guerreiro et al., 2005; Ferreira, Guedes et al., 2007a), France (Funalot, Nichols et al., 
2006), Greece (Xiromerisiou, Hadjigeorgiou et al., 2007), Italy (Goldwurm, Di Fonzo et 
al., 2005), Chile (Perez-Pastene, Cobb et al., 2007) and the United States (Paisan-Ruiz, 
Jain et al., 2004; Mata, Kachergus et al., 2005; Pankratz, Pauciulo et al., 2006), only a 
single heterozygous carrier female was found by Deng and colleagues in North American 
population. Interestingly, although she apparently had no Spanish relatives she was 
Hispanic (Deng, Le et al., 2006). 
The fact that this mutation appears in sporadic patients in our population and elsewhere 
(Mata, Taylor et al., 2005; Deng, Le et al., 2006; Gaig, Ezquerra et al., 2006) either 
suggests a lack of information on other family members of those sporadic patients who 
might be affected by a milder or subclinical form of PD, or that other environmental or 
genetic factors might greatly affect disease penetrance. Interestingly, Gonzalez-
Fernandez and collaborators in a genetic study of LRRK2-associated parkinsonism, found 
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10 families from the Basque country with the p.R1441G substitution being present in 6 
asymptomatic carriers with an age range of 32-75 years, indicating a low penetrance of 
this mutation (Gonzalez-Fernandez, Lezcano et al., 2007). Moreover, for those 15 
symptomatic carriers they found, clinical features differ from the first p.R1441G Basque 
families reported (Paisan-Ruiz, Jain et al., 2004), where late-onset disease was common 
and tremor was the predominant initial symptom resulting in the term dardarin (Basque 
for tremor) to describe the protein encoded by LRRK2. This variation in the clinical 
phenotype of the p.R1441G pathogenic substitution must be influenced by other factors, 
genetic or environmental.  
Collecting more family members and studying all available p.R1441G carriers is now 
crucial to better estimate the penetrance of this pathogenic substitution and provide 
appropriate genetic counseling to patients and their families. 
 
 
5.2. LRRK2 IS EXPRESSED IN BRAIN AREAS AFFECTED IN PD IN THE 
ADULT MOUSE BRAIN 
 
Previously, Northern blot analysis showed that LRRK2 is expressed in the cerebellum, 
cerebral cortex, medulla, spinal cord, occipital pole, frontal lobe, temporal lobe and 
putamen (Paisan-Ruiz, Jain et al., 2004). However, a complete and detailed map of 
LRRK2 mRNA localization in the central nervous system was still lacking. Thus, with the 
objective of providing a complete atlas of the LRRK2 mRNA distribution, we performed 
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an in situ hybridization analysis with digoxigenin-labeled RNA probes on mice brain 
coronal sections.  
The results obtained, clearly show that LRRK2 mRNA is distributed throughout the 
mouse brain. However, a stronger hybridization signal appears in specific brain regions 
such as the deep cerebral cortex layers, cingulate cortex, piriform cortex, Ammon’s horn 
and dentate gyrus, caudate putamen, substantia nigra, some parts of the amygdala, 
reticular thalamic nucleus or cerebellar granular cell layer. 
Among these high LRRK2 expression areas, the caudate putamen, the substantia nigra 
pars compacta and the granular cell layer of the cerebellum, are involved in the 
regulation of motor activity. As most clinical PD symptoms are related to motor 
dysfunction, this expression data may indicate a role of LRRK2 in motor activity 
regulation. 
Regarding the appearance of LRRK2 mRNA in the granular cell layer of the cerebellum, 
currently cerebellar symptoms have not been described in PD patients. However, several 
groups (including ourselves, see sections 1.6.3.8, 3.4, 4.4 and 5.4) have related the 
appearance of parkinsonian motor features (parkinsonism) to the expansion of CAG 
repeats encoding polyglutamine tracts within spinocerebellar ataxia-related genes 
(Gwinn-Hardy, Chen et al., 2000; Wu, Lin et al., 2004; Simon-Sanchez, Hanson et al., 
2005). The phenotype of these spinocerebellar ataxia patients is variable and may cause a 
disease that clinically overlaps with PD. 
Other structures indirectly related to motor activity regulation also express LRRK2 
mRNA. We detected strong hybridization signals in the hippocampus, piriform cortex, 
cingulated cortex, olfactory tubercle, amygdala or reticular thalamic nucleus. Potential 
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relationships between these expression areas and PD pathology have been suggested by 
several groups studying PD and atrophy. Patients with PD and cognitive decline, show 
grey matter volume decreases in several brain regions such as the putamen, accumbens 
nuclei, some parts of the thalamus, hippocampus or cingulate cortex (Summerfield, 
Junque et al., 2005). Moreover, Camicioli et al. found that a hippocampal atrophy was 
more often displayed in PD patients than in healthy subjects regardless of any existing 
cognitive dysfunction (Camicioli, Moore et al., 2003). In relation to the amygdala, 
Junque and colleagues found that both demented and nondemented PD patients have 
clear amygdalar and hippocampal atrophies (Junque, Ramirez-Ruiz et al., 2005). As the 
amygdala and the hippocampus are key structures of the limbic system, LRRK2 may play 
a role in this function. In this respect, it is interesting to note the absence of cognitive 
dysfunction in most PD patients with dardarin mutations (see for example (Paisan-Ruiz, 
Saenz et al., 2005). 
As we have previously mentioned, we also found a strong LRRK2 mRNA expression in 
the olfactory tubercle and some other olfactory related areas, such as the piriform cortex. 
It could be speculated from this finding that dardarin might play a role in the known loss 
of sense of smell in idiopathic PD (Berendse, Booij et al., 2001). 
One important finding from this work that may be relevant to the etiopathogenesis of PD 
is the strong LRRK2 expression in the putamen which contrasts with a lower or non 
signal in the globus pallidus. We can speculate that compensatory mechanisms between 
both areas might be disrupted as a consequence of dardarin dysfunction. 
Wszolek and colleagues reported the finding of different pathological signatures in brain 
tissue from four members of a PD family with the p.R1441C dardarin mutation (Wszolek, 
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Pfeiffer et al., 2004). These authors found Lewy body pathology in two of the four 
individuals. One of the two Lewy body positive patients also had tau inclusions. A third 
patient of this family had solely tau inclusions whereas a fourth one only showed 
neuronal loss and gliosis in the substantia nigra as found in the other three cases. Our 
results are consistent with these observations in that LRRK2 is expressed in all the areas 
where Wszolek and colleagues found evidence of pathological lesions. 
 
Expression data from other studies published afterwards are generally consistent with 
ours, showing that LRRK2 is expressed throughout the brain, especially in striatum and 
cortex (Galter, Westerlund et al., 2006; Melrose, Lincoln et al., 2006; Miklossy, Arai et 
al., 2006; Taymans, Van Den Haute et al., 2006; Higashi, Moore et al., 2007; Melrose, 
Kent et al., 2007). However, large controversy is seen on regard to LRRK2 expression in 
dopaminergic neurons of the substantia nigra. On this regard, two reports using 
radioactive oligonucleotide probes concluded to the absence (Galter, Westerlund et al., 
2006; Melrose, Lincoln et al., 2006) or extremely low presence (Higashi, Moore et al., 
2007) of LRRK2 mRNA from the SNC. These reports concluded that dysfunction of 
LRRK2 affects only dopamine-receptive brain regions such as caudate-putamen, leading 
to the degeneration of the nigrostriatall pathway. 
On the other hand, our data are largely in agreement with the study of Taymans and 
colleagues (Taymans, Van Den Haute et al., 2006) that also used non-radioactive probes 
for their in situ hybridization experiments. The reasons of this controversy may be driven 
by difference on the techniques used. On this regard, non-radioactive RNA probes create 
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mores stable hybrids than radioactive oligonucleotide probes (shorter) making them more 
specific and sensitive (Tecott, Rubenstein et al., 1989). 
Expression of LRRK2 in substantia nigra has been further supported by means of 
immunohistochemical analysis (Higashi, Biskup et al., 2007; Melrose, Kent et al., 2007). 
 
In summary, we demonstrated the existence of LRRK2 mRNA in many brain regions and 
nuclei. These results suggest that mutations in LRRK2 could affect several motor 
structures that play an important role in PD development. In accord with this, most brain 
regions involved in the nigrostriatal pathway abundantly express LRRK2 mRNA. The 
discovery of strong LRRK2 expression in structures such as the hippocampus, amygdala 
or olfactory tubercle, may indicate that LRRK2 dysfunction leads to the appearance of the 
non-motor symptoms that are characteristic of PD. 
 
 
5.3. OMI/HTRA2 IS NOT ASSOCIATED WITH PD IN A NORTH AMERICAN 
POPULATION. 
 
In molecular genetics, as important as the initial description of a genetic association 
between genetic variability and a trait is independent confirmation of such an association. 
In order to confirm the results published by Strauss and colleagues in which they 
described loss of function mutations in OMI/HTRA2 in German PD patients (Strauss, 
Martins et al., 2005), we sequenced the entire coding region of this gene in a large series 
of both young- and late-onset PD cases and age-matched neurologically normal controls 
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from the NINDS neurogenetics repository at Coriell 
(http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10). The data here shows that 
the p.G399S variant, previously described as a PD-causative mutation in the German 
study, is not associated with the disease in our population and was found at the same 
frequency in controls as cases (Fisher’s p value = 1, OR=1.069, CI 95% = 0.3256-3.511). 
Moreover, a rare polymorphism previously described to be associated with PD (Strauss, 
Martins et al., 2005) was not associated with disease in our cohort (Fisher’s p value = 
0.2365, OR = 0.7348, CI = 0.4566-1.182). 
We also performed single marker association between 3 SNPs (exon 1 and introns 4 and 
5) and disease. Results derived from this analysis are consistent with a lack of 
contribution of the OMI/HTRA2 locus to the risk of sporadic PD. 
Interestingly, we have identified 8 novel variants in our population in both cases and 
controls, 4 of which are non-synonymous changes: p.W12C, p.P128L, p.F172V and 
p.A227S. p.W12C and p.P128L were detected in two different control samples 
meanwhile p.F172V and p.A227S in two different PD cases. Although it can not be ruled 
out, it seems unlikely that these variants are related to disease in these patients and are 
likely rare benign alterations.  
It is worth noting that while the p.G399S change was identified in 6 controls, half of 
these were relatively young (ages 25, 42, 46, 62, 70 and 85 years); however, we do not 
feel that it is reasonable to suppose that these patients could be control patients who 
would convert to disease at a later date; first the average age that patients who carried this 
alteration in our case cohort was 53.2 years (range 30-77 years) and thus we would have 
expected some of these controls to convert to PD cases already; second, a pathogenic 
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change should be enriched in a case cohort even when compared to a random population 
cohort and this is particularly true in a disease which is relatively rare in occurrence. 
While we can not rule out a small genetic risk at this locus particularly one present only 
in a subset of patients such as those with young-onset disease, the present study did have 
sufficient power to identify an effect of the magnitude and type originally described; thus 
the weight of evidence presented here suggests that variability at OMI/HTRA2 does not 
contribute to risk for PD. 
Another report examining the contribution of genetic variability in OMI/HTRA2 to PD 
risk has recenently been published (Bogaerts, Nuytemans et al., 2008). In this report, the 
authors sequenced the entire coding region of OMI/HTRA2 and its 5’ and 3’ regulatory 
regions in a series of 266 PD cases and 273 controls from Flanders, Belgium. Results 
derived from this analysis showed a PD-specific p.A404W variant and 6 PD-specific 
variants in the 5’ and 3’ regulatory regions of OMI/HTRA2. Although it can not be ruled 
out that p.A404W is related to disease in this patient, further mutation analysis in a larger 
series of both cases and controls should be performed before establishing an association 
between this variant and PD risk. In silico analysis of the 4 variants they found in the 5’ 
regulatory region of OMI/HTRA2, predicted that they all change binding sites of 
transcription factors. In order to investigate this possibility in vitro, the authors performed 
luciferase reporter gene analysis for all four 5’ regulatory region variants identified in 
their population. Results derived from this analysis showed that two of these variants 
(g.53572436C4G and c.-442C4T) statisticaly decreased transcription activity in 
dopamine cells. Although modest effects seen between mutant and wild type alleles can 
be important in vivo (Knight, 2004), reporter analysis results can largely be affectd by the 
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experimental design, tissue and cell type, genetic backround and environmental context 
(Cirulli and Goldstein, 2007). Thus further analysis of OMI/HTRA2 5’ regulatory variants 
should be done before drawing any conclusion about its contribution to PD pathology. 
OMI/HTRA2 was included in the original PARK3 locus, spanning 10.3cM from marker 
D2S134 to D2S286 (Gasser, Muller-Myhsok et al., 1998). Refinement of this locus 3 
years later to 2.5 Mb by West and colleagues (West, Zimprich et al., 2001) excluded 
OMI/HTRA2. However, since several independent linkage and association studies suggest 
the existence of a disease-modulating gene outside this refined PARK3 region (Pankratz, 
Uniacke et al., 2004), Strauss and colleagues unsuccessfully looked for mutations in the 
coding region of this gene in families B, C, D and K that defined PARK3 locus. Since no 
mutations were found in these PARK3-linked families, OMI/HTRA2 was later designated 
as PARK13 (OMIM #610297). Along with PARK3 this would be the second locus 
identified in the German population (3 out of the 6 families used to define PARK3 had a 
German background) and not replicated elsewhere, maybe because of the design of the 
original studies. 
The data presented here suggest that mutations of OMI/HTRA2 are not a significant risk 
factor or cause of PD and show the necessity independent replication after an original 
description of association. 
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5.4. ANALYSIS OF SCA-2 AND SCA-3 GENES IN PARKINSONISM 
 
Here, we present the identification of a single case (374-1) with expansion at ATXN-2. 
Assessing relatives of 374-1 demonstrated an affected sibling, 374-5, who also showed 
pathogenic expansion at ATXN-2 and an unaffected sibling (374-9) who did not have 
ATXN-2 expansion, showing that this mutation is the cause of disease in this family. The 
clinical signs and symptoms associated with disease in these two affected members of 
family 374 are consistent with mild levodopa-responsive PD and are consistent with our 
hypothesis that mutations at ATXN-2 locus may cause typical PD.  
To date, several families worldwide have been described to harbor expansion mutations 
within ATXN-2 that co-segregate with a range of phenotypes including parkinsonism and 
pure PD with no cerebellar affection and the absence of any obvious ataxia (Gwinn-
Hardy, Chen et al., 2000; Gwinn-Hardy, Singleton et al., 2001; Shan, Soong et al., 2001; 
Furtado, Farrer et al., 2002; Ragothaman, Sarangmath et al., 2004; Wilkins, Brown et al., 
2004; Modoni, Contarino et al., 2007). Our data, along with that published so far, 
indicates that ATXN-2 expansion mutations could be a cause of familial parkinsonism 
ranging from 1.5 to 8% of cases depending on ethnicity, being the highest among in 
Chinese population (Gwinn-Hardy, Chen et al., 2000; Shan, Soong et al., 2001). Thus, 
this gene should be tested when positive family history is reported. 
Finally, comprehension of factors determining a predominantly parkinsonian phenotype 
in SCA2 may shed light on the pathogenesis of PD. 
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5.5. WHOLE-GENOME SNP GENOTYPING IN PARKINSON’S DISEASE 
AND NEUROLOGICALLY NORMAL CONTROLS. STAGE 1 
 
5.5.1. Whole-genome association 
We have undertaken a preliminary analysis in an attempt to localize common genetic 
variation exerting a large effect on risk for PD in a series of 552 cases and neurologically 
normal controls from North Americans. Although we are aware that our sample size is of 
limited power, it is worth indicating that the description of a GWAS as unpowered is 
largely a misused term. The ability of GWAS to succeed depends on many factors, 
including the sample and individual effect size, and risk allele frequency. The size of 
each individual genetic effect within the sample being analyzed and the number of 
samples analyzed are primary limitations on any study. Thus, the smaller the risk 
associated with a common disease, the more samples will be required to identify this 
variant. Another factor to take into account is the risk allele frequency, as the more 
common the variant related to disease the more power to detect association at that variant. 
These factors are of course interrelated and thus, a risk variant with a high odds ratio that 
is relatively rare in the population is much more difficult to identify using genome-wide 
approaches than a variant linked to moderate or mild risk that is common within the 
population. The classic example of such a study happened to be one of the first GWAS 
performed, where variability at CFH was identified as a risk factor for age-related 
macular degeneration using only 96 cases and 50 controls. In this case, the risk allele was 
both common and exerted a substantial effect, increasing risk ~ 4-7 fold (Klein, Zeiss et 
al., 2005). 
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Our data suggest that there are no common genetic variants that exert an effect of greater 
than an OR of 4 in PD. From the standpoint of experimental design this information is 
very useful; however, there are important drawbacks to this interpretation. First, these 
results can strictly only be applied to the current population. Second, analysis of YOPD 
cases, where a genetic effect is thought to be stronger, could reveal genetic variants with 
an effect of this size (Tanner, Ottman et al., 1999; Payami, Zareparsi et al., 2002). Third, 
this statement is reliant on either genotyping the causal variant or efficient and complete 
tagging of the causal variant. 
To date, the locus most robustly associated with risk of PD is the SNCA gene. We did not 
identify a significant association at this locus (table 35); however, given that the OR 
associated with this locus is estimated at 1.4 it is not surprising that we were unable to 
identify this association. The OR associated for this locus comes from a global genetics 
consortium that conducted a collaborative analysis of data on Rep1 polymorphism in 
SNCA promoter (see section 1.6.2.1) and its flanking markers (Maraganore, De Andrade 
et al., 2006), 
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Position Succesful HWE Genotype Dominant Additive Recessive 2-marker haploype 3-marker haplotype 
SNP ID 
Genome build 36.1 genotypes P value P value P value P value P value P value P value 
rs356174 90,849,924 537 0·852 0·919 0·711 0·808 0·960 0·050 0·289 
rs11931074 90,858,538 537 0·411 0·199 0·123 0·092 0·243 0·157 0·179 
rs6842093 90,866,888 537 1·000 0·335 0·154 0·199 0·996 0·176 0·391 
rs3775423 90,876,514 537 0·411 0·230 0·152 0·114 0·243 0·242 0·242 
rs356204 90,882,565 537 0·262 0·334 0·143 0·186 0·510 0·220 0·228 
rs356168 90,893,454 537 0·262 0·334 0·143 0·186 0·510 0·228 0·502 
rs2736990 90,897,564 534 0·298 0·297 0·123 0·166 0·496 0·563 0·282 
rs356191 90,907,143 537 0·161 0·334 0·473 0·756 0·269 0·227 0·253 
rs356188 90,910,560 529 0·202 0·270 0·404 0·693 0·245 0·277 0·253 
rs3775439 90,928,764 537 0·124 0·116 0·057 0·041 0·248 0·274 0·271 
rs2197120 90,948,625 537 0·161 0·334 0·473 0·756 0·269 0·618 0·565 
rs3822095 90,955,540 536 0·508 0·655 0·672 0·452 0·364 0·372 0·274 
rs1812923 90,958,562 535 0·252 0·804 0·738 0·993 0·678 0·380 0·544 
rs10005233 90,962,354 537 0·491 0·646 0·784 0·457 0·350 0·800 0·909 
rs2583978 90,96,9349 537 0·262 0·469 0·473 0·698 0·419 0·950 0·758 
rs1471483 90,973,315 536 0·489 0·650 0·842 0·492 0·356 0·814 0·948 
rs2583985 90,974,962 537 1·000 0·895 0·639 0·685 0·916 0·873 0·661 
rs1372519 90,97,6332 536 0·126 0·693 0·617 0·781 0·569 0·885 0·970 
rs2301134 90,977,968 537 0·343 0·694 0·406 0·576 0·943 0·889 0·971 
rs7687945 90,983,722 537 0·343 0·766 0·467 0·576 0·862 0·889 0·955 
rs1372522 90,984,303 532 0·435 0·702 0·426 0·621 0·993 0·834 - 
rs2736988 90,99,368 537 1·000 0·861 0·638 0·586 0·683 - - 
 
Analysis of our data showed 26 loci with a two-degree of freedom p value less than 
0.0001 (table 28), with odds ratios ranging from 0.2 (95% CI 0.04–0.5) to 0.6 (0.5–0.8) 
and from 1.7 (95% CI 1.3–2.2) to 2.2 (95% CI 1.6–3.2). However, an important caveat to 
the power of GWAS is that genetic coverage comes at a statistical price; since hundred of 
thousand of statistical tests are applied to look for association, low p values can be seen 
as a result of chance only rather than because of biological association. Thus, while p 
values of 0.0001 would normally be convincing, in this context a p value of that order of 
magnitude is most likely a false positive association. In order to correct this caveat, 
different methods are applied. One of the most widely used is the Bonferroni correction, 
that states that if a experimenter is testing n independent hypotheses, the statistical 
Table 35: p values across SNCA locus, previously describe to be associated with risk for Parkinson’s disease. 
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significance level that should be used for each hypothesis separately is 1/n times what it 
would be if only one hypothesis were tested. Thus, a stringent Bonferroni correction 
based on 408,803 independent tests means that a precorrection p value of less than 
1.2×10–7 would be needed to provide a corrected significant p value of less than 0.05. 
Thus, none of the values listed were significant after correction. Although speculation on 
the plausibility and biological significance of these candidate loci is tempting, we regard 
these data as hypothesis generating. Furthermore, given the inevitably high false-positive 
rate of genome-wide association studies (see below), the next step in these analyses 
should involve genotyping in additional sample series. In the first instance, this work 
should be done in a cohort comprising patients and controls of similar demographic 
characteristics to reduce the confounding factors of allelic and genetic heterogeneity 
between ethnic groups (see sections 3.6, 4.6 and 5.6). 
A secondary objective of this experiment was to generate and release genome-wide 
genotype data for publicly available PD patients and controls so that these data could be 
mined and augmented by other researchers; 
The release of genotype data and not just allele frequency data means that genotype data 
from additional samples can be added easily to the current set allowing investigators to 
undertake joint analysis rather than replication-based analysis. The former approach is 
more powerful than the latter in identifying common genetic risk factors (Skol, Scott et 
al., 2006). It is worth noticing that the control samples in the current study have been 
specifically obtained so that they can be used for other neurological disorders, including 
but not restricted to stroke and amyotrophic lateral sclerosis, so these data will also be of 
use to other researchers outside of the PD specialty. 
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A GWAS of PD had been previously reported. Although this experiment consisted of 
fewer than half of the SNPs we typed in our experiments, the multistage design used 
added substantial power and sensitivity to the results (Maraganore, De Andrade et al., 
2005). The authors of these experiments suggested that their data revealed 13 SNPs 
associated with risk for Parkinson’s disease. However, several studies failed to replicate 
such an association (Clarimon, Scholz et al., 2006; Elbaz, Nelson et al., 2006; Farrer, 
Haugarvoll et al., 2006; Goris, Williams-Gray et al., 2006; Li, Rowland et al., 2006). 
Side by side comparison of our data and the most significant SNPs, published by 
Maraganore and colleagues (Maraganore, De Andrade et al., 2005), did not show a 
replication of any of these published associations (table 36). 
Our calculations show that at least 32,127 SNPs are shared between Maraganore’s and 
our study. However, at writing, they have not released raw genotype data, thus, a pooled 
analysis of the two studies is not possible. 
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In summary, we present here the generation and release of genotype data derived from 
publicly available PD cases and neurologically normal control samples. All DNA 
samples, raw genotype data, and significance test results are publicly available at 
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gap. 
These data suggest that there is no common genetic variant that exerts a large genetic risk 
for late-onset PD in white North Americans. These data are now available for future 
mining and augmentation to identify common genetic variability that results in minor and 
moderate risk for disease. 
Chr. 
Location SNP ID Location bp 
HWE 
p-value 
2DF   p 
value 
Dominant 
Model p value 
Additive 
Model p value 
Recessive Model 
p value 
2 marker 
Haplo. 
3 marker 
Haplo 
rs7702187 9385281 
rs3797980 9381316 5p15.2 
rs1205731 9388344 
0.411 
0.375 
0.818 
0.279 
0.972 
0.132 
0.834 
0.110 
0.535 
0.352 
0.172 
0.132 
0.291 
0.095 
rs10200894 228525376 
rs1524029 228521122 2q36 
rs1715826 228527516 
0.600 
0.664 
0.918 
0.549 
0.994 
0.785 
0.821 
0.721 
0.694 
0.360 
0.815 
0.686 
0.868 
0.535 
4q31.1 rs2313982 139007510 0.786 0.587 0.315 0.355 0.993 0.432 0.055 
rs17329669 36818454 
rs9986865 36807127 7p14 
rs6969810 36834535 
0.754 
0.247 
0.012 
0.135 
0.910 
0.046 
0.312 
0.107 
0.004 
0.667 
0.296 
0.306 
0.509 
0.408 
rs7723605 5407615 
rs2964145 5401640 5p15.3 
rs10059715 5413890 
0.146 
1.000 
0.300 
0.431 
0.566 
0.352 
0.994 
0.249 
0.237 
0.268 
0.091 
0.480 
0.219 
0.611 
rs16851009 166338953 
rs4667836 166334852 2q24 
rs4621175 166357038 
0.284 
0.314 
0.278 
0.744 
0.186 
0.462 
0.490 
0.442 
0.704 
0.693 
0.499 
0.122 
0.198 
0.126 
rs2245218 14012413 
rs2245197 14011783 1p36.2 
rs6663564 14017281 
0.178 
0.727 
0.295 
0.303 
0.191 
0.960 
0.374 
0.763 
0.698 
0.135 
0.284 
0.983 
0.633 
0.883 
rs7878232 150597031 
rs4363323 150595500 Xq28 
rs7879285 150597950 
0.000 
0.000 
0.020 
0.014 
0.034 
0.041 
0.205 
0.327 
0.922 
0.780 
0.260 
0.266 
0.380 
0.237 
rs1509269 138973174 
rs978890 138963394 4q31.1 
rs6815259 138982861 
0.836 
0.770 
0.008 
0.281 
0.094 
0.326 
0.344 
0.595 
0.031 
0.346 
0.457 
0.026 
0.193 
0.060 
rs11737074 125300823 
rs11736972 125300772 4q27 
rs2162138 125317106 
0.859 
0.095 
0.380 
0.864 
0.218 
0.668 
0.173 
0.617 
0.354 
0.666 
0.395 
0.295 
0.198 
0.209 
rs682705 54410005 
rs3795360 54409790 1p32 
Rs7520966 54417850 
0.897 
0.456 
0.740 
0.836 
0.467 
0.578 
0.534 
0.549 
0.996 
0.710 
0.622 
0.622 
0.622 
0.622 
Table 36: Comparison of significant loci identified by Maraganore et al., with the current data set. 
Only two SNPs overlapped between the sets (rs2313982 and rs7520966), so in every other instance the closest flanking SNPs are shown. SNPs 
described as significant by Maraganore and colleagues are shown in bold italics. 2 marker haplotype or 3 marker haplotype p value of disease 
association to a two marker or three marker haplotype where the interrogated SNP is the first of two or three contiguous SNPs placed into a haplotype. 
Chrom = chromosome. Haplo = haplotype. 
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5.5.2. Extended homozygosity in control population. 
Analysis of B allele frequency and log R ratio metrics (see data analysis in section 
3.5.2.2) allowed us to score tracks of contiguous homozygous calls in any given sample. 
Here, we describe a striking level of homozygosity in a cohort of aged, out-bred North 
American Caucasians. These data extend upon previous observations of large tracts of 
homozygosity in subjects typed as part of the HapMap initiative (Gibson, Morton et al., 
2006) and in subjects from reference families from the Centre d’Etude du Polymorphisme 
Humain (Broman and Weber, 1999). In the analysis of individuals genotyped as a part of 
the HapMap initiative Gibson and colleagues identified contiguous tracts of 
homozygosity >5 Mb in length in 3.8% of the subjects assessed (8 of 209) and multiple 
tracts >5 Mb in half of these subjects (Gibson, Morton et al., 2006). Our data derived 
from a single population of aged individuals, shows a comparable prevalence of 
homozygous tracts of 5 Mb and larger (9.5%), and multiple homozygous tracts in almost 
half of these individuals (42.3%). While events such as segmental uniparental disomy 
could explain our data, the observation that individuals with at least one large tract of 
homozygosity are likely to harbor other large regions of homozygosity supports the idea 
that parental consanguinity is the cause. One would presume, given the increased 
mobility of North Americans in the last 50 years, that analysis of younger subjects would 
reveal a lower incidence of individuals with extended tracts of homozygosity. These data 
suggest the utility of whole genome SNP analysis to perform homozygosity mapping of 
disease loci not only in families in which a recessive mode of inheritance is detected, but 
in cohorts of apparently unrelated young-onset cases. Any indication of parental 
consanguinity (isolated population, etc.) would prioritize a sample for analysis. This 
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approach would allow rapid fine mapping of disease intervals, with the advantage of 
simultaneously revealing copy number changes often associated with recessive loss of 
function alleles. In samples from individuals with disease, one would compare the 
regions of coincident extended homozygosity among cases with those in neurologically 
normal controls. Clearly, successful application of this approach will require large data 
sets, or enrichment of mutations, either by using a population in which one suspects a 
founder mutation or by using young-onset PD patients, in which recessive disease and 
structural genomic alteration is believed to play a larger role than in late-onset PD. 
Notwithstanding these limitations, the relative speed and ease of performing GWAS 
experiments suggests that the next several years will see leverage of this technique in the 
identification of recessive loci underlying disease. 
 
5.5.3. Copy number variation in neurologically normal controls 
Until recently, the use of genome-wide SNP assays as a direct method of determining 
copy number variation (CNV) has not been widely appreciated (Peiffer, Le et al., 2006). 
In our experiments, we identified genomic copy number changes in 182 control samples 
(340 changes in total). In an effort to demonstrate whether these changes were a result of 
the creation or passage of LCLs or not, we repeated the genotyping experiment in those 
24 samples in which alterations were detected with the Human-1 array. Thirteen of the 
identified changes were readily detected in the source tissue used for immortalization, 
and concordance rates were higher for smaller structural alterations (75% for those 
changes <5 Mb; 13% for those changes >5 Mb). Notably, this method discriminates 
heterosomic and heterozygous genomic deletions, as each allele for each SNP is assayed 
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multiple times. This redundancy can be used to provide a proportion for allele calls at 
each SNP, thus significant deviation from homozygous (100% allele A or allele B) and 
heterozygous (50% allele A and 50% allele B) clusters, particularly when observed in 
multiple contiguous SNPs not only indicates structural alteration but gives a measure of 
the proportion of cells containing this genomic change. The single simple deletion that 
we observed with the Human-1 array, was present in both tissues examined. 
In the case of the identified heterosomic deletions, we can establish these events as 
somatic, occurring in the source tissue in one instance, with the remaining events 
resulting from, or emphasized by, the process of LCL creation. An analogous process can 
be used to assess heterosomic duplications although in this case, the resolution is more 
difficult because one needs to interpret deviations from a 66% / 33% read which is more 
challenging. Real-time PCR analysis of sample ND04946, which whole-genome 
genotyping assay suggested a heterosomic deletion resulting in a ∼30% drop in copy 
number, also revealed a drop in copy number of ∼30%. Previous reports have identified 
structural alterations in the human genome as small as 1 kb; however, these approaches 
rely either on the availability of high density parent offspring genotype data (Rosenberg, 
Vaske et al., 2000; Conrad, Andrews et al., 2006; Mccarroll, Hadnott et al., 2006), or the 
use of custom manufactured arrays (Iafrate, Feuk et al., 2004; Sebat, Lakshmi et al., 
2004; Sharp, Locke et al., 2005).  
The lower limit in terms of size of structural genomic variability detected in the current 
study is ~ 0.02 Mb, a limit which is sensitive to the relative density and informativity of 
SNPs assessed in any one region; thus, the average limit of resolution is likely to be in the 
range of hundreds of kilobases as is most often seen in the data described here. Although 
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the inability of this method to detect balanced translocations would suggest that this will 
not yet replace current approaches aimed at defining chromosomal abnormalities, the 
simple and transferable nature of this technique means it may augment these methods.  
In addition to the usefulness of this technique for quickly mapping structural variability 
with good resolution, this methodology is appealing because it is easily transferable 
between laboratories. This would greatly facilitate the rapid accumulation of equivalent 
data to produce an encyclopedia of normal and abnormal structural genomic variation, 
similar to previous efforts for gross chromosomal abnormalities (http://jws-edck. 
wiley.com:8096/) (Borgaonkar, Bolling et al., 1975; Rosenberg, Vaske et al., 2000; 
Iafrate, Feuk et al., 2004; Sebat, Lakshmi et al., 2004; Sharp, Locke et al., 2005; Conrad, 
Andrews et al., 2006; Mccarroll, Hadnott et al., 2006; Peiffer, Le et al., 2006) and enable 
standardized comparison between laboratories. For this purpose, The Database of Genetic 
Variants (http://www.tcag.ca) gathers detailed information about all the copy number 
variation identified so far (including ours) in control population. 
The utility of this methodology to address other research questions is striking. One can 
envisage using these assays to catalog the occurrence of both germ-line and somatic 
structural mutation, both in disease and healthy states. This method also promises to 
enable genetic characterization of many of the key tools used within laboratories. For 
example, chromosomal rearrangements have been described in cell lines commonly used 
in molecular biology laboratories. This may be an evolving process, rather than a stable 
alteration, and if so, would presumably affect experimental outcome. Routine assay of 
standard cell lines would allow inter-laboratory standardization. The effect of creating 
stem cell lines on the genome has not been established; again this technique offers a 
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quick first-pass assay for analyzing the effects of clonally deriving stem-cell lines both 
for research and for therapies. In all instances the availability of a standardized product to 
perform these assessments is of great importance. Clearly, a weakness of the current 
approach is that scoring of structural variability was performed using a largely subjective 
measure; while we attempted to minimize the false positive and false negative rate by 
independent calling of structural variation by two experienced data analysts it is likely 
that some variability was missed. The development of a publicly available tool that uses a 
statistical basis for the detection of structural variation that can be applied to these data 
would greatly enhance the ease with which these analyses can be performed. Wang and 
colleagues have recently developed PennCNV, an algorithm for copy number variation 
detection demonstrated to be reliable for finemapping of copy number variation through 
high-density SNP genotyping. (Wang, Li et al., 2007) 
(http://www.neurogenome.org/cnv/penncnv).  
Our study shows that the relative effects of LCL creation and passage on the genomic 
architecture of both individual samples and the cohort as a whole are minimal and that the 
genetic content of LCLs is relatively faithful to that of the starting material used for LCL 
creation. In the context of GWAS the variation which appears to have resulted from, or 
have been amplified by, the process of creating LCLs is unlikely to significantly interfere 
with allelic or genotypic associations. This variability is limited to a relatively small 
number of samples and in these samples the genomic region affected represents a small 
percentage of the genome. Thus, the aggregate effect of this variability will be to alter 
<0.1% genotype calls (∼25,000 individual genotypes potentially affected, from a total of 
30 million surveyed). While this bodes well for the use of these data for genetic 
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association studies, further experiments defining the effect of extended culture and 
passage, if any, will be required to see if this increases structural alteration and 
potentially effects allele calling. In conclusion, this study provides public access to whole 
genome array data in a large series of Caucasians and illustrates that such data is useful, 
not only for GWAS for which it was planned, but also for determining the extent of 
inbreeding and structural mutations. Its simplicity suggests unexpected uses for this 
technology in the assessment of standard laboratory cell lines, stem cells and high 
resolution cytogenetic testing. Its speed and ease may lead it to replace traditional linkage 
analysis strategies, especially for recessive diseases but also because it will allow easy 
assessment of linkage disequilibrium between laboratories without the need for uncertain 
standardization against CEPH controls. The data presented here also show that the effects 
of LCL creation and passage on genotypes and genetic architecture are minimal and 
unlikely to confound the results of a genomewide case–control study. 
 
5.5.4. Copy number variation in Parkinson’s disease patients 
The aim of this analysis was to assess the role of structural genetic variation in risk for 
PD both genomewide, and at previously described PD loci. Most of the changes 
described herein (79.1% of the multiplications and 72.6% of the deletions found) had 
previously been described in control samples (http://www.tcag.ca). Although we can not 
rule out the remaining alterations (38 duplications and 44 deletions) as genetic loci 
related to PD etiology; it is likely, given the large number of unique CNVs seen in control 
samples, that the majority, or all, are benign variants; however, we have provided a 
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comprehensive list of these alterations (see supplementary material, table S4 and S5) to 
serve as the foundation for future work looking at structural genomic alterations in PD. 
While this method was applied primarily to detect novel regions related to sporadic PD, 
we have identified some biologically interesting results in previously PD-linked loci. Not 
only did this technique reveal a homozygous deletion, which is likely pathogenic, but it 
also showed the presence of other structural mutations in PARK2, in both cases and 
controls. The pathological relevance of single heterozygous PARK2 mutations, 
particularly to late-onset PD, has been an area of much discussion (Klein, Pramstaller et 
al., 2000; Hoenicka, Vidal et al., 2002; Oliveira, Scott et al., 2003; Sun, Latourelle et al., 
2006; Kay, Moran et al., 2007). In contrast to the data presented here there is 
considerable evidence, primarily from family based studies, that single PARK2 mutations 
may be a risk factor for late-onset disease. However, as discordant penetrance rates in 
families versus populations attest, the ascertainment bias in family-based studies is 
considerable and these should not necessarily be relied upon to assess the relative 
contribution of genetic risk factors to disease. One point of interest, however, is the 
observation that in control samples, only PARK2 duplications and not deletions have been 
identified. This is conceivably a result of chance but it could also indicate that these 
duplications do not necessarily interrupt the open reading frame of PARK2. Although 
heterozygous deletions at PARK2 were only found in PD samples, lack of statistical 
evidence after Fisher’s exact test prevents us on stating that these mutations are causal of 
disease in these samples. 
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5.6. WHOLE-GENOME SNP GENOTYPING IN PARKINSON’S DISEASE 
AND NEUROLOGICALLY NORMAL CONTROLS. STAGE 2. 
 
As discussed in section 5.5.1, in order to gain statistical power and be able to identify 
common genetic variation (SNP) related with a risk of PD, the GWAS should be 
complemented by genotyping a larger cohort comprising patients and controls of similar 
demographic characteristics to reduce the confounds of sample size, individual effect size 
and risk allele frequency. Besides, since in YOPD the genetic effect seems to be larger 
(Tanner, Ottman et al., 1999; Payami, Zareparsi et al., 2002), individuals with this variant 
of the disease should be included as well. Taking into account these two points, we 
increased our sample size to 4,134 individuals, including 880 late-onset PD, 183 YOPD 
and 3,071 control samples (before quality control clean–up). Each of these samples was 
genotyped at greater as 545,066 unique SNPs genome-wide with Infinium technology. 
Genotyping data for all these samples will be released on the database of Genotype and 
Phenotype (dbGaP, http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gap) as part of a 
National Institutes of Health initiative to publish all genotypic data produced with 
intramural funding (data deposition in progress).  
As explained in section 5.5, the data set utilized for stage 1 of this project (sections 3.5, 
4.5 and 5.5) did not provide enough statistical power to detect association between SNCA 
and PD. However, data from this later stage of the project, allows the detection of 
variability exerting an OR as low as 1.3. Thus, it is not surprising that 3 of the 10 SNPs 
with the lowest p values (1.06 x 10-7, 4.8 x 10-7 and 2.04 x 10-6) were obtained in this 
locus. 
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Although association of SNCA with PD is widely known, these results show the 
robustness of our dataset and can be used as a positive control for association seen in 
other loci. On this last regard, no evident association with any other locus was detected in 
our analysis. These data indicate that, at least in our population and considering that the 
causal variant is either typed or completely tagged with one of the SNPs assayed, there is 
not a genetic factor exerting a risk for PD as large as variability at SNCA. 
In order to add power to our dataset, we undertook a close collaborative analysis with 
Drs. Gasser and Toda, who have performed a similar approach in German and Japanese 
populations respectively. Because of genetic background differences between these 
populations, different approaches were taken for the collaborative analysis. Thus, 
genotype counts from the results of genotyping the German series, were merged with 
ours. Although it could be argued that genetic heterogeneity (different risk genes in 
different populations) and allelic heterogeneity (different risk alleles in same gene in 
different populations) could mask association when pooling different populations for 
analysis, empirical evidence generated thus far supports the notion that this is not likely 
in relatively close populations such as North European and North American Caucasians 
(Saxena, Voight et al., 2007; Scott, Mohlke et al., 2007; Zeggini, Weedon et al., 2007). 
On the other hand, given the considerably genetic distance between Caucasian and Asian 
populations, this approach could not be performed for those results from Dr. Toda’s lab. 
Thus, side by side comparison was performed in this case. 
Combined results for the German and the US cohorts, confirmed the strong association 
with SNCA, with 4 out of the 6 most associated SNPs being located at this locus (p values 
of 3.99 x 10-9, 2.61 x 10-8, 3.5 x 10-8 and 5.86 x 10 -8). Interestingly, another gene highly 
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related to the pathogenesis of PD (MAPT) showed a strong association to PD in this 
cohort (see section 1.6.3.9). Several studies suggest that protein tau can coaggregate with 
α-synuclein in the Lewy bodies, and both may interact to promote the formation of 
synuclein fibirlls (Ishizawa, Mattila et al., 2003). Interestingly, this was genetically 
suggested by Goris and collaborators, who not only showed evidence for a contribution 
of common variation in MAPT and SNCA to PD, but that the combination of both risk 
genotypes doubled the risk for PD (Goris, Williams-Gray et al., 2007). 
Mutations in LRRK2 are the most common cause of PD, accounting for about 1-2% 
(Gilks, Abou-Sleiman et al., 2005) of sporadic and up to 13% of familial PD cases 
(Paisan-Ruiz, Jain et al., 2004; Zimprich, Biskup et al., 2004; Berg, Schweitzer et al., 
2005). However, whether LRRK2 common variants (such as SNPs) are associated with 
common forms of PD is still controversial (Paisan-Ruiz, Lang et al., 2005; Paisan-Ruiz, 
Evans et al., 2006). Interestingly, although we did not find association in LRRK2 locus, 
combined analysis of the German and the US samples, showed 23 SNPs with p values 
below 0.05 (ranging from in 5.2 x 10-6 to 0.05) in a gene ~ 0.5 Mb apart from LRRK2. 
This gene’s name is SLC2A13 (solute carrier familiy 2, member 13) and is a facilitated 
glucose transporter. Interestingly, results obtained in the Japanese cohort showed that 33 
SNPs within this locus had p values below 0.05 (ranging from 1.82 x 10-5 to 0.04. 
Whether this association is driven because of proximity to LRRK2 or is a product of 
chance only, will be ruled out by follow-up studies in different populations. 
Interestingly, 7 SNPs out of those 113 with trend p values below 1 x 10-5 in the combined 
Caucassian analysis where located in CUL2, a component of E3 ubiquitin ligase 
complexes, involved in degradation of multiple proteins. A neighboring gene (CREM, 0.1 
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Mb apart) also showed two hits below this threshold in the combined German and US 
analysis. Interestingly, although no strong association was seen in either of these genes in 
the Japanese cohort, a gene (PARD3) ~ 0.9 Mb had 11 SNPs with trend p values of the 
order 1 x 10-4, showing different haplotype structures across populations exert different 
association to disease. Figure 47 shows association values for this region in chromosome 
10 across all populations studied. Again, replication experiments in other populations are 
needed to establish any association. 
 
 
In summary, we present here the second stage of a GWAS of PD in a large series of PD 
and control samples. Although association found should be confirmed by an appropriate 
follow-up study in different populations (ongoing project), several factors add robustness 
Figure 47: -log trend p values of ~ 7 Mb region of interest in chromosome 10 in all populations assayed. 
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to the results herein presented. First, a close collaboration with Dr. Gasser’s group, 
allowed us to perform a combined analysis that substantially increased our dataset and 
thus, power to add association. Second, collaboration with Dr. Toda’s group provided us 
the opportunity to side-by-side compare our results with a population with a notably 
different genetic background, adding considerable reliability to any association found 
across populations. Last, strong association signals found in genes previously linked to 
PD (SNCA and TAU) can be considered as positive controls, adding power to other results 
found genome-wide. These data suggest that there is no common genetic variant that 
exert a larger genetic risk to PD that SNCA or TAU do in the populations studied. 
All DNA samples, raw genotype data, and significance test results are publicly available 
at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap as part of a National Institutes of 
Health initiative.  
On regard to the mentioned follow-up expeiments, these will be done using Illumina’s 
custom GoldenGate genotyping technology for VeraCode (Illumina, 
http://www.illumina.com). This technology is being used to genotype those 384 SNPs in 
which lowest p value has been detected in the US-German combined analysis. These 
genotyping experiments are being performed in ~ 3,000 PD cases and ~ 3,000 PD 
neurologically normal controls originally from the United Kingdom, Germany and North 
America. 
 
5.7. AUTOZYGOSITY MAPPING IN BRAZILIAN FAMILIES 
We identified two consanguineous families from Southeast-central Brazil with a distinct 
young-onset movement disorder, most commonly presenting with dystonia, but also with 
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parkinsonism. The two families, DYT16-1 and DYT16-2, were apparently unrelated and 
resided in two cities approximately 350 Km apart within Minas Gerais state, Brazil 
(figure 48). Given the resemblance of the clinical features between affected members 
across both families, we hypothesized that they were ancestrally related and shared a 
minimum interkindred haplotype leading to disease.  
 
 
 
 
 
Autozygosity mapping with a high-density whole-genome SNP analysis revealed a large 
disease-segregating region of homozygosity identical by state in all six affected family 
members. Sequence analysis of genes and predicted transcripts from this interval and two 
smaller disease-segregating intervals revealed a single disease-segregating mutation, 
Figure 48: Geographical location of cities were families DYT16-1 (Dores de 
Guanhães, filled in blue) and DYT16-2 (Bom Despacho, filled in red) are 
originally from 
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c.665C>T (p.P222L), in exon 7 of PRKRA (position based on NCBI accession numbers 
NM_003690 and NP_003681). This mutation was not identified in the NCBI SNP 
database or by sequence similarity search of the human nucleotide collection at NCBI 
(figure 49). Of note, in family DYT16-2, affected members have been confirmed in two 
generations (figure 46). In addition an affected family member (mother of 2035-119) was 
also reported to be affected, which may suggest additional parental consanguinity. 
However this member was not examined and we, therefore can not rule out the possibility 
of phenocopy or inaccurate reporting of the affected status. Interestingly, we found this 
same homozygous mutation in an additional patient with generalized dystonia from Para 
de Minas city, 276 and 80 km apart from Dores de Guanhães and Bom Despacho 
respectively within Minas Gerais state. This patient latter revealed to have a region 
spreading from rs6738749 to rs10497541 (∼1.16 Mb), identical by state with all affected 
members of families DYT16-1 and DYT16-2. Identification of such a segregating region, 
in a single rare disorder, strongly suggests that the genetic mutation causing this disease 
resides in this genomic region. 
Screening for this mutation failed to reveal any carriers in 11 other dystonia cases from 
Brazil, 294 young-onset PD cases from the United States, 948 Neurologically normal 
controls from the United States, or 738 samples from diverse human populations 
including 44 Brazilian samples. 
We have not examined 5’ or 3’ untranslated regions, or the predicted regulatory regions 
in these families, and we therefore can not rule out non-coding variability as a cause of 
the disease. However, absence of the specific p.P222L mutation from a large cohort of 
control samples indicates that this variant is the underlying causal mutation in these 
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families. This supposition is bolstered by the fact that no other segregating mutations 
were identified in the 457 other known and predicted exons of this region. However, to be 
absolutely confident that this mutation in PRKRA underlies this disease, independent 
identification of disease-segregating mutations is required. Interestingly, prompted by the 
fact that the mother of individual 2035-19 (a homozygous carrier of p.P222L mutation) 
was affected and could not be genotyped in our experiments, Sebler and coworkers 
hypothesized that heterozygous mutations in PRKRA may be related to dystonia (Seibler, 
Djarmati et al., 2008). In order to investigate this possibility, they performed a mutation 
analysis of PRKRA in a series of cases and controls from Germany. Interestingly enough 
they found a heterozygous frameshift mutation in exon 3 of PRKRA (c.266_267delAT; 
p.H89fsX20) in a patient with young-childhood-onset leg dystonia. His family history 
was unremarkable for any movement disorder, secondary causes of dystonia were 
excluded, and brain MRI was normal. At his last examination, the patient, who is now 
aged 9 years, had generalised dystonia that spared only the cranial and facial muscles, his 
walking was severely impaired, but his cognition was normal (Seibler, Djarmati et al., 
2008). 
Although these results do not confirm that p.P222L mutation in PRKRA causes disease in 
our families, they support the idea of PRKRA as a risk factor for generalized dystonia. 
The biological mechanism by which the p.P222L mutation in PRKRA may cause 
dystonia-parkinsonism is not clear. PRKRA encodes protein kinase, interferon-inducible 
double-stranded RNA-dependent activator (aliases PACT, RAX, HSD14). In response to 
extracellular stresses, prkra activates the latent protein kinase pkr, a protein involved in 
signal transduction, cell differentiation, cell proliferation, antiviral response, and 
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apoptosis (Patel, Handy et al., 2000). More specifically, pkr is thought to inactivate the 
eukaryotic translation initiation factor 2α (eif2α), which in turn inhibits protein synthesis 
(D'acquisto and Ghosh, 2001). Of note, wild-type prkra is a component of the human 
RNA-induced silencing complex, which also regulates protein synthesis via cleavage of 
mRNA (Lee, Hur et al., 2006). The p.P222L mutation alters an aminoacid that is 
conserved across mammalian species at a residue between the second and third RNA-
binding motifs (figure 49). This mutation may cause structural alteration of prkra and/or 
affect substrate affinity. Unfortunately, the crystal structure of this or related proteins has 
not been solved and thus we can not make any confident predictions about the likely 
effect of this variant on protein conformation or function. 
 
 
 
 
 
Figure 49: In silico sequence analysis of PRKRA. Sequence analysis predicts that PRKRA encodes three copies of a double-
stranded (ds) RNA-binding motif (DSRM). DSRM is a conserved domain in various proteins, including dsRNA-dependent protein 
kinase PKR, RNA helicases, Drosophila melanogaster staufen protein, Escherichia coli RNase III, RNases H1, and dsRNA-
dependent adenosine deaminases. Upper panel shows the sequence-to-structure alignment between PRKRA sequence and the 
three-dimensional structure of a dsRNA-binding domain (gi:670350, NCBI Structure database). The yellow-brown bar plot shows 
conservation and alignment quality. The red swirl ribbons and arrowed ribbons show the α-helix and β-strand, respectively, in the 
three dimensional structure of DSRM motif. The location of the p.P222L mutation is indicated with a red arrow. 
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On the basis of our data, DYT16 disease should be considered when a patient presents 
with an apparent or suspected recessive pattern of inheritance of generalized dystonia, 
with involvement of the muscles of the neck and trunk to a greater extent than that of the 
limbs. Other typical features are oromandibular (sardonic smile), laryngeal dystonia, and 
parkinsonism, although the latter is less important than the dystonic features. All patients 
examined thus far have presented spasmodic dysphonia and sardonic smile. All patients 
failed to improve with any pharmacological treatment, including levodopa and high-dose 
anticholinergics. In contrast to DYT16, patients with DYT1 first have limb involvement 
that rapidly spreads to other limbs and the trunk, ultimately becoming severe; 
furthermore, DYT1 is a pure dystonia with an autosomal dominant mode of inheritance 
(although it is worth noting that the reduced penetrance could lead to suspicion of 
recessive inheritance) (De Carvalho Aguiar and Ozelius, 2002). The lack of response to 
levodopa in patients with DYT16, the absence of myoclonus, and sensitivity to alcohol 
differentiate this disease from DYT5 and DYT11, respectively (De Carvalho Aguiar and 
Ozelius, 2002). There are many similarities between DYT16 and DYT12, such as 
prominent bulbar signs and rostro-caudal gradient; however, DYT12 has an abrupt onset 
and a clear autosomal dominant mode of inheritance (Brashear, Dobyns et al., 2007). 
DYT16 may also be easily differentiated from the PARK loci associated with 
parkinsonism and dystonia such as PRKN and PARK9-linked disease. The observed 
dystonia in PRKN disease is usually focal in nature and does not progress to a generalized 
dystonia, and patients with PRKN diseases are usually responsive to levodopa therapy. 
PARK9 disease is associated with both dementia and a supranuclear gaze palsy, 
(Ramirez, Heimbach et al., 2006) both of which are absent in DYT16 disease. 
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In summary, we have described a novel autosomal recessive dystonia-parkinsonism 
syndrome in Brazilian patients that we have designated DYT16. Using high density SNP 
genotyping arrays, we have identified a genetic locus associated with disease. The 
homozygous track of SNPs shared between all mutation-positive samples clearly shows 
that this region is derived from a common ancestor. After complete sequence analysis of 
all coding regions within the locus, we show a single disease-segregating mutation within 
PRKRA. This mutation was present in three of 14 probands with generalized dystonia 
from the Brazilian population, representing 21.4% of independent cases. The P222L 
variant might be not pathogenic, and could be in linkage disequilibrium with the actual 
disease-causing variant. However, the absence of the mutation in such a large series of 
controls and our inability to identify other mutations, despite screening all other genes in 
the identified region, clearly supports our assertion that mutation in PRKRA is the 
causative genetic mutation in DYT16. 
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6. SUMMARY 
 
Parkinson’s disease (PD) is a heterogeneous disorder in which genetic factors play an 
important role. To date, six genes have unequivocally been linked to familial forms of the 
disease and a handful of genomic loci related to both the sporadic and the familial 
variants. This grouping into familial and sporadic variants does not imply that these two 
types of the disease should be considered as different entities. In fact, because of the 
clinical and pathological similarities existing between familial and non-monogenic PD, 
knowledge of the genes causing the familial disease could bring new ideas for the 
research of sporadic forms of the disease and vice-versa. Thus, in order to help 
understanding the etiology of the disease, we have analyzed different groups of patients 
in which different variants of PD had been diagnosed including autosomal dominant, 
autosomal recessive and sporadic.  
 
The first approach we took to fulfill this objective was helping to determine the minimal 
common haplotype carrying the gene with mutations leading to autosomal dominant PD 
in four families from the Basque Country previously linked to PARK8 locus. This 
approach led to the discovery of LRRK2 as the gene carrying the mutation that causes PD 
in these families. Interestingly, this mutation was also present in ~7% of PD patients from 
the Basque country including both familial and apparently sporadic cases. Haplotype 
analysis in al these patients led us to conclude that all had inherited the mutation as part 
of an ancestral chromosome. Further mutations have been identified in this gene being 
one of them (p.G2019S) the most common cause of both familial and apparently sporadic 
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PD. To further investigate the role of this gene in PD pathology, we thought that it would 
be interesting to provide a complete atlas of its mRNA distribution. With this objective 
we performed an in situ hybridization analysis with digoxigenin-labeled RNA probes on 
mice brain coronal sections. This approach showed that LRRK2 was expressed in brain 
regions related with PD like the substantia nigra pars compact or the caudate putamen. 
 
After helping to the identification of the gene carrying the mutation that cause the PARK8 
variant of autosomal PD, we thought it might be interesting to investigate if mutations in 
another autosomal dominant locus (PARK13) were actually involved in PD pathology. 
Mutation in OMI/HTRA2 had recently identified to cause PD in German patients and this 
locus given the name of PARK13. Since in genetic research, as important as an original 
finding is replication of this finding in a different population, we thought it would be 
interesting to confirm PARK13 results in a large series of Caucasian individuals from 
North America. Data obtained from these experiments showed that those variants 
previously described as pathogenic are present in neurologically normal control 
population and not associated with PD in our cohort. We feel this is a critical and 
important finding; this locus has already been given a PARK designation 
(http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=610297) and we feel, given the 
evidencepresented, that such a designation is probably misleading. 
 
Another contribution to the understanding of autosomal PD was taken in a set of 
populations from different locations worldwide in which we analyzed expansion 
mutations in ATXN2 and ATXN3 genes. These genes are a known cause of 
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spinocerebellar ataxias type 2 and 3 respectively but had also been related to clinical 
features of PD. We failed on finding any mutations in ATXN3. However, we found 
segregating expansion mutations in ATXN2 in a Caucasian family, showing the necessity 
of testing these expansion mutations when positive family history is reported. 
 
On regard to the autosomal recessive variant of parkinsonism, we identified two 
consanguineous families from Southwest Brazil with a rare recessive dystonia-
parkinsonism syndrome. Because of similarities in the phenotype they presented and 
because of the relatively proximity of the cities this families were from, there is a high 
possibility that affected individuals had inherited both copies (paternal and maternal) of 
the mutated gene from a common ancestor. Autozygosity mapping in these families led 
us to the identification of PRKRA as the gene carrying the mutations that cause disease in 
these two kindreds. 
 
As for the non-Mendelian forms of PD, in order to unveil the role of common genetic 
variation in sporadic PD, we embarked a genome-wide association study in a population 
of North American Caucasians. In the first stage of this project, we genotyped more than 
408,000 SNPs in a series of 552 idiopathic PD cases and neurologically normal controls 
from the National Institute of Neurological Disorders and Stroke (NINDS) funded 
Neurogenetics repository. Given the limited power of the cohort genotyped in this stage 
of the project, it is not surprising that we did not find any convincing disease-associated 
loci. Although it would be disingenuous to suggest that we were not aiming to identify 
genetic risk loci, an important aim of this work was also to provide a set of publicly 
Javier Simón Sánchez  Summary 
 253
available genome wide SNP data for others to work with and augment. Interestingly, 
these data have been downloaded several hundred times and used in several publications 
originating from outside our group. 
Besides SNPs, whole-genome genotyping technologies allow the identification of copy 
number variants (CNVs) as well as the detection of extended homozygosity. Extensive 
analysis of our data revealed 201 novel CNVs in control population that have been 
published at the database of genomic variants (http://www.tcag.ca) to help the 
construction of an encyclopedia of this type of variation. On regard to PD, we identified 
82 novel CNVs not published in the database of genomic variants. Although we can not 
rule out that these are at genetic loci related with PD, it is likely, given the large number 
of unique CNVs seen in control population, that the majority, or all, are benign variants. 
However we provided a comprehensive list of these alterations to serve as a foundation of 
future works. While this method was applied primarily to detect novel regions related to 
sporadic PD, we have identified a homozygous deletion, which is likely pathogenic, and 
other structural mutations in PARK2 in both cases and controls. Although heterozygous 
deletions at PARK2 were only found in PD samples, lack of statistical evidence after 
Fisher’s exact test prevents us on stating that these mutations are causal of disease in 
these samples. 
Besides, we found striking levels of homozygosity in ostensibly control population. The 
observation that individuals with at least one large tract of homozygosity are likely to 
harbor other large regions of homozygosity supports the idea that parental consanguinity 
is the cause. These data suggest the utility of whole genome SNP analysis to perform 
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homozygosity mapping of disease loci not only in families in which a recessive mode of 
inheritance is detected, but in cohorts of apparently unrelated young-onset cases. 
 
In the second stage of this project, our dataset was increased to ~545,000 unique SNPs 
typed in 880 PD patients and 3,071 controls. In order to add power to our genome-wide 
association study we undertook a collaborative analysis with a German (742 cases and 
944 controls) and a Japanese group (1,000 cases and 2,500 controls). Results derived 
from these experiment showed strong association of two genes largely related to the 
etiology of PD: SNCA and MAPT. These results support the robustness of our analysis 
and serve as positive controls for other association detected in other loci not previously 
related to PD. On this regard, although should be replicated in other populations, 
interesting association was detected in several loci including SLC2A13 (<0.5 Mb away 
from LRRK2) and a locus in chromosome 10 including CUL2, CREM3 and PARD3. In 
order to verify the results obtained in this second stage of the genome-wide association 
project we are currently genotyping the top 384 “hits” obtained in the USA-German 
combined analysis in various populations worldwide. 
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7. CONCLUSIONS 
 
1. Mutation p.R1441G in LRRK2 is the cause of Parkinson’s disease in ~7% of PD cases 
with and without positive family history from the Basque Country. 
 
2. All p.R1441G carriers from the Basque Country share a common minimal disease 
haplotype suggesting that they have inherited the mutation from a common ancestral 
chromosome. This haplotype was shared by a group of p.R1441G carrier cases from 
Asturias, suggesting a gradient of this mutation in Northern Spain. 
 
3. LRRK2 is expressed throughout the mouse brain. However, a stronger expression is 
seen in specific brain areas such as the deep cerebral cortex, cingulate cortex, piriform 
cortex, Ammon’s horn and dentate gyrus, caudate putame, substantia nigra, some 
parts of the amygdala, reticular thalamic nucleus or cerebellar granular cell layer. 
 
4. Mutations in OMI/HTRA2 (PARK13) are not a significant risk factor or cause of 
Parkinson’s disease a North American population. 
 
 
5. Expansion mutations in ATXN-2 are a cause of parkinsonism with clinical features 
overlapping those of Parkinson’s disease in 1.5 to 8% of cases with positive family 
history. Thus, this gene should be tested when positive family history is suspected. 
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6. We have identified 201 novel copy number variants (CNVs) in control population 
that have been published at the database of genomic variants (http://www.tcag.ca) to 
help the construction of an encyclopedia of this type of variation. 
 
7. We have identified 82 novel CNVs not published in the database of genomic variants. 
Although we can not rule out that these are at genetic loci related with Parkinson’s 
disease, it is likely, given the large number of unique CNVs seen in control 
population, that the majority, or all, are benign variants. Type and location of these 
variants have been published so that they can serve as foundation of future works. 
 
8. We have identified a homozygous PARK2 deletion in a patient with young-onset 
Parkinson’s disease. These finding suggests the utility of whole genome genotyping 
techniques to find structural changes causing disease. Althoug heterozygous deletions 
at PARK2 were only found in Parkinson’s disease samples, lack of statistical evidence 
after Fisher’s exact test prevents us on stating that these mutations are causal of 
disease in these samples. 
 
9. A genome-wide association study in a large series of Caucasian samples from North 
America suggests that, at least in this population and considering that the causal 
variant is either typed or completely tagged with one of the SNPs assayed, there is not 
a genetic factor exerting a risk for PD as large as variability at SNCA. This conclusion 
was expanded to MAPT in a combined analysis of US and German samples. 
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10. Although should be replicated in other populations, interesting association was 
detected in several SLC2A13 (<0.5 Mb away from LRRK2) and a locus in 
chromosome 10 including CUL2, CREM3 and PARD3.  
 
11. p.P222L mutation in PRKRA is the cause of a weird syndrome presenting with 
juvenile dystonia and parkinsonism in two consanguineous  families from Southeast 
Brazil. 
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